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CHAPTER 1
INTRODUCTION
1.1 The chromatin
The chromatin is a complex structure of DNA, RNA and proteins, which
allows an orderly genome packaging in eukaryotic cells (1). The compaction
of chromatin involves several levels of highly organized folding. The higher
level of compaction is the chromosome and the nucleosomes are the funda-
mental organizational units of chromatin (2). A classical model of chromatin
folding is given in Fig. 1.1, although the nature of higher-order structures
is controversial. Some authors [see, for instance, (3)] think that the 30 nm
fibres observed in vitro only occur in diluted chromatin and that in vivo,
especially in the highly compacted metaphasic chromosomes, nucleosomes
adopt a more irregular disposition. Anyway, the higher order structure of
chromatin changes temporal and spatially along the cell cycle and in the dif-
ferent subnuclear localizations.
Chromatin structure plays a role in the regulation of all the metabolic
processes of DNA such as replication, repair, recombination and transcrip-
tion. Two forms of chromatin can be found along of chromosome: the hete-
rochromatin and the euchromatin (4; 5). The heterochromatin is a form of
chromatin more condensed than the rest and represents approximately the
10% of the chromatin in a typical eukaryotic cell (6). This form of chromatin
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can be functionally separated in facultative and constitutive. The faculta-
tive heterochromatin is a mechanism for gene silencing, because the genes
are strongly repressed when its DNA is condensed within heterochromatin
(7). Constitutive heterochromatin is usually composed by repetitive DNA
and is associated with particular chromosome structures, for example the
centromeres and telomeres (8).
Figure 1.1: Compaction of DNA in a eukaryotic chromosome [adapted from
(9)].
The euchromatin is a less condensed form of chromatin, where active gene
expression (transcription) occurs. Transcriptionally active chromosomal re-
gions are characterized also by the presence of nucleosomes with particular
compositions and modifications (see below).
1.1.1 The nucleosome
The nucleosome is the fundamental repeating structural unit of chromatin
(10) and it is composed of the core histones proteins, double-stranded DNA
(Fig. 1.2) and linker histone H1 (or H5 in some cases) (11). The linker hi-
stone stabilizes the condensation of nucleosomes to higher order structures
(12). The core histones are wrapped by 1.75 superhelical turns of double-
stranded DNA. The length of the nucleosome is about 200 bp, of which 147
bp are tightly bound around the histone core and the remainder serve as
linker DNA between nucleosomes (13; 14).
2
The histone core is an octamer composed by two copies each of the hi-
stones H2A, H2B, H3 and H4. Histones H3 and H4 associate in two het-
erodimers (H3:H4)2 and represent the tetrameric “hinge region” of the nu-
cleosome. Histones H2A and H2B form the two independent heterodimers
(H2A:H2B) (14; 15). The core histones are highly conserved and possess
three functional domains; the histone fold domain, an N-terminal tail do-
main, and in some histones accessory helices and less structured regions (16).
Figure 1.2: Crystal structure of the nucleosome core particle at 2.8 A˚ res-
olution (red: H3; black: H4; blue: H2A; green: H2B; dark green: DNA).
Structure extracted from Protein Data Bank, access code 1AOI and viewed
in PyMOL.
The histone fold domain consists of a helix-fold-helix motif with a long
median helix (mH), and two shorter terminal helices; N-terminal helix (NH)
and the C-terminal helix (CH). The helices are joined to the mH by two
loops, one at the N-terminal side (NL) and the other one at the C-terminus
(CL). The formation of heterodimer pairs is accomplished through a “hand-
shake” pairing in which the mH helices of the handshake partners align in
opposite orientations such that the NL loop of one partner aligns in a par-
allel orientation with the CL loop of the other. The histone fold domain is
the essential structural motif for bending DNA to the nucleosome structure
(14; 16; 17).
Accessory domains in the core histones include: a N-terminal accessory
3
helix in H3 that is involved in binding and stabilizing DNA (18); a short
C-terminal accessory helix in H2B, which with the rest of the C-terminal
tail, forms a large portion of the protein faces of the nucleosome; and the
C-terminal domain of H2A, which is responsible for docking the dimer to the
tetramer and to interact with linker DNA (19). The N-terminal tail domains
of the core histones contain the main part of the residues, whose covalent
modifications form an epigenetic code (20).
1.1.2 Epigenetic modifications
Epigenetics refers to the study of heritable changes that have effects on
gene regulation without changing the DNA sequence (21). The main execu-
tors of epigenetic control are DNA methylation and histone modifications,
which together with nuclear architecture, chromatin remodeling complexes,
Histone variants and non-coding RNAs, define the chromatin structure of a
gene and its transcriptional activity (22; 23).
The histone modifications occur mainly in the highly basic amino (N)-
terminal tails. These tails protrude from their own nucleosome and make con-
tact with adjacent nucleosomes, so these modifications affect inter-nucleosomal
interactions and thus to the overall chromatin structure (18). Modifications
not only regulate chromatin structure, but are also involved in the recruit-
ment of other factors, as remodelling enzymes that utilize the energy derived
from the hydrolysis of ATP to reposition nucleosomes. In this way the histone
modifications influence transcription, repair, replication and recombination
(24).
The combination of events of histone modification creates binding surfaces
for protein recognition modules, which recruit specific functional complexes
to their proper sites of action. The repertoire of modifications possible in
the histones and their combination of events are immense. In addition each
of these modifications can be “read” by other proteins usually referred to as
“readers” (25). The enzymes that produce these modifications are be named
as “writers” and the enzymes that remove them are called “erasers” (26).
This as a whole is called histone code (27), and plays a fundamental role in
chromatin dynamics and hence, on gene transcription (28). There are over
60 different residues on histones where modifications have been detected ei-
ther by specific antibodies or by mass spectrometry, although it is believed
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that this count is a huge underestimate of the number of modifications that
can take place on histones (29). There are at least eight distinct types of
modifications found on histones (Table 1.1), the small covalent modifica-
tions acetylation, methylation and phosphorylation being the most studied
(29; 30). Each type of modification is carried out by a group of specific
histone-modifying enzymes (Table 1.2) (29; 31).
Chromatin Modifications Residues Modified Functions Regulated
Acetylation K-ac Transcription, Repair, Replication, Condensation
Methylation (lysines) K-me1, K-me2, K-me3 Transcription, Repair
Methylation (arginines) R-me1, R-me2a, R-me3s Transcription
Phosphorylation S-ph, T-ph Transcription, Repair, Condensation
Ubiquitylation K-ub Transcription, Repair
Sumoylation K-su Transcription
ADP ribosylation E-ar Transcription
Deimination R > Cit Transcription
Proline Isomerization P-cis > P-trans Transcription
Table 1.1: Different classes of histone modifications, from (29).
1.1.2.1 Histone acetylation
Histone acetylation occurs specifically in the amino acid lysine (K) and
consists in the transfer of an acetyl group (COCH3) to the ε-amino group of
lysine side chains (33). This reaction is catalysed by the histone acetyltrans-
ferases (HATs), using the acetyl CoA as acetyl donor (34). The opposite
process is known as deacetylation and is carried out by histone deacetylases
(HDACs) (35) (Fig. 1.3). Mammalian cells contain at least 17 HATs and 18
HDACs (32; 36).
There are two major classes of HATs: type-A and type-B. The type-
B HATs are predominantly cytoplasmic, acetylating free histones but not
those already deposited into chromatin. The type-A HATs are a more diverse
family and can be classified into at least three separate groups: Family GNAT
(ex. GCN5), Family MYST (ex. TIP60) and the orphan family CBP/p300.
(24).
The acetylation causes a change in the electrostatic change of histones
which alters the structural properties of histone and their binding to DNA.
This helps to relax the inter- or intra-nucleosomal DNA-histone interactions,
so it is a mark of euchromatin (28). Also, the acetylation, together with
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Enzymes that modify histones Modified residues
Acetyltransferases
HAT1 H4 (K5, K12)
CBP/P300 H3 (K14, K18), H4 (K5, K8)
CBP/P300 H2AK5, H2B (K12, K15)
PCAF/GCN5 H3 (K9, K14, K18)
TIP60 H4 (K5, K8, K12, K16), H3K14
HB01 H4 (K5, K8, K12)
Deacetylases
HDAC1, HDAC2 H3K56, H4K16
HDAC3 H3 (K9, K14), H4 (K5, K12)
SirT1 H1K26, H4K16, H2AXK5, H3K56
SirT2 H4K16, H3K56
SirT6 H3K9
Lysine Methyltransferases
SUV39H1, SUV39H2, G9a, ESET/SETDB1 H3K9
EuHMTase/GLP, CLL8, RIZ1 H3K9
MLL1 to MLL5, SET1A, SET1B, ASH1 H3K4
SET2, NSD1, SYMD2 H3K36
DOT1 H3K79
Pr-SET 7/8, SUV4 20H1, SUV420H2 H4K20
EZH2 H3K27
Lysine Demethylases
LSD1/BHC110 H3K4
JHDM1a, JHDM1b H3K36
JHDM2a, JHDM2b, JMJD2B, JMJD2D H3K9
JMJD2A/JHDM3A, JMJD2C/GASC1 H3K9, H3K36
Arginine Methyltransferases
CARM1 H3 (R2, R17, R26)
PRMT4 H4R3
PRMT5 H3R8, H4R3
Serine/Threonine Kinases
Haspin H3T3
MSK1, MSK2 H3S28
CKII H4S1
Mst1 H2BS14
Ubiquitylases
Bmi/Ring1A H2AK119
RNF20/RNF40 H2BK120
Table 1.2: Some human histone modifying enzymes and modified residues.
Adapted from (29) (32). For a detailed list of human histone modify-
ing enzymes and modified residues see the histone infobase (HIstome) in
http://www.actrec.gov.in/histome/writer.php.
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Figure 1.3: Lysine acetylation is catalyzed by HATs and reversed by HDACs.
Acetyl-lysine readers consist mainly of proteins containing a bromodomain,
but other acetyl-lysine binding domains (indicated) have been reported [from
(32)].
other modifications, recruits specific functional complexes (26). For exam-
ple the protein domains like the bromodomain, present in ATP dependent
remodelling complexes like Swi/Snf, recognize the acetylated lysine and as-
sist in binding of the complex to acetylated chromatin activating nucleosome
remodelling and gene transcription (25).
1.1.2.2 Histone methylation
The term methylation is used to describe the reaction in which S-adenosyl-
methionine (SAM) donates a methyl group to carboxyl residues of glutamate,
cysteine and leucine, or to nitrogen atoms of lysine, arginine and histidine,
leaving a S-adenosyl-L-homocysteine molecule (SAH) as a result (37). The
histone methylation occurs only in the nitrogen atoms of the side chains of
the amino acids arginine and lysine and is a stable epigenetic mark that does
not alter the overall charge of the histone tails (34; 38). The lysines may be
mono, di or trimethylated and the arginines may be mono, symmetrically or
asymmetrically dimethylated (Fig. 1.4).
The enzymes responsible for adding the methyl marks to histones are the
protein lysine methyltransferases (PKMTs or HKMTs) (40) and the protein
arginine methyltransferases (PRMTs) (41). These have two binding pock-
ets: the substrate binding pocket which binds to lysine and arginine, and a
cofactor binding site for SAM binding (38). Most of the HKMTs have the
SET domain; an exception is Dot1. The human genome encodes 73 SET
domain-containing proteins and all of them catalyse the transfer of a methyl
7
Figure 1.4: Lysine and arginine methylation [from (39)].
group from SAM to a lysine ε-amino group (25). Furthermore, each enzyme
modify the appropriate lysine to a specific degree (mono, di and/or trimethyl
state). For examples, DIM5 can trimethylate H3K9, but SET7/9 can only
monomethylate H3K4 (24).
The PRMTs are classified into two classes: type-I that generate Rme1 and
Rme2as (asymmetric); and type-II enzymes that generate Rme1 and Rme2s
(symmetric). All of these enzymes transfer a methyl group from SAM to the
ω-guanidino group of arginine (24).
The opposite process is catalysed by histone demethylases. The argi-
nine demethylation is carried out for example by the protein JMJD6 that
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performs the demethylation reaction of H3R2 and H4R3 (42). The lysine
demethylation reaction is carried out by LSD1 that is compatible with mono
and dimethylated lysine substrates (43).
Histone methylation is associated with both transcriptional activation
and repression. Lysine methylation can be related to transcription initi-
ation (e.g. H3K4me3), transcriptional elongation (e.g. H3K36me1 and
H3K79me1) or repression (e.g. H3K9me2 and H3K9me3) (25). In addi-
tion, lysine methylation (H3K9me2, H3K9me3, H3K27me3 and H4K20me3)
determines the interaction and recognition of the heterochromatin protein 1
(HP1) (44). HP1 is a small non-histone chromosomal protein which is asso-
ciated with pericentric heterochromatin, so it is involved in heterochromatin
formation and gene silencing, but also it participates in the maintenance of
chromosome integrity and in processes such as euchromatic gene expression
(45). The arginine methylation is associated with activation of transcription
(46).
1.1.2.3 Histone phosphorylation
The phosphorylation is the addition of a phosphate group (PO34
−) from
ATP to the hydroxyl group of the residues of serine, threonine and tyrosine
(Fig. 1.5). This modification adds significant negative charge to the histone
influences the chromatin structure. The enzymes responsible for adding the
phosphate marks to histones are the protein kinases and the remove process
is catalysed for phosphatases (47; 48).
A substantial number of phosphorylated histone residues are associated
with gene expression and are related to the regulation of genes involved in
proliferation. The H4S1ph modification play a role in transcription elon-
gation and negatively regulate H4 acetylation during DNA damage repair.
Surprisingly, the transcription start site (TSS) is enriched in H4S1ph in a
huge number of genes and colocalizes with H4ac (48; 49).
The H2BS36ph has been detected within promoters and coding regions of
AMPK-responsive genes, and loss of this modification leads to their reduced
expression and lower rates of cell survival in response to metabolic stress
(49). Phosphorylation at H2BS14 is correlated with programmed cell death
in vertebrates (50). The H3Y41ph and H2BS36ph are associated with tran-
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Figure 1.5: Serine, threonine and tyrosine phosphorylation (adapted from
http://urei.bio.uci.edu).
scription activation and cell proliferation. The phosphorylation of H3T11
and H3T6 are associated whit prostate cancer (51).
Some phosphorylation sites such as H3S10 and H3S28 were identified as
involved in cell cycle processes during mitosis and meiosis (48) and in the
regulation of immediate-early genes (52). These genes are directly linked to
signaling cascades (as MAP kinase) without a requirement for the biosyn-
thesis of new proteins (29). Consequently, the histone phosphorylation is
involved in most cellular processes.
1.1.3 Remodelling machines
The packaging of chromosomal DNA by nucleosomes organizes compactly
the 75-90% of the genome, but nucleosomal DNA is much less accessible to
the many proteins that act on naked DNA to carry out essential genetic
functions (53). The nucleosomes must be disassembled to allow access of
regulatory factors and transcriptional machinery to the target sequences. In
this way, nucleosomes may function as both general repressors and activators
of gene expression. Nucleosome stability is regulated by the combined effects
of nucleosome-positioning sequences, epigenetic modifications, chromatin re-
modellers, histone chaperones and histone variants (53; 54).
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It has to be noted that there are patterns within sequences that con-
tribute to nucleosome positioning. The DNA sequences at the center of
highly positioned nucleosomes are enriched for G/C nucleotides, whereas the
flanking sequences are more A/T rich in vitro. Moreover, internucleosomal
linker DNA is shorter at actively transcribed genes. On the other hand, the
CpG islands are relatively nucleosome free. The CpG islands are genomic
regions that contain high frequency of CpG dinucleotides that can contain
5-methylcytosine (5MeC) residues (56). However, DNA sequences alone can-
not solely determine nucleosome positioning in mammals (57).
The histone variants and epigenetic modifications also influence the struc-
ture and stability of the nucleosome. Nucleosomes containing histone variants
might have altered bonds and interactions with DNA, which could result in
changes in DNA sequence preferences and nucleosome positions (58). More-
over, the histone modifications indirectly influence the structure of nucleo-
somes recruiting transcription factors and chromatin remodellers (59).
The remodellers work with other chromatin factors to control packaging
and unpackaging of the DNA. All eukaryotes contain at least four families of
chromatin remodellers: SWI/SNF, ISWI, CHD and INO80 (Fig. 1.6). All
the families contain an ATPase with a conserved catalytic domain, flanked
by unique domains (55).
The SWI/SNF family remodellers are composed of 8 to 14 subunits. Most
eukaryotes utilize two related SWI/SNF family remodellers, built around two
related catalytic subunits (60). A common feature is a multilobe structure
and the presence of a large cavity able to accommodate the nucleosome. The
catalytic ATPase includes an HSA (helicase-SANT), a post-HSA, and a C-
terminal bromodomain (55; 61). This family, has a role in the sliding and
ejection of nucleosomes at many loci, but is not involved in chromatin assem-
bly. The human SWI/SNF family has biological functions in differentiation,
development, elongation, signalling, splicing and it acts as well as a tumour
suppressor (62).
The imitation switch (ISWI) remodellers contain 2 to 4 subunits. The
ISWI family shows a disc-shaped architecture with one flat and one convex
side (55). This is a dimeric structure where two ATPases bind one nucleo-
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Figure 1.6: Human remodeller families, showing their composition and the
ATPases domains [from (55)].
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some from opposite sides (61). A characteristic set of domains reside at the C
terminus of ISWI family ATPases, a SANTdomain (NCoR, TFIIIB) adjacent
to a SLIDE domain (SANT-like ISWI), which together form a nucleosome
recognition module (63). Many ISWI family complexes possess specialized
attendant proteins, that can optimize nucleosome spacing to promote chro-
matin assembly. They may also participate in the repression of transcription
and assist RNApol II activation, showing the diversity that can be imparted
by attendant subunits (55).
The chromodomain-helicase-DNA binding (CHD) family remodellers com-
bine 1 to 10 subunits and has two tandemly arranged chromodomains on the
N terminus of the catalytic subunit (55; 64). The recent crystal structure
show that the double chromodomain unit of the Chd1 remodeller blocks DNA
binding and activation of the ATPase motor in the absence of nucleosome
substrates (65). Certain CHD remodellers slide or eject nucleosomes to pro-
mote transcription, but others have repressive roles (61).
The inositol requiring 80 (INO80) family remodellers contain more than
10 subunits including the SWR1 related complexes. The defining feature
is a split ATPase domain, with a long insertion present in the middle (66).
INO80 has diverse functions, including transcriptional activation and DNA
repair. SWR1 can re-structure the nucleosome by removing canonical H2A-
H2B dimers and replacing them with H2A.Z-H2B dimers (55; 67).
1.2 Transcription in eukaryotes
The process by which the information contained in DNA is transferred to
RNA is called transcription. The details given below are centred in the tran-
scription of structural genes, carried out by RNA polymerase II (RNA pol
II) (68). The mRNA synthesis process requires a complex machinery that
should be assisted by additional protein factors and finely regulated (69).
The process of transcription of a eukaryotic gene can be divided roughly into
three phases: initiation, elongation-splicing and termination (70).
Eukaryotic transcription takes place within the micro-environment of the
cell nucleus, generally in the euchromatin. So, gene activity is controlled
at different levels of chromatin organization, that go from chromosome ar-
rangement and chromatin folding, to sequence of the DNA and proteins that
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conform the nucleosome. These levels are interconnected and influence each
other (71). Therefore, transcriptional regulation includes all the mechanisms
involved in the regulation of chromatin structure: remodeling of nucleosomes,
epigenetic modifications, etc., apart from the transcriptional factors and all
the mechanisms acting on the transcriptional machinery (72).
1.2.1 Regulatory elements in the promoter and tran-
scription initiation
Most of the genes must be activated to begin transcription, and repressed
to end the process. The elements responsible for this function are called
activators and repressors respectively. Together, these elements are called
trans-elements and the DNA segments that interact with these are called cis-
elements. These elements bind other regulatory proteins called coactivators
and corepressors that not bind DNA but rather to the trans-elements (73).
The cis-element include core promoters, proximal promoters, distal en-
hancers, silencers, insulators/boundary elements, and locus control regions
(Fig. 1.7) (74). The core promoter is an approximately 60 bp DNA sequence
at the start of a gene, that serves as the docking site for the basic tran-
scriptional machinery and preinitiation complex (PIC) assembly, and defines
the position of the TSS (nucleotide +1) as well as the direction of transcrip-
tion (75; 76). The cis-elements characteristic in the core promoter are the
initiator element (Inr, in nearly half of promoters), downstream promoter
element (DPE, in roughly one fourth of promoters), TFIIB-recognition ele-
ment (BRE, in roughly one fourth of promoters), TATA box (in one eighth of
promoters) and other more specific of each gene. A particular core promoter
may contain some, all, or none of these elements (76; 77).
The proximal promoters are usually within 70-200 bp upstream of the
TSS, just 5’ of the core promoter. The cis-elements tend to be located in
clusters; some of these may include the CAAT box, which is a binding site
for the CAAT-binding protein (CBP) and the CAAT/enhancer-binding pro-
tein (C/EBP), and the GC box that is a binding site for the transcription
factor specific protein 1 (SP1)(76). There are many other cis-elements that
are found in the promotor of a small group of genes. An example is the cis-
element GCG (G/T) GGGCG, recognized by the transcription factor EGR1,
which controls the activation or repression of a small group of genes (78).
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Figure 1.7: Regulatory elements in the promoter [adapted from (76)].
The promoters in the ∼60% of human genes are near a CpG island, a
DNA sequence in which the dinucleotide CG is abundant. Indeed, the pres-
ence of a CpG island is the most reliable indicator for predicting the presence
of a gene. The promoters with CpG island usually contain BREs, but not
TATA box. The trans-elements that bind to proximal promoter do not al-
ways directly activate or repress transcription, but might serve to recruit long
range regulatory elements, such as enhancers, to the core promoter (76; 77).
The first step in the transcription is the PIC assembly which involves a
series of highly ordered processes. Once activators bind to the promoter,
they trigger a cascade of recruitment of coactivator complexes such as chro-
matin remodelling complexes, histone modification enzymes and mediator
(79). The mediator is a bridge between gene-specific transcription factors
bound to regulatory DNA elements (RE) and the general transcription ma-
chinery, stabilizing the PIC at the core promoter (80). These coactivator
complexes facilitate stronger binding of activators to DNA and make nucleo-
somal DNA elements more accessible to general transcription factors (GTFs)
that include TFIIA, TFIIB, TFIID, TFIIE, TFIIF, and TFIIH (75; 81).
The mechanism of transcription initiation has been well studied, espe-
cially in the yeast Saccharomyces cerevisiae. A model of how the formation
of the PIC and the initiation of transcription may occur at a chromatin
level is shown in Fig. 1.8. The silent promoter contains a nucleosome-free
region (NFR) of about 200 pb, flanked at both sides by nucleosomes contain-
ing Htz1, the yeast analog of the histone variant H2A.Z. Htz1 is especially
abundant in promoters of genes poised for transcription (81; 82). There also
exist other distal regulatory elements, such as the yeast upstream-activating
sequence (UAS), recognized by a trans-element, which, in turn, recruits var-
ious coactivators, such as the remodeler SWI/SNF and several HATs. This
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results in the hyperacetylation of H3 and H4 at the promoter proximal re-
gion, with the concomitant increase in nucleosome mobility. It is unknown
if Htz1 loss occurs before (Fig. 1.8, left) or after the formation of PIC or if
this is partially assembled before joining the RNA pol II (Fig. 1.8, right).
In the left model, the combination of acetylation and chromatin remodelling
causes a rapid eviction of Htz1 in the promoter. This suggests that Htz1 it
is specifically positioned at the promoter, where some nucleosomes have to
be removed to accommodate PIC formation (79; 81; 82).
Figure 1.8: Models of chromatin regulation during transcription initiation
[from (81)].
In the genes that contain TATA box, the first GTF to associate with
template DNA is transcription factor of RNA pol II D (TFIID), which is
composed of the TATA-binding protein (TBP) and 14 TBP-associated fac-
tors (TAFs). Upon TFIID binding, TFIIB joins the growing assemblage.
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The TFIIB-TBP-DNA complex signposts the direction for the start of tran-
scription by RNA pol II this binds to the N-terminal zinc ribbon domain
of TFIIB, and indicates which strand of the DNA double helix acts as the
template (76; 83). RNA pol II loading onto promoter also requires TFIIF,
which forms a tight complex with the polymerase. Entry of TFIIB in the
cis-element of core promoter, and TFIIF in the growing assemblage leads to
binding of TFIIE which, in turn, recruits TFIIH, and Mediator. Together
these factors form the PIC. TFIIH is the protein kinase most complex of all
the GTFs and phosphorylates the carboxyl-terminal domain (CTD) of RNA
pol II. This is the signal required for the polymerase to leave the promoter
and begin the transcription (75; 76).
1.2.2 Elongation complex
Recent studies indicate that in many genes, including immediate-early
genes, after transcribing some length of DNA, RNA pol II pauses. It has
been proposed that this event constitutes a regulatory checkpoint in the
elongation of transcription. RNA pol II remains paused until some modifi-
cations (see below) occur that allow the processivity of the enzyme to start
productive transcription (84).
Transcription elongation begins when RNA pol II escapes from GTFs
and travels into the coding region, signalling the recruitment of the elonga-
tion machinery (85). During this step, the downstream DNA is unwound to
provide access to the polymerase active site and then is rewound upstream
forming a hybrid duplex with growing mRNA of approximately 8 bp long
(86). This duplex is taking off gradually during the advance of RNA pol II
and the DNA is re-hybridize with the complementary strand. In the unwound
region, the RNA pol II synthesizes a nascent mRNA strand in direction 5’-3’,
from the template DNA, thus requiring four ribonucleosides 5-triphosphate
(NTPs: ATP, GTP, CTP and UTP) as substrate and the ion cofactors. The
addition is performed in the 3’-hydroxyl group of the ribonucleotide, acting
as a nucleophile. The RNA chain is synthesized following the pairing interac-
tions of bases and according to the given reading in the template DNA strand
in the direction 3’ to 5’ (87; 88). Transcription ends when a modified residue,
called cap, is added to the 5’ end and a polyA tract of 80-250 nucleotides is
added to the 3’ terminus [for a complete review of transcription termination
see (89)].
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Nucleosomes represent a barrier to transcription elongation, so they should
be partially ejected and reassembled after the passage of the transcription
machinery (90; 91). In consequence the elongation machinery must posses a
sophisticated array of factors to control chromatin architecture.
When elongation starts, serines 5 and 2 of the CTD of RNA pol II are
phosphorylated. The reactions are catalysed, respectively, by TFIIH and Ctk
kinase. These two modifications of the CTD appear to control the elongation
by promoting the escape of the paused polymerase and are involved in the
alterations of chromatin structure (81; 92; 93). The dynamics of nucleosomes
is regulated during the transcription elongation as depicted in Fig. 1.9. Sev-
eral factors and enzymes participate in this process. The elongation factor
PAF/RTF facilitates the binding of the histone H3K4 methyltransferase Set1
complex (COMPASS), of histone chaperones and, in some cases, of ubiquitin-
transfer enzymes, whereas the methyltransferase Set2 is recruited by Ser2ph
of CTD. All these events result in the accumulation of H3K4me3 at the 5’
end of the ORF and of H3K36me3 at the 3’ end (Fig. 1.9 A). In some genes,
the ubiquitination of H2B also occurs (81; 94). HATs are recruited in front
of RNA pol II and the induced histone acetylation, together with the ac-
tion of histone chaperones, contribute to the disassembly and reassembly of
H2A/H2B dimers from the nucleosomes to destabilize them and facilitate
the processivity of RNA pol II, with the aid of remodellers (95; 96). Finally,
H3K36me3 is recognized by the chromodomain of Eaf3, a subunit of the
Rpd3S deacetylase complex (97), which deacetylate nucleosomes to stabilize
them after transcription (Fig. 1.9 B) (81).
The putative mechanism set out above may explain roughly the complex
machinery required for RNA pol II to perform the synthesis of mRNA during
elongation. Finally, the mature mRNA does not incorporate all the mRNA
synthesized. So, splicing process coexists with transcription elongation (98).
1.2.3 Splicing
The splicing is canonically defined as the process by which the introns of
a gene, transcribed in the nascent mRNA are removed, to obtain a single
messenger RNA formed by exons. This process is carried out by the spliceo-
some, composed by small nuclear ribonucleoproteins (snRNPs: U1, U2, U4,
U5 and U6) and other splicing factors (SFs) (99).
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Figure 1.9: Regulation of nucleosome dynamics during transcription elonga-
tion. A) The chromatin landscape during elongation is determined by the
factors associated with different forms of RNA pol II. B) Maintenance of nu-
cleosomal stability during transcription. The RNA pol II requires other HATs
to acetylate the nucleosome in front of elongation machinery. The passage of
Pol II causes histone displacement, that are redeposited onto the DNA behind
Pol II via concerted actions of histone chaperones. These newly deposited
nucleosomes are somehow hyperacetylated and are immediately methylated
by Set2. Rpd3S removes the acetyl marks and leaves the nucleosome in a
stable state. [extracted from (81)].
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Usually, the short exons are within a nucleosome, and it is believed that
this situation is product of the nucleotide composition of exons and the sur-
rounding introns. This area is also characterized by the presence of some
histone modifications. During the transcription elongation, the RNA pol II
is associated with different SFs, and while transcription machinery is respon-
sible for modular access to DNA, the SFs recognize the splice site (98). The
SFs that are previously associated to the CTD, are detached and bind to the
3’ splice site (3’ SS) of the precursor mRNA (pre-mRNA). After that, addi-
tional SFs are bound at the intronic and exonic splicing regulatory elements
in the 5’ splice site (5’ SS) (Fig. 1.10 A)(100).
The spliceosome recognize the cis-elements in the exon-intron junctions
at the 5’ and 3’ ends (the 5’ SS and 3’ SS), the branch point sequence (BPS,
upstream of the 3’ SS), and the polypyrimidine tract (PPT, between the 3’
SS and BPS) (99). The splice-site recognition is facilitated by the binding
of U1 and U2 snRNPs and these interact with each other to form the pre-
spliceosome (complex A) (102), depending on the helicases Prp5 (pre-mRNA-
processing 5) and Sub2. After this, the preassembled U4-U6-U5 catalysed
by Prp28, is recruited to form complex B (103). This complex is rearranged
to form a catalytically active complex B (complex B*), with the participa-
tion of multiple RNA helicases (Brr2, U5, Snu114 and Prp2) and results in
the release of U4 and U1. Subsequently, the active complex B carries out
the first catalytic step of splicing, generating complex C (104), resulting in
a free exon 1 (Ex1) and the intron-exon 2 loop intermediate. Complex C,
after additional rearrangements, carries out the second catalytic step, lead-
ing to post-spliceosomal complex formation, that contains the lariat intron
and spliced exons. Finally, the spliced product is released, this step being
catalysed by Prp22. The U2, U5 and U6 snRNPs are released and recycled
for additional rounds of splicing (Fig. 1.10 B) (101).
1.2.4 Alternative splicing
The 20,000-25,000 protein-coding genes identified in the human genome
do not explain the large protein diversity in eukaryotic cells (105). Alter-
native splicing is essential in creating this protein diversity by generating
multiple RNA variants from a single gene. It is believed that the 92-94% of
human genes undergo alternative splicing (106).
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Figure 1.10: Step-wise assembly of the spliceosome and catalytic steps of
splicing. A) Nucleosome occupancy marks exons and is coupled to transcrip-
tion [from (100)]. B) Cross-intron assembly and disassembly cycle of the
major spliceosome [from (101)].
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The alternative splicing process is attributed to the recognition and se-
lection of cis-splicing sites in exons and introns. These are exonic splic-
ing enhancers (ESEs) (107; 108), intronic splicing enhancers (ISEs) (109),
exonic splicing silencers (ESSs) (110) and intronic splicing silencers (ISSs)
(111). Recognition of these sites is carried out by the serine/arginine (SR)
proteins, heterogenous nuclear ribonucleoproteins (hnRNPs), polypyrimidine
tract-binding (PTB) proteins, and more. The union of these proteins to their
target sites can promote or repress the use of a splice site (112).
Accordingly, there are a variety of possible types of alternative splicing
that occur during processing of the mRNA. That include the exon skipping
(ES), intron retention/including (IR), alternative 3’ splicing site (A3SS), al-
ternative 5’ splicing site (A5SS), alternative first exon (AFE, or alternative
promoters), polyadenylation alternative site (PAS), mutually exclusive exons
(MXE) (Fig. 1.11) (100). One or more events of alternative splicing, origi-
nate different mRNAs with different functions (isoforms).
Figure 1.11: Types of alternative splicing events [from (100)].
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The mechanism by which the alternative splicing is carried out is not yet
entirely clear, but it is known that the structure of chromatin and epige-
netic modifications are involved (113). There occur organized deposition
of histone modifications across the bodies of transcribed genes. For ex-
ample H2BK5me1, H3K4me1, H3K4me2, H3K9me1, H3K9me2, H3K9me3,
H3K27me1, H3K27me2, H3K27me3, H3K36me3, H3K79me1, H3R2me1, H3
R2me2, H4K20me1, H4K20me3 and H4R3me2 in the exons, and H3K36me1
in the introns of highly expressed genes (114; 115). H3K36me3 is strongly
associated with exonic sequences and correlates with the level of gene expres-
sion and the rate of exon inclusion during alternative splicing. The methyl-
transferase Kmt3a (Set2/Setd2/HYPB) is responsible for the methylation of
histone H3 tails at lysines 36 and together with other factors is part of the
elongating RNA pol II complex (116). These enzymes, along with hnRNP-
L and Aly/Ref1 are recruited by the spliceosome and form a complex that
appear to be responsible for the H3K36 trimethylation (Fig. 1.12 A). Al-
ternative exons in general have lower levels of H3K36me3 than constitutive
exons, although this evidence does not demonstrate that this modification is
related to the exon inclusion (114).
In this respect, two models, that are not mutually exclusive have been
proposed: the kinetic model [see (117; 118)] and the recruitment model. The
firt one proposes that the presence of nucleosomes decreases the speed of
RNA pol II processivity thus allowing more time for splicing to occur. The
recruitment model proposes that alternative splicing is controlled by the fac-
tors recruited by both, the histone modifications at the splicing sites and the
RNA pol II CTD, which can bind these factors before leaving the promoter
(Fig. 1.12 B and C). In this model, the H3K36me3 histone modification is
recognized by different factors causing different results in alternative splic-
ing. In the Fig. 1.12 B, the MRG15 recognises the H3K36me3 mark and
recruits Ptbp1, resulting in exon excluding. While in the Fig. 1.12 C, Psip1
recognise the H3K36me3 mark and recruit SR protein family members (Srsf1
and Srsf3) and promote exon recognition by recruiting the U1 and U2 (114).
Evidently, it is necessary to provide more evidence on the role of the chro-
matin in the alternative splicing order to establish the mechanisms involved.
Given that the ratio of the expression of different isoforms in one or more
genes has been linked to diseases as cancer, understanding this mechanism
could provide new strategies for the treatment of this disease.
23
Figure 1.12: Recruitment model for the control of splicing by H3K36me3
[from (114)].
24
1.3 Cell proliferation
Transcription controls all cellular processes, including cell proliferation
and in turn is influenced by them. Alterations in the DNA sequence, in
isoform expression or transcription machinery in general, can result in the
deregulation of the cell cycle, causing cell apoptosis or uncontrolled cell pro-
liferation (119).
The cell cycle comprises four phases: G1, that comprises the period in
which the cell is preparing to initiate DNA synthesis; S, that comprises the
DNA synthesis; G2, which is a period of time elapse after the cell has com-
pleted DNA replication but before it enters the next phase M, mitosis, which
is the period in which the cell is divided (120). The duration of the cell cycle
is not fixed; some cell populations are subjected to rapid replacement, so that
are in constant division, while others enter a state of cellular quiescence or
senescence and this step is called G0. The senescence is an irreversible event,
whereas the quiescent cells retain the capacity to re-initiate the cell cycle.
In this case, activation of the cell cycle can be rapidly induced by signalling
from the cellular environment (121).
An example of quiescent cells is the liver (122). Most of its cells are in
quiescent state, but the cell cycle is activated fast and synchronously when
a part of the liver is removed by a partial hepatectomy (123). This is a
common surgical practice in patients that either have been diagnosed with a
liver tumour or suffer from a localized liver damage. The partial hepatectomy
result in liver regeneration. The model of liver regeneration is of great interest
in the study of in vivo signaling transduction pathways in the cell cycle and
genes involved in this process, such as immediate early genes.
1.3.1 Signal transduction
The cell is not isolated, is part of the same environment with other
cells to form a tissue, so that extracellular signals influence the intracel-
lular processes. The environment signals can be biological as growth factors
(124); chemical such as drugs or mitogens as 4β-12-O-tetradecanoylphorbol-
13-acetate (TPA) (125); and physical such as UV radiation (126). These
signals are received by membrane receptors that activate intracellular sig-
nalling cascades, leading in turn to transcriptional activation in the nucleus.
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Each combination of factors activate different signalling pathways and cause
different functional results. The study of the signalling pathways responsible
for the response to stress is of special interest, since its deregulation has a
direct relation to the development of diseases (127).
The Mitogen-Activated Protein Kinases (MAPK) cascade, is one of the
most important cascades in the stress response (128). In mammals, MAPK
enzymes have diverse biological functions, including regulation of nucleosome
and gene expression, mRNA stability and translation, and cell proliferation
and survival. These are divided in the conventional MAPKs and atypical
MAPK enzymes. The conventional ones include the extracellular signal reg-
ulated kinases 1 and 2 (ERK1/2), c-Jun amino-terminal kinases 1 to 3 (JNK1,
JNK2, JNK3), p38 (α, β, γ, and δ), and ERK5 families. The atypical enzymes
include ERK3/4, ERK7/8, and Nemo-like kinase (NLK) (129; 130). Activa-
tion of the MAPK cascade or the p38 cascade by mitogens (as TPA), growth
factors, stress, or UV irradiation leads to the activation of MSK1/2 kinases,
which phosphorylate H3S10 in a fast and transient form, and result in the
activation of only a particular group of genes, the immediate early response
genes (34).
1.3.2 Immediate-early genes: the example of Egr1
The Early Growth Response 1 (Egr1 ) gene, also known as TIS8; Zenk;
Egr-1; NGFIA; Zfp-6; ETR103; Krox-1; Krox24; NGF1-A; NGFI-A; Zif268;
Krox-24 and A530045N19Rik, is an immediate early response gene, as c-
Fos, c-Jun and c-Myc. Egr1 is an member of the early growth response
(EGR) family, formed also by Egr2, Egr3 and Egr4 (131). This family
is rapidly, but transiently, upregulated by a wide variety of extracellular
stimuli including activation, growth and differentiation signals, mitogens,
tissue injury and apoptotic signals (132). This gene encode the EGR1 pro-
tein, which is a nuclear phosphoprotein that acts as a transcription factor.
EGR1 contains a highly conserved DNA-binding domain composed of three
zinc fingers that bind to the prototype target GC-rich consensus sequence
GCG(G/T)GGGCG (133).
In an in vitro model, using the hepatocyte progenitor MLP29 cell line
activated with TPA, Tur et al describes that the Egr1 transcription starts
at 5 min and returns to baseline at 180 min after activation, and the level
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of Egr1 mRNA peaks at 45 min. Egr1 promoter contains two clusters of
serum-responsive elements (SRE), cAMP-response element (CRE), the Ets-
like-1 (ELK1) element, an EGR1 binding site (EBS) and two cis-elements for
SP1 (CG box) (Fig. 1.13). The SP1 binds to the site at -49 and maybe to the
canonical site at -277; EGR1 mainly binds the site at -593. The EBS element
in the promoter of Egr1 could be controlling itself cycle of expression. The
extent of CREB, SP1, and EGR1 binding to Egr1 promoter changes with
gene expression (78).
Figure 1.13: Factor binding sites in the Egr1 promoter [from (78)].
Figure 1.14: EGR1 mechanism of activation [from (133)].
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Increased transcription of EGR1 is mediated by the MAPK signalling
pathway. The ERK1/2 family mediates EGR1 expression in response to
growth factors, and a combination of ERK1/2, p38MAP-K and/or JNK is
required to induce Egr1 in response to stress. Some studies show that EBS
is found in the promoter of genes such as p53 and other genes implicated in
cell growth, cancer progression, senescence and apoptosis (Fig. 1.14) (133).
1.4 Human diseases: cancer
The World Health Organization (WHO) defines cancer as a generic term
for a large group of diseases that can affect any part of the body, character-
ized by the uncontrolled growth and spread of cells that arises from a change
in one single cell and which can then invade adjoining parts of the body and
spread to other organs (urlhttp://www.who.int/en/).
Cancer is a leading cause of disease worldwide; about 12.7 million cancer
cases and 7.6 million cancer deaths are estimated to have occurred in 2008
(134). An estimated 14.1 million new cancer cases, with 8.2 million deaths
occurred in 2012 (135). The worldwide burden of cancer continues to in-
crease largely due to the aging and an increasing adoption of cancer causing
behaviors.
Lung, female breast, colorectal and stomach cancers accounted for more
than 40% of all cases diagnosed worldwide. As shown in the figure 1.15,
cancer presents a high range of incidence in countries of Europe, as well as
in the US, Canada and Australia (135).
Despite the impact that cancer has on the world population and efforts
for treatment, there are a large number of questions regarding this disease.
In the last two decades there have been major discoveries that have led to
progress rapidly in understanding the factors causing cancer. It has been
concluded that cancer is, in essence, a genetic disease, because the clonal
accumulation of genetic alterations by the cell allows uncontrolled growth,
evasion of cell death, local invasiveness, and metastatic potential (136; 137).
However, epigenetic changes are also involved in all the processes that lead
to the development of cancer, so their study is of great interest for the de-
velopment of new treatments in this context (138).
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Alterations in three types of genes (oncogenes, tumour-suppressor genes
and stability genes) are responsible for tumourigenesis (137; 139). Oncogenes
are mutated in ways that render the gene constitutively active or active under
conditions in which the wild-type gene is not. Tumour-suppressor genes are
targeted in the opposite, mutations reduce the activity of the gene product.
Stability genes includes the mismatch repair (MMR), nucleotide-excision re-
pair and base excision repair genes responsible for repairing subtle mistakes
made during normal DNA replication or induced by exposure to mutagens.
Mutations in these three classes of genes can occur in the germline, resulting
in hereditary predispositions to cancer, or in single somatic cells, resulting in
sporadic tumours (137).
Figure 1.15: World cancer incidence 2012. Adapted from the World cancer
factsheet 2014 (135).
Due to the great advances in the technologies of genetic study, a large
number of genes involved in cancer have been identified. However, depending
on the type of cancer being studied, new genes involved reappear and the
genes already known change their frequency of occurrence and of the muta-
tions that affect them. However, there is a small group of genes which are
mutated at high frequency in most types of cancer (136; 140).
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1.4.1 Colorectal cancer
Colorectal cancer (CRC) is the third most common cancer worldwide,
with more than 1.36 million new cases diagnosed annually (135). The CRC
incidence rate is rapidly increasing in several areas historically of low risk,
including Spain. Such unfavorable trends are thought to reflect a combina-
tion of factors including changes in dietary patterns, obesity and an increased
prevalence of smoking (134).
Less than 10% of CRC cases are explained by inheritance and approxi-
mately an 90% are sporadic without family history or genetic predisposition.
For the sporadic cases of CRC as well as for other cancers, three main causes
are described. The first one is the chromosomal instability (CIN), that is
observed in 70% of sporadic CRC cases and consist in an accelerated rate of
gains or losses of whole or large portions of chromosomes that results in kary-
otypic variability from cell to cell (141). The second one is the microsatellite
(nucleotide repeat sequences of 1-6 base pairs in length) instability (MSI)
(142), which is caused by dysfunction of MMR genes, leading to genetic hy-
permutability and is found in about 15% of all CRCs. Third is the CpG
island methylator (CIMP) (143), that causes gene silencing due to hyperme-
thylation of CpG islands. These three genetic inevitabilities are not mutually
exclusive and may occur together in certain cases. (141; 144; 145).
The CIN can result from defects in pathways that ensure accurate chro-
mosome segregation. This, also can be driven by telomere dysfunction, in-
hibition of the anaphase promoting complex/C and abnormal number and
function of the centrosome (136; 146). Also the DNA damage response ma-
chinery can be altered, causing a loss of heterozygosity. CIN tumours are
distinguished by the accumulation of a characteristic set of mutations in spe-
cific oncogenes and tumour suppressor genes. It is not clear whether CIN
creates the appropriate environment for the accumulation of these mutations
or vice versa (141; 144). The most common genes mutated in CRC patients
with CIN are APC, PT53 and KRAS, shown in as Fig. 1.16 (136), a few
signalling pathways being the most frequently involved in the development
of cancer.
The earliest genetic event in colorectal tumourigenesis is activation of
Wnt signalling (Fig 1.17), which is disrupted by one or more mutations in
93% of patients (136; 147; 148). The genetic disruption of Adenomatous
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Figure 1.16: Genes most frequently mutated in chromosomal instability. Pro-
file determined from 193 patients with CIN [Extracted from (136)].
Polyposis Coli (APC) gene also is an early event in tumour initiation (Fig
1.18) (149). The APC gene product is a large protein with multiple func-
tional domains that regulates differentiation, adhesion, polarity, migration,
development, apoptosis, and even chromosomal segregation. Somatic APC
mutations are observed in as many as 72% of sporadic tumours. Mutant APC
disrupts complex formation and the increased cytoplasmic levels of β-catenin
(CTNNB1) can translocate to the nucleus, where it drives the transcription
of multiple genes implicated in tumour growth and invasion. Mutations in
β-catenin have been identified in as many as 50% of colon tumours with in-
tact APC (144; 150).
The activation of RTK/RAS/PI3K signalling occurs later (Fig. 1.17),
and this pathway is disrupted in over 80% of patients (136). The mutations
in Kirsten rat sarcoma viral oncogene homolog (KRAS ) are observed in 40%
to 60% of nondysplastic or hyperplastic of aberrant crypt foci, leading to
constitutive activation of RAS downstream signalling (151). RAS regulates
multiple cellular functions through effectors, as the Raf-MEK-ERK pathway.
PIK3CA, one of the main effector pathways of Ras, is mutated in almost 20%
of CRCs activating pathways for the late adenoma to invasive cancer states.
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Figure 1.17: Principal cancer pathways deregulated by somatic mutations in
human CRC. Activated genes in light red. Inactivated genes in light Blue.
Deep red or blue are genes significantly mutated in CRC patients. Alterations
are defined by somatic mutations, homozygous deletions, high level focal
amplifications, and, in some cases, by significant up or down regulation of
gene expression (black up-triangle). Lighter shade genes are not mutated
significantly in this cohort but contribute to pathway disruption in some
patients [Extracted from (136)].
RAS can also induce TP53 and the dysfunction of P53, can activate path-
ways for the development of invasive cancer (see Fig. 1.18) (144; 152). TP53
mutations are reported in 50%-75% of CRCs (144; 153). Other events such
as aberrant overexpression of cyclooxygenase-2 (COX-2 )(43% of adenomas
and 86% of carcinomas) and allelic loss at chromosome 18q (70% of primary
colorectal tumours) also participate in the process of tumourigenesis (144).
Of course, alterations in the expression of the EGF receptor also contribute
to the onset of CRC.
The large amount of information has increased the understanding of the
disease and all the aforementioned genes are potential molecular markers for
CRC diagnosis, prognosis and targeted therapy, but more work remains to
be done in this line.
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Figure 1.18: Multistep genetic model of CRC [Extracted from (144)].
1.4.1.1 Therapy for colorectal cancer
The traditional treatments for CRC are surgery (all stage), radiofrequency
ablation and radiation therapy (stage II, III, IV), chemotherapy (stage II, III,
IV) and at these traditional therapies adds targeted therapy (stage IV and
recurrent CRC). The surgery is the most common treatment for all stages
of colon cancer. If the cancer is found at a very early stage surgery consists
in a local excision of colon for removing the affected zone. If the cancer is
larger, a partial colectomy removing the affected tissue and a small amount
of healthy tissue around it is performed. The radiofrequency ablation con-
sists in the use of a special probe with tiny electrodes that kill cancer cells.
The radiation therapy uses high-energy X-rays or other types of radiation to
kill cancer cells or keep them from growing. The chemotherapy uses drugs
to stop the growth of cancer cells, either by killing the cells or by stopping
them from dividing. The targeted therapy includes monoclonal antibodies
and angiogenesis inhibitors, that attack specific cancer cells without harming
normal cells and are being tested in clinical trials (see http://www.cancer.gov
and http://www.cancer.org) (154).
The targeted therapy is specially interesting because it can act on specific
genetic and/or metabolic dysfunctions present in an individual tumour, in-
creasing treatment efficiency and reducing toxicity. In clinics, for more than
a decade, the targeted therapy most commonly used is represented by mon-
oclonal antibodies against the extracellular domain of the epidermal growth
factor receptor (EGFR) ( Fig. 1.17) (155).
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EGFR, also know as ErbB1 or HER1, is a member of the human EGF
receptor tyrosine kinase family, which further includes HER2, HER3 and
HER4. These transmembrane proteins contain an extracellular ligand-binding
domain. Domains I and III participate in ligand binding; domain II par-
ticipates in homo and heterodimer formation with ErbB family members;
domain IV participate in disulphide bond formation. They also contain a
single membrane-spanning region, a juxtamembrane nuclear localization sig-
nal (NLS), a cytoplasmic tyrosine kinase domain (TKD) and a C-terminal
tail housing several tyrosine residues for propagating downstream signalling
(156).
Under homeostatic conditions, receptor activation is tightly regulated by
the availability of ligands, which collectively form the EGF growth factor
family (157). In the general mechanism for the activation of EGFR, the lig-
and binds to the ectodomains of receptor molecules and induce the formation
of an activated dimerization state. Then the juxtaposed cytoplasmic kinase
domains catalyze the phosphorylation of tyrosine residues (158). EGFR acti-
vation stimulates many complex intracellular signalling pathways. The three
primary ones are the RAS/RAF/MEK/ERK, PI3K/AKT and PLCγ/PKC
axes (Fig. 1.19)(156).
The deregulated EGFR activity has been linked to the development, pro-
gression and metastatic spread in most types of cancer, including CRC. Ef-
forts have focused to develop inhibitors that effectively target to EGFR,
because the over-expression, increased activity or mutations of EGFR may
be a causative factor in the etiology of human epithelial cancers. This is the
case of monoclonal antibodies Cetuximab, which was approved in 2004 by
US Food and Drug Administration (FDA), and Panitumumab, which was
approved in 2006 by FDA (158).
Cetuximab and Panitumumab are monoclonal antibodies that bind the
extracellular segment of the tethered inactive state of EGFR and directly
blocks activating ligand binding, thereby limiting the activation of several sig-
nal transduction pathways downstream from EGFR including Ras/Raf/MEK
/ERK1/2, PI3K/Akt, and protein kinase C (Fig. 1.19) (155; 158). Rego-
rafenib is a multi-protein kinase inhibitor also used in some cases. This is
approved for the treatment of patients with metastatic CRC (mCRC) that
had been treated previously with all standard therapies (158).
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The combination of targeted therapy with chemotherapy in patients with
KRAS-wild-type liver metastases has further extended tumour response rate
to more than 70%. The overall survival (OS) also results favourable when
compared with chemotherapy alone (155). However the targeted therapy is
not effective in all patients and the prognosis for patients with mCRC remains
poor. For the patients treated with cetuximab therapy, the median OS and
progression-free survival (PFS) are 20 and 13 months, respectively (159).
Moreover, many studies show that the CRC patients with mutations in KRAS
gene are not favoured by this treatment, and the survival do not increase,
when being treated with anti-EGFR antibodies alone or in combination with
chemotherapy. Therefore, it is evident the need of obtaining new targets for
the therapy against CRC (156; 158; 160; 161).
Figure 1.19: Selected signalling pathways targeted by clinical therapeutic
agents [Extracted from (155)].
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1.4.1.2 Epigenetic therapy of cancer
As discussed above, the development and progression to cancer usually are
attributed to the mutations in tumour suppressor and oncogenes. However,
the epigenetic machinery also has an essential role. In fact, it has been
shown that the epigenetic deregulation may provoke aberrant gene expression
patterns that give rise to all typical cancer characteristics (138). In this
sense, the genetic alterations in the elements implicated in the regulation of
chromatin can alter the epigenetic landscape, resulting in an initiation or
maintenance of the cancer (162; 163).
Consequently, currently exist a first generation epigenetic therapies ap-
proved by the FDA. These include those targeting the DNA methyltrans-
ferases, histone deacetylases, and Janus kinase 2 (JAK2). However, these
therapies alter non-specifically the epigenomic landscape and may have un-
wanted side effects (164). So, new epigenetic therapies are being developed
in preclinical and clinical stages. These include inhibitors of the enzyme
poly ADP ribose polymerase (PARP), lysine-specific histone demethylase
1A (KDM1A), CBP/EP300 and others (162).
Despite these promising developments, there are still many questions to
be answered. For instance, it would be desirable to found mechanisms that
allow a gene-specific epigenetic regulation.
1.4.1.3 Kirsten rat sarcoma viral oncogene homolog
The KRAS gene, also know as NS; NS3; CFC2; KRAS1; KRAS2; RASK2;
KI-RAS and C-K-RAS, is a proto-oncogene member of the Ras gene family
which consists of three members: KRAS, NRAS and HRAS. KRAS gene is
located on the short arm of chromosome 12 at position 12.1 (Chr12:25358180-
25403870, GRCh37) and encodes a 21 kD guanosine triphosphate/guanosine
diphosphate binding protein, which is a member of the small GTPase super-
family. This contains over 154 members, classified in five subfamilies: Ras,
Rho, Rab, Arf and Ran (161; 165).
Ras protein family is formed by four protein members NRAS, HRAS,
KRAS4A and KRAS4B (Fig. 1.20) (166). They consist of a G domain, rang-
ing from amino acids 1 to 165 and C-terminal hypervariable domain, from
amino acids 165-188/189. The G domain includes the phosphate-binding
loop (P loop), from amino acids 10 to 16, which binds the γ-phosphate of
GTP; the switches I (from amino acids 32 to 38) and II (from amino acids
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59 to 67), which regulate binding to Ras regulators and effectors. The first
85 amino acids are identical in all proteins and are responsible for the bind-
ing of guanosine diphosphate (GDP) and guanosine triphosphate (GTP).
The next 80 amino acids (85-165) show 85-90% sequence identity. The
C-terminal hypervariable domain specifies membrane localization through
post-translational modifications. This modifications include the farnesyla-
tion of each isoform on the C-terminal CAAX motif (CVLS, CVVM, CIIM
and CVIM, see Fig. 1.20) and palmitoylation of key cysteines on HRAS,
NRAS and KRAS4A (165).
Figure 1.20: Members of Ras protein family, representing the G domain
(functional areas are shown in blue and the rest in light blue) and C-terminal
hypervariable domain (light brown). A box at the bottom of each isoform
shows the conserved residues in magenta and the variable residues in pink.
Somatic RAS mutations found in cancer introduce amino acid substitutions
at positions 12, 13 and 61.[Extracted from (165)].
The Ras proteins performed the cycle between inactive guanosine diphos-
phate (GDP)-bound (Ras-GDP) and active guanosine triphosphate (GTP)-
bound (Ras-GTP) conformations, at cellular membranes. They transmit
signals originating from extracellular stimuli, such as growth factors, which
bind to cell-surface receptors and result in activated receptor complexes.
These complexes contain adaptors such as SH2-containing protein (SHC),
growth-factor-receptor bound protein 2 (GRB2) and GRB2-associated bind-
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ing (Gab) proteins. These proteins recruit SHP2 and SOS1, the latter in-
creasing Ras-GTP levels by catalysing nucleotide exchange on Ras. The
GTPase-activating protein (GAP) neurofibromin (NF1) binds to Ras-GTP
and accelerates the conversion of Ras-GTP to Ras-GDP, which terminates
signalling. GTP-bound Ras can interact productively with more than 20
effectors, including Raf (BRAF, ARAF and RAF1) and PI3K, to regulate
various cellular responses as proliferation, survival and differentiation (see
Fig. 1.21). In this manner, the degree and duration of Ras activation influ-
ences cell fate decisions (151; 153; 165).
Figure 1.21: The Ras signalling pathway highlights proteins affected by mu-
tations in developmental disorders and cancer [Extracted from (165)].
Mutations in KRAS account for 86% of the RAS mutations found in
CRC (167) with an incidence of approximately 15% in all human tumour
types (168) and 30-50% in CRC (169; 170). Oncogenic missense mutations
at codons 12 and 13 account for the majority of activating mutations and
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there also are some less common mutations in codon 61, 63 and 146 (<5%
of total KRAS mutations) (171; 172).
KRAS mutations in codons 12 and 13 of exon 2 (Fig. 1.22) limit the use
of anti-EGFR therapies Cetuximab or Panitumumab to around 50% of pa-
tients with mCRC. In wild type KRAS proteins, glycine occupies positions 12
and 13. The corresponding codons are frequently changed in mutant KRAS,
the most common mutations being G12V, G12D and G13D (172).
The KRAS mutations in codon 12 and 13 lead to alterations in encoded
amino acids in the P loop, adjacent to the GDP/GTP binding pocket (Fig.
1.23). This change results in the projection of larger amino acid side chains
into the GDP/GTP binding pocket of the protein, interfering with GTP
hydrolysis due to steric hindrance (172). The strongly attenuated GTPase
activity cause KRAS to accumulate in the active GTP-bound state, resulting
in constitutive activation of downstream signalling, independent of external
signals (growth factor independence) and anti-EGFR antibodies (170; 173).
Figure 1.22: Types of KRAS mutations at codons 12 and 13 [adapted from
(174)].
Recent studies have shown that different mutations in KRAS and the
interaction of these with mutations in other oncogenes, have different reper-
cussions on signalling pathways and in the response of CRC to treatment
(172; 173; 175). There remain to be solved, however, many questions con-
cerning the ultimate consequences of that alteration of the signaling path-
ways. Moreover, it is also noteworthy that although mutations that affect
to KRAS gene are well characterized, the epigenetics of this gene is poorly
studied.
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Figure 1.23: Structural analysis of of GTP-binding residues in the (A) WT,
(B) G12D and (C) G13D KRAS mutated proteins. The images were gener-
ated by the PyMOL software [Extracted from (172)].
1.5 RNAseq and bioinformatics approach
The bioinformatics is a critical discipline after the human genome project
since the large information generated needs to be stored and analysed (176).
Moreover, the biological information generated with the new sequencing tech-
nologies started the omics era, being the genomics, transcriptomics, and pro-
teomics the main ones (177). The omics term refers to the global study
of DNA (genomics), RNA (cDNA state, transcriptomics), proteins (pro-
teomics), epigenetic modifications (epigenomics), among others (178). This
era highlights the need for using bioinformatic tools for maintenance and
analysis of information (179).
Due to the advances in sequencing technologies and in bioinformatics,
there have been major international collaborative projects that seek to decode
the genome. Among these projects, there is the haplotype map of the hu-
man genome (HapMap: http://hapmap.ncbi.nlm.nih.gov/) (180), to create
a catalog of common genetic variants that occur in human beings; the Ency-
clopedia of DNA Elements (ENCODE: http://genome.ucsc.edu/ENCODE/)
project (181), whose objective was the identification of all functional elements
in the human genome sequence; the 1000 genomes project (http://www.1000
genomes.org/), which aims at obtaining a deep characterization of human ge-
netic variations that have a frequency of at least 1% in the study populations
(182); the Catalog of Somatic Mutations in Cancer (COSMIC: http://cancer.
sanger.ac.uk/cosmic), which is currently the most comprehensive global re-
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source for information on somatic mutations in human cancer; and The Can-
cer Genome Atlas (TCGA: http://cancergenome.nih.gov/), which is a com-
prehensive and coordinate effort to accelerate our understanding of the molec-
ular basis of cancer through the application of genome analysis technologies,
including large-scale genome sequencing (183). Besides these big interna-
tional consortia, research groups around the world must publish the omics in-
formation obtained in the respective databases. Among these databases, the
National Center for Biotechnology (NCBI: http://www.ncbi. nlm.nih.gov/),
is currently the most used one. The NCBI provides access to most of the
biological information obtained in the last two decades. It also has bioinfor-
matic tools for managing and analysing this information.
Moreover, in recent years new technologies have been developed and with
them, new bioinformatics tools for their analysis. In this respect, in 2006 a
second generation technique for sequence the entire transcriptome, namely
the massively parallel sequencing of RNA (RNAseq) in form of cDNA, was
incorporated (184). The transcriptome study began in the late 90s with the
development of microarray technologies. These studies only gave a quanti-
tative measurement of the expression of the genes known at that time, thus
allowing the comparison of the differences in their expression under two or
more conditions. Whith the RNAseq is not only possible to compare tran-
script levels in different conditions, but also to know the sequence of the
transcribed cDNA. This was an important step in the large-scale study of
alternative splicing, which allowed the discovering of new isoforms and their
quantification. All these results gave valuable information in the study of
the occurrence of alternative splicing in cancer cells (185; 136).
Nonetheless, the complexity of the bioinformatic analysis of RNAseq rep-
resents a barrier in the study of the transcriptome. One challenge is to
efficiently map the readings of 25-50 bp throughout the entire genome, be-
cause these fragments also contain exon-exon junctions, exon-intron, exon
and intron breaks. In this context, the process should allow the identifica-
tion of these events for a proper analysis of the data. Since 2006 algorithms
that allow reliable analysis of information have been developed. However,
these algorithms initially were unreliable and were computationally expen-
sive (186).
In 2010 Trapnell and collaborators put at the disposal to the scientific
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community, a RNAseq analysis protocol. This protocol consists of using of
Bowtie software to index the reference genome; TopHat software to align
the sequences in the reference genome; Cuﬄinks software to estimate the
abundance of each transcript in a sample; Cuffmerge software to have a
reference genome coordinates with associated transcripts in two samples or
more; Cuffdiff software to compare the abundance of genes and isoforms be-
tween two or more samples; and Cummerbund R package, to allow sorting
the information and entering it into R (the software for statistical data analy-
sis) (187). The RNAseq analysis allows studying the differences between the
transcriptome of two or more cell conditions at the level of a single mutation.
These studies gave a quantitative measurement of the expression of the genes
known at that time, thus allowing the comparison of the differences in their
expression under two or more conditions. In this way a relationship between
the presence of mutation and the changes in gene expression that directly or
indirectly are being affected may be established.
After the development of these technologies, and in conjunction with ge-
nomic studies (such as mutations and identification of regulatory elements
in the DNA sequence) it is possible to study the profiling of cancer molecu-
lar expression. A large number of oncogenes, tumour suppressor genes and
stability genes were identified and their frequency of occurrence in various
cancers, including CRC (177), were established (136). Moreover, epigenomics
studies identified the occurrence of histone modifications, methylation areas,
the presence of remodellers and other regulatory elements throughout the
genome (by ChIP-seq, bisulphite, etc.)(188; 189).
The unification of the omics, creates an overall landscape of the mech-
anisms involved in cancer. Moreover, by including network studies, it is
possible to know the effects of each alteration in signalling pathways. All in-
formation generated is stored in specialized databases such as NCBI, GEO,
SRA, among others. These data are at the disposal of the scientific commu-
nity for analysis with new tools or to test new hypotheses.
The power of these new study strategies allows to elucidate the mecha-
nisms by which a single mutation in synergy with other, may alter cellular
regulation. In this way, bioinformatic tools provide a valuable method to
identify novel therapeutic targets by means of in silico analysis that allow to
predict the possible in vitro effects.
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CHAPTER 2
OBJECTIVES
It is widely accepted that any approach to understanding the mechanisms
of transcriptional regulation in eukaryotes has to take into account that nu-
clear DNA is organized in the complex structure of chromatin. When going
from an inactive to an actively transcribing gene, its chromatin structure
has to be remodeled to allow the binding of many regulatory protein factors,
as well RNA polymerase processivity. Along with nucleosome remodeling,
histones acquire precise and definite epigenetic marks to allow transcription
of a gene.
Recent genome-wide studies have allowed us to obtain a general knowl-
edge of the landscape of these processes, but to gain a more profound insight
on the molecular mechanisms involved it is necessary to study the structural
and epigenetic fate of individual nucleosomes.
The present work was aimed at the study of the regulatory mechanisms of
gene expression at mononucleosomal level. Two aspects of these mechanisms
were specifically studied. First, the changes occurring in the promoter, as
they are of decisive importance for transcriptional initiation. Secondly, the
mechanisms involved in the regulation of alternative splicing, which, in turn,
involve in many cases the escape of RNA polymerase from a paused complex
and the coupling between RNA polymerase processivity and splicing.
To achieve these objectives the following tasks will be developed:
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To study the chromatin changes occurring in
the promoter of a gene through the implemen-
tation of a methodology for the study of posi-
tioning and epigenetic modifications at mononu-
cleosomal level.
For this first general objective the murine Egr1 gene was selected given
that previous research carried out in our laboratory has characterized many
aspects of the architecture of its promoter, including the fine analysis of factor
binding and the gross changes in epigenetic marks. These circumstances
make this gene the material of choice to start studying the methodology to
detect the transcription-related temporal changes in nucleosome occupancy
and in epigenetic marks at mononucleosome level. Two models of induction
of Egr1 gene transcription will be used.
1. In an in vitro model with treatment of mouse cell line MLP29 with
TPA:
(a) To determine the position of nucleosomes on the proximal pro-
moter and the start of the transcribable region in the transcription
cycle of Egr1 gene.
(b) To study the effect of Egr1 knockdown on the position of individ-
ual nucleosomes in the promotor of this gene.
(c) To analyse the temporal changes of histone modifications in indi-
vidual nucleosomes on the proximal promoter and the start of the
transcribable region of Egr1 gene.
2. In an in vivo model of liver regeneration after partial hepatectomy in
mice:
(a) To check whether the methodology for nucleosomal positioning
used in the in vitro experiments can be extrapolated in vivo.
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(b) To compare the position of nucleosomes with the in vitro model
in the studied region.
To study the positioning and epigenetic modi-
fications in genes with altered alternative splic-
ing events in CRC cell lines depending on KRAS
mutational status.
The disregulation of alternative splicing is involved in many pathologi-
cal processes, including cancer. Our group is currently working in a project
devoted to the investigation of the influences of the KRAS mutation in the
resistance to anti-EGFR drugs in CRC. Preliminary data suggest that some
epigenetic patterns and chromatin structure changes may influence onco-
genicity by affecting alternative splicing. In this way, the study of the reg-
ulatory mechanisms of alternative splicing at a chromatin level has especial
relevance.
The specific objectives are:
1. To identify by in silico RNAseq analysis of genes showing differential
isoforms produced by alternative splicing in CRC cell lines related to
KRAS mutation.
2. To select, from the above list of genes, those with greater interest in
translational oncology and to verify the differential level of isoforms in
cell lines that differ in KRAS mutation status.
3. To study the chromatin structure and epigenetic modifications in the
regions where alternative splicing of the selected genes take place.
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To study the structure and epigenetic modifi-
cations of chromatin in the regions involved in
alternative splicing of KRAS gene in CRC cell
lines.
It has been described that the transcription of KRAS gene produces two
isoforms by alternative splicing, which are translated to proteins differing in
their subcellular location and function. It is known that the higher the ratio
KRAS 4B/KRAS 4A the poorest the prognostic in CRC patients. These
reasons led us to include the analysis of structure and epigenetic marks of
chromatin in the region of KRAS involved in the alternative splicing.
The specific objectives are:
1. To determine the levels of expression in CRC cell lines of the KRAS
isoforms generated by alternative splicing.
2. To study the nucleosome occupancy and histone epigenetic modifica-
tions in the region of exons 5, 6 and 7, involved in the alternative
splicing events.
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CHAPTER 3
MATERIALS AND METHODS
3.1 Cell lines
3.1.1 Cell culture
The mouse progenitor hepatocyte cell line MLP29, was grown in Dulbec-
cos Modified Eagles Medium (DMEM) (Sigma) supplemented with 10% heat
inactivated fetal bovine serum (FBS) (Gibco), 1% penicillin-streptomycin so-
lution (Sigma) and 1% fungizone (Gibco).
The human colorectal carcinoma parental cell line HCT116 (ATCC CCL-
247) derived from epithelial tissue of adult male, was grown in McCoys 5A
Medium (Sigma) supplemented with 10% heat inactivated FBS, 1% penicillin-
streptomycin solution and 1% of L-glutamine (Sigma). This line has a muta-
tion in codon 13 of the KRAS proto-oncogene (+/G13D) and in codon 1047
of the PIK3CA proto-oncogene (+/H1047R). The human colorectal carci-
noma isogenic cell line HAE6 (-/G13D) and HAF1 (+/-), a generous gift
from Dr. Bert Volgestein, were grown in the same medium.
The human colorectal adenocarcinoma parental cell line DLD-1 (ATCC
CCL-221) derived from epithelial tissue of an adult male, was grown in Mc-
Coys 5A Medium (Sigma) supplemented with 10% heat inactivated FBS,
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1% penicillin-streptomycin solution and 1% of L-glutamine. This line has a
mutation in codon 13 of the KRAS proto-oncogene (+/G13D), in codon 545
and 549 of the PIK3CA proto-oncogene (+/E545K; D549N) and in codon
241 of the TP53 proto-oncogene (+/S241F). The human colorectal adeno-
carcinoma isogenic cell line DMUT1 (-/G13D) and DWT7 (+/-) a generous
gift from Dr. Bert Volgestein, were grown in the same medium.
The human colorectal carcinoma cell line RKO (ATCC CRL-2577), was
grown in DMEM supplemented with 10% heat inactivated FBS, 1% penicillin-
streptomycin solution and 1% of L-glutamine. This cell line has a mutation
in codon 600 of the BRAF proto-oncogene (+/V600E) and in the codon 1047
of the PIK3CA proto-oncogene (+/H1047R).
The human colorectal adenocarcinoma of epithelial cell line Caco-2 (ATCC
HTB-37), was grown in DMEM supplemented with 10% heat inactivated
FBS, 1% penicillin-streptomycin solution (Sigma) and 1% of L-glutamine.
This cell line has a mutation in codon 204 of the TP53 proto-oncogene
(+/E204X).
The human colorectal adenocarcinoma cell line SW48 (ATCC CCL-231),
was grown in RPMI-1640 Medium (Sigma) supplemented with 10% heat in-
activated FBS, 1% penicillin-streptomycin solution and 1% of L-glutamine.
This cell line is derived from epithelial tissue of an 82 years female and is not
mutated in the proto-oncogenes.
Cells were grown at 37◦C in a humid atmosphere containing 5% CO2. For
cell maintenance, subcultures were prepared from 1:5 to 1:10 dilutions when
confluence was near the 90%. This procedure was performed by aspirating
the medium and washing with PBS (Sigma); the cells were afterwards peeled
off with 0.25% trypsin-EDTA 1X (Gibco) and resuspended in medium.
3.1.2 Cell cryopreservation
The cells were detached by trypsinization and resuspention in medium and
recovered by centrifugation at 400 g for 4 min at room temperature. The
pellet was then resuspended in FBS with a 10% DMSO (Sigma). Cells were
then stored in cryovials and placed at -80◦C for 1 day in a container with
isopropanol (to decrease the temperature slowly, around 1◦C/min), before
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being placed in a liquid nitrogen tank for long term storage.
3.1.3 Cell defrosting
The cryovial was removed from the liquid nitrogen tank and thawed
quickly in a 37◦C water bath. Cells were then resuspended in 10 ml of
warm medium (37◦C) in order to dilute the DMSO as soon as possible and
the suspension was centrifuged at 400 g for 4 min, resuspended in 12 ml of
medium and cultured. The next day, when cells were attached to the plate,
the medium was removed and replaced by fresh one.
3.1.4 MLP29 treatment with TPA
MLP29 cell line was treated with TPA, to induce the Egr1 gene activation.
In this case, 1.5x106 cells were plated in 75 cm2 flasks and and grown to 70%
confluency. The cells were washed with PBS and the medium was changed
for DMEM supplemented with 0.5% FBS, 1% penicillin-streptomycin and
1% fungizone. After 20 h, the cells were treated with 50 nM TPA (78) for
5, 15, 30, 60 and 180 minutes. The control without TPA was called time 0.
3.2 Animals
3.2.1 Animal characteristics and care
For in vivo experiments, adult mice (8-10 weeks) of the CD1 strain were
held at 22◦C with a 12 h light/12 h dark cycle and fed ad libitum with free
access to water. Animals were cared for and handled in conformance with
European Union guidelines.
3.2.2 Partial hepatectomy
Liver regeneration was triggered by partial hepatectomy, by removing
the median and left lobes after ligation under light isoflurane anaesthesia.
The method is based on the classical technique implemented by Higgins and
Anderson in 1931 [for a method description see (123)]. The remnant livers
were removed at various times. Sham-operated control animals were treated
in a similar way, but the ligations and lobe removal were omitted. All the
procedures involving live animals were performed in a properly equipped
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operating room. The study was approved by the Ethical Research Committee
of the University of Valencia.
3.3 Total RNA extraction
For the RNA extraction 100 mg of tissue were homogenized in a Potter-
Elvehjem homogenizer in 1 ml of Trizol (Ambion). For cell lines, 1 ml of
Trizol per 10 cm2 of surface area culture dish was added directly to the
cells in the culture dish. The cells were homogenized by vortexing for 20 s.
Subsequently, 200 µl of cold chloroform were added, and the suspension ho-
mogenized by vortexing for 20 s, incubated 15 min at room temperature and
centrifuged at high speed at 4◦C. The aqueous phase was transferred (in ice)
to a new tube, 1 volume of cold isopropanol was added, mixed and incubated
10 min at room temperature. This was centrifuged 15 min at 1700 g at 4◦C.
The supernatant was removed and 1 ml of cold 75% ethanol (prepared with
sterile water for RNA) was added. This mixture was vortexed to float the
pellet (5 s) and centrifuged 15 min at 1700 g at 4◦C. The supernatant was
removed, the pellet was dried at room temperature, resuspended in sterile
deionized water and stored at -80◦C.
3.4 Genomic DNA extraction and sonication
For the genomic DNA extraction, 3x107 cells were lysed in 300 µl of di-
gestion buffer [10 mM Tris-HCl pH 8,0; 100 mM NaCl; 0.5% SDS (p/v); 25
mM EDTA; 100 µg/ml proteinase K] and incubated at 50◦C under stirring
for 15 h. For purification of DNA, 1 volume of phenol: chloroform: isoamyl
alcohol (25:24:1) was added and centrifuged 10 min at 1700 g. The aqueous
phase was transferred to a new tube and the DNA was precipitated with 1/2
volume of 7.5 M ammonium acetate and 2 volumes of 100% ethanol, washed
with 70% ethanol, dried and resuspended in deionized sterile water (190).
For genomic DNA extraction from regenerating liver, 100 mg of tissue
were grinded in 1.2 ml of digestion buffer and processed as above.
Genomic DNA was sonicated with 8 pulses of 10 s each at amplitude of
35% in a Vibra cell sonicator (SONIC) and genomic DNA fragments of an
average size of 300 bp were obtained.
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3.5 Isolation of mononucleosomes
To isolate mononucleosomes from cell lines, they were fixed with 1%
formaldehyde in PBS by shaking gently at room temperature for 5 min.
The reaction was stopped with 1.5 M glycine (final concentration 0.125 M)
and the suspension was shaken at room temperature for 5 min. Cells were
collected, washed with cold PBS, and resuspended in cell lysis buffer [10
mM Tris-HCl pH 7.5; 100 mM NaCl; 3 mM MgCl2; 30 mM sucrose; 10
mM EDTA; 0.5% (v/v) Nonidet P-40] supplemented with 2 µl/ml protease
inhibitors (Sigma). Cells were lysed in a manually operated Potter-Elvehjem
homogenizer, and they were allowed to stand at 0◦C for 15 min. The 500 g
sediment (5 min) was resuspended in washing buffer [15 mM Tris-HCl pH
7.5; 15 mM NaCl; 3 mM MgCl2; 60 mM KCl; 20% (v/v) glycerol]. The
nuclear fraction was digested with 25 units of micrococcal nuclease (MNase)
(Roche Applied Science) per A260 unit to give a nuclease concentration of
500 units per ml of a washing buffer supplemented with 3 mM CaCl2. Diges-
tion was carried out for 15 min at 37◦C and, for the nucleosome occupancy
experiment, it was stopped by adding EDTA to 10 mM and treated with
5 µg/ml RNase for 1 h at 60◦C. After that, the sample was treated with
200 µg/ml of proteinase K for 1 h at 60◦C and then was purified using the
GeneJET PCR Purification Kit (Fermentas).
To isolate mononucleosomes from regenerating liver, the remaining lobes
of the hepatectomized animals were removed and immediately fixed for 15
min at room temperature with 1% formaldehyde in PBS with gentle shaking.
After stopping the reaction with 0.125 M glycine (final concentration) in PBS
for 5 min, the liver fragments were rinsed and suspended in 10 ml of PBS with
2 µl/ml protease inhibitor mixture (Sigma). Fixed livers were homogenized
in a Potter-Elvehjem tissue grinder. The homogenate was filtered through
gauze and centrifuged at 3000 g for 5 min. The cell pellet was suspended in
cell lysis buffer and processed as above.
3.6 Nucleosome occupancy
To investigate nucleosome occupancy, a MNase protection assay was per-
formed. DNA isolated from mononucleosomes (see section 3.5) was used as a
template for quantitative PCR. Primers were designed to amplify amplicons
of about 60-120 bp along the promoter and coding region. The amplicons
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were identified by the position of their center relative to the TSS.
The corresponding primers and amplicon sizes for Egr1 nucleosome oc-
cupancy are given in the Table 3.1. The primers for ZNF518B are given in
the Table 3.2 and for KRAS in the Table 3.3.
To correct for the different efficiency of the primers, the results were
normalized using the data obtained with genomic DNA, sonicated to an
average size of 300 bp.
Amplicon Forwad Reverse Size (pb) From To
+405 TACCCCAAACTGGAGGAGATGAT GCAGCACCGAGGAACTGG 62 bp +375 +437
+305 CCACCCAACATCAGTTCTCC GTGGGTGAGTGAGGAAAGGA 119 bp +246 +365
+241 GTGTGCCCTCAGTAGCTTCG GCGAGCTGGAGAACTGATGT 64 bp +209 +273
+171 GGGGCCCACCTACACTCC GTTGGCCGGGTTACATGC 58 bp +142 +200
+60 CGAGAGATCCCAGCGCGCAG TGGTGGACGCAGGGCTGCC 119 bp -1 +118
-69 GCCGGTCCTTCCATATTAGG TCAAGGGTCTGGAACAGCAC 90 bp -114 -24
-126 GTGCCCACCACTCTTGGAT GCAGGAAGCCCTAATATGGA 80 bp -166 -86
-178 GCTTTCCAGGAGCCTGAGC AGCCCTCCCATCCAAGAGT 81 bp -218 -137
-240 GGCAAGCTGGGAACTCCA AGGCTCCTGGAAAGCCTAGT 75 bp -277 -202
-307 CGCCTTATATGGAGTGGCCC CTGGAGTTCCCAGCTTGCC 96 bp -354 -258
-342 CGCCGGAACAGACCTTATTT CTCCCAGAGCCGGAAGC 77 bp -380 -303
-373 GACCCGGAAACGCCATATAAG CCATATTGGGCCACTCCATATAAG 91 bp -418 -327
-425 CTCCCAGTTGGGAACCAAG GGGATCCTTCCTGCTCCTTA 88 bp -470 -382
-494 CCGCGCGCCCAGCTCTAC CCTCCTTGGTTCCCAACTG 93 bp -540 -447
-550 GCCTGGGCTTCCCTAGC CCAGGCGCGTAGAGCTG 73 bp -586 -513
-600 CCAGGATGACGGCTGTAGAA CGAGCTGGGCTAGGGAAG 78 bp -639 -561
-666 TCTGCCCTAGCCCGCCCTGCC TTCTACAGCCGTCATCCT 94 bp -620 -714
-746 GCCTCAGTTTTCCCGGTGACA AGGGCGGGCTAGGGCAGAGGC 102 bp -696 -798
-787 TGCTAGCTAGGCAGTGTCCCAA GCCCTGACCTGAGCCTCTACTAAT 108 bp -734 -842
Table 3.1: Primers used for qPCR of Egr1 nucleosome ocupancy.
Amplicon Forwad Reverse Size (pb) From To
11285 TTCATGATTTGGCTAAAGTGGTC ACAGAGTTGGCAAGTAAGCCTAA 81 bp 10645 10726
11318 TAGGGGGCTGAGTTTGAAAATGT AACGTATGATTTTAGACGCATGTT 91 bp 10673 10764
11387 AACATGCGTCTAAAATCATACGTT AAGAGTTTGGCTAAGCTATTAACAA 95 bp 10740 10835
11466 TGTTAATAGCTTAGCCAAACTCT TGCATGATCCCAAAATATGACTGC 113 bp 10810 10923
11493 TTGTTTTCCTTTAGTGTTACCTGG CAGTAGGTGCATGATCCCAAAAT 73 bp 10857 10930
11549 GGATCATGCACCTACTGCGG TAGGGGCGCAGCTACTTCTT 76 bp 10911 10987
11621 GCCCCTACCCATCACAAACT GAGCCAACTAAAATTCAGAAAGT 82 bp 10980 11062
11693 AGTTGGCTCTTTTTAGAAATGCAGA TATGTCCGCCGTTCAAGTGT 81 bp 11053 11134
11752 CTACACACTTGAACGGCGGA GTCTATTTGGCCGAGGTGCT 84 bp 11110 11194
11768 TCCTTGACCATGTCACCCAAAC GCTTCTTGTCTATTTGGCCGAG 65 bp 11136 11201
11808 ATGCTAATGGAGCACCTCGG ATGGTCATCATGGCAGCCTC 88 bp 11164 11252
11878 AGGCTGCCATGATGACCATT CCTTCCCTGTACCCTTCTGC 90 bp 11233 11323
11946 GGTACAGGGAAGGACGGTATG AAAATGAAAATTGGGAGGAGCTG 72 bp 11310 11382
11988 GTGCAGCTCCTCCCAATTTTC TTTATTTCCAACATGAGTCGCAC 65 bp 11356 11421
12061 AAACTTCTCAAGTTCTGTCAATAGC TATCACAATAGTATTTGCCTGGCT 71 bp 11426 11497
12101 GGAACTTTAAGCCAGGCAAATAC CTTTTTGTACTGCAGCGGGTC 74 bp 11464 11538
Table 3.2: Primers used for qPCR of ZNF518B nucleosome ocupancy.
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Amplicon Forwad Reverse Size (pb) From To
25606 TGAGAGAGATACAAGGTTTCTGTT TCCACTACACCAAATTTTCCTTCC 84 bp 25564 25648
25675 TTTGGTGTAGTGGAAACTAGGAA TCTTTCAAAACCTGTCCACAACT 82 bp 25634 25716
25746 AGTTGTGGACAGGTTTTGAAAG ACATCTTCAGAGTCCTTAACTCTT 106 bp 25693 25799
25819 GGACTCTGAAGATGTACCTATGGTC TGTGTCTACTGTTCTAGAAGGCAA 70 bp 25784 25854
25885 ACACAAAACAGGCTCAGGACT TCTTGTCTTTGCTGATGTTTCAA 71 bp 25850 25921
25898 GCTCAGGACTTAGCAAGAAGT TCAGTGTTACTTACCTGTCTTGT 77 bp 25860 25937
26010 CTGTTTTCTGCAAAATCATAACTGT CAATGCCCTCTCAAGAGACAA 120 bp 25950 26070
26102 GTCTCTTGAGAGGGCATTGCT ACATGTGCTCAGAATTGAAGAGA 103 bp 26051 26154
35757 ACCTGTGTTTAGGCTTGTCAT TGGGCTAGAATCCTGGTTTGTT 113 bp 35701 35814
35814 ACTGACTTTTAAGAACAAACCAGGA TGTTTGAATAAAACTGAGGATGCAG 70 bp 35779 35849
35853 ACAAACCAGGATTCTAGCCCA GCCATGTGCAAGAAGTTTGAGA 120 bp 35793 35913
35961 CTTGCACATGGCTTTCCCAG TTGTCGGATCTCTCTCACCA 120 bp 35901 36021
36009 TGTGTTTTACAATGCAGAGAGTG AGGAGTCTTTTCTTCTTTGCTGA 101 bp 35959 36060
36112 AGACTCCTGGCTGTGTGAAAAT GTGGTTGCCACCTTGTTACCT 120 bp 36052 36172
36156 TAATTTTGGCAGAAAGCAGATGTC ACACCTAAGTAGTTCTAAAGTGGTT 70 bp 36121 36191
41350 GACTTAGGTTTGCCAATGTGGA AGGATAACCAATGGCACAGAA 97 bp 41302 41399
41386 GTTCTCCTGTGAAAAAGTCG ACAGGAACACTAATTTTCAC 84 bp 41344 41428
41420 CTGTGCCATTGGTTATCCTTGT CATCCGCATAGGTGTTTTGTCA 78 bp 41381 41459
41479 ACAAAAACCTATGCGGATG TCTCTTCAGGCAACTGAA 79 bp 41440 41519
41545 TTCAGTTGCCTGAAGAGA TAGCTTCATGTGTACAGG 90 bp 41500 41590
41600 CCTGTACACATGAAGCCATCGT AAGGCATCATCAACACCCTGA 75 bp 41563 41638
41659 TCAGGGTGTTGATGATGCCT ACCATCTTTGCTCATCTTTTCTTT 76 bp 41621 41697
41704 GAAAAGATGAGCAAAGATGGT CACACTTTGTCTTTGACTTCT 55 bp 41677 41732
41817 GGCATACTAGTACAAGTGG TAACAGTCTGCATGGAGCA 99 bp 41767 41865
Table 3.3: Primers used for qPCR of KRAS nucleosome ocupancy.
3.7 RNA retrotranscription
The RNA was quantified in the NanoDrop 2000 Spectrophotometer (Ther-
mo Scientific) and 1 µg of total RNA was retrotranscribed to cDNA for reac-
tion. The sample was treated with DNase I Amplification Grade (Invitrogen)
for 20 min at 37◦C (10 µl final volume). The reaction was stopped with 1 µl
of 25 mM EDTA and incubated for 10 min at 65◦C, and 1 min at 90◦C. After
that, the M-MLV Reverse Transcriptase (Invitrogen) was used following the
manufacturer instructions.
The cDNA was amplified by real-time PCR using specific primers for each
gene and isoform. The primers are given in Table 3.4.
3.8 Real time PCR
The real time PCR (qPCR) was performed in a thermocycler Bio-Rad
C1000 using SYBR Green (Bio-Rad) following the manufacturer instructions.
The amplification cycle is depicted in the Fig. 3.1, where the annealing
temperature was experimentally adjusted to each primer. It was routinely
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Amplicon Forwad Reverse Size (bp)
KRAS CTTGTGGTAGTTGGAGCTGGT TGTTGGATCATATTCGTCCACAA 90 bp
KRAS 311936 4B CACAAAACAGGCTCAGGACTT ATCAACACCCTGTCTTGTCTT 106 bp
KRAS 256078 4A AAGAAAAGACTCCTGGCTGTGT AGGCATCATCAACACCCAGAT 70 pb
KRAS 556131 AGTGCCTTGACGATACAGCTAAT AAGGCATCATCAACACCCTCTATT 80 bp
KRAS 557334 ACAATTTCAAGAGGAAATCCCCG TCTGCCAATTCCATGAGATGCT 92 bp
ZNF518B GGGCCTGAGGTTGTGAAACT AAAACCGTGGCAAGTCCCAT 91 bp
ZNF518B 507515a CGGTGTAGACGCCCCTTC CAGGTAACACCGGCAGGC 60 bp
ZNF518B 507515b CTGCCGGTGTTACCTGGAAT GCGCAGCTACTTCTTGGGT 118 bp
ZNF518B 326756 GCTACAGGCAGGAATGTTACC CGCAGTAGGTGCATGATCCC 75 bp
ZNF518B 515072 AGTTTCGAGGTCATTATTCTCTACT CTGCAGGAGACAGCCTGATT 83 bp
ZNF518B 500268 CTGGCGTCGTGGCAAGTG CGTGGACTGCCATGAGTTTC 116 bp
ZNF518B 503068 GCACAGCAGTGTCAAGTCAA TAGTCGGCAGGAAGTGAGGG 78 bp
EPDR TGAAACCTGGATTGGCATCTATAC TGTAGTTTATGGTAAAGGTTTCCTG 71 bp
EPDR 425345a GAGGAGGGTCTCTTGGGGAT GCTGGGTGTTACTGAGTCCC 96 bp
EPDR 425345b CGAGGCGGTGGCAGATTATT TGCTTGGTGGCTTGGTCAAT 96 bp
EPDR 199448 GAGAGGAAGGCGCTGATCC TGGCTTGGTCAATCTGAAACA 88 bp
EPDR 476620 GACATGTGGCCCATCTCTGTAG ACAATGTTGTCAGCTTCTGCCT 70 bp
EPDR 423717 TCTCCTACGACGGGCTCA AGGTTTCATCTCTTGCAGGG 79 bp
HSP90B1 299767a CGGGAAGTGGGGGTGAAAAG GGTTCGGATCCTCACACCTC 83 bp
HSP90B1 299767b GTGGGTTCATGTTTCCCGTC CACTACACCGCAAGCAGGTC 75 bp
Actb Mouse CCCTAGGCACCAGGTAAGTGA CACCCTGTGGAAGGGAACAG 104 bp
ACTB Human GTGCTATCCCTGTACGCCTC GAGGGCATACCCCTCGTAGA 99 bp
Egr1 TACCCCAAACTGGAGGAGATGAT GCAGCACCGAGGAACTGG 62 bp
Table 3.4: Primers used for qRT-PCR.
checked that the designed oligonucleotide primers gave a single amplification
product by recording the melting profiles. Results were analyzed with CFX
Manager 2.1 software (Bio-Rad). The relative gene expression and MNase
protection values were calculated according to the comparative Ct method
(2−∆∆Ct) (191).
Figure 3.1: The amplification cycle for qPCR
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3.9 Mononucleosomal immunoprecipitation
The mononucleosomal immunoprecipitation (Nu-ChIP) allows the study
of histone modifications at the level of a single nucleosome.
3.9.1 Dynabeads-antibody conjugation
For each antibody plus a negative control, 40 µl (per sample) of dynabeads
with protein G (Invitrogen) were used. The beads were washed three times
with PBS/BSA (5mg/ml). To these beads the amount of antibody necessary
to immunoprecipitate 3.5 units of chromatin per sample was added (except
for the negative control which did not include antibody), plus 2 µl of tRNA
(10mg/ml) and brought to a volume of PBS/BSA. The mixture was incu-
bated with stirring at 4◦C overnight.
The antibodies used were: anti-H3K9ac (Abcam, ab-4441); anti-H3K9me3
(Abcam, ab-8898); anti-H3K27ac (Abcam, ab-4729); anti-H3K27me3 (Milli-
pore, 07-449); anti-H3K4me3 (Abcam, ab-8580); anti-H3S10phK14ac (Mil-
lipore, 07-081); anti-H3K14ac (Millipore, 07-353); anti-H4K16ac (Millipore,
07329); anti-H3 (Abcam, ab-1791); anti-H3K36me3 (Abcam, ab9050); H4
K20m (Abcam, ab9051).
3.9.2 Treatment and preclearing of the MNase digested
chromatin
After digesting the nuclei with MNase and stopping the reaction with
EDTA to 10mM (see section 3.5), 1/5 volume of 5X supplementation buffer
[25 mM Tris-HCl pH 8.6; 675 mM NaCl; 0.5% SDS (w/v); 5% Triton X-100
(v/v)] was added. The mixture was incubated 10 min on ice and then it was
centrifuged at 26000 g for 10 min at 4◦C and the supernatant was recovered
in ice. The absorbance at 260 nm was measured and the samples were then
diluted to a concentration of 7 units of A260 per ml in IP buffer[20 mM
Tris-HCl pH 8.1; 1 mM EDTA; 0.1% SDS (w/v); Triton X-100 1% (v/v);
150 mM NaCl] plus 2 µl/ml of protease inhibitor.
For preclearing 20 µl of dynabeads per milliliter of chromatin immuno-
precipitated were used. The dynabeads were washed 3 times with PBS/BSA
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and resuspended in 50 µl of PBS/BSA per sample. Then 50 µl were added
to each sample and incubated 60 min at 4◦C under stirring.
3.9.3 Incubation of chromatin with dynabeads-antibody
The antibodies incubated overnight with dynabeads were centrifuged 30 s
at 1600 g, washed with PBS/BSA and resuspended in 30 µl of PBS/BSA per
sample. After standing for 60 min the beads were removed from the chro-
matin pre-washing and aliquots of 3.5 A260 units of chromatin were placed in
siliconized eppendorf tubes. Then, 30 µl of a dynabeads suspension bound to
the corresponding antibody or negative control, as appropriate were added.
The samples were incubated at 4◦C under stirring for 6 h.
The supernatant of the negative control (no antibody) was collected in
siliconized eppendorf tubes, and it was further referred to as the input of
each sample. RNase (5 µg/ml) was added to the input fraction and it was
incubated at 65◦C for 2 h.
3.9.4 Washing and elution of the immunoprecipitated
DNA
The immunoprecipitated samples were washed twice with low salt buffer
[50 mM Tris-HCl pH 8.0; 15 mM NaCl; 0.1% SDS (w/v); 1% Triton X-100
(v/v); 2 mM EDTA]; the process was repeated with high salt buffer [50 mM
Tris-HCl pH 8.0; 0.5 M NaCl; 0.1% SDS (w/v); 1% Triton X-100 (v/v); 2
mM EDTA] and LiCl buffer [25 mM Tris-HCl pH 8.0; 0.25 mM LiCl; 1%
NP40 (v/v); 1 mM EDTA]. In the last washing with LiCl buffer, the samples
were centrifuged 1 min at 1600 g, the sediment washed with 1 ml of TE buffer
[10 mM Tris-HCl pH 8.0; 1 mM EDTA] and the content was transferred to
non siliconised eppendorf tubes.
For elution of the immunoprecipitated material, 50 µl of elution buffer [50
mM NaHCO3; 1% SDS (w/v)] were added and the mixture was vigorously
shaken, incubated for 10 min at 65◦C, centrifuged for 1 min at 1600 g, and the
supernatant was recovered. This elution step was repeated and the sample
was recovered in the same tube. The input and immunoprecipitates were
treated with proteinase K 200 µg/ml at 65◦C overnight. The DNA was
purified using the Gene Jet Purification Kit.
56
3.10 Chromatin immunoprecipitation
3.10.1 Antibodies
The dynabeads-antibody conjugation was performed as described for Nu-
ChIP. The antibody used was anti-HP1γ (Millipore, 05-690).
3.10.2 Treatment and preclearing of the sonicated chro-
matin
For the chromatin immunoprecipitation (ChIP), the procedure is the same
as in the Nu-ChIP, except for the preparation of chromatin after cell lysis.
The nuclear pellet was obtained as indicated in the section 3.5. Nuclei were
resuspended in nuclear lysis buffer [50 mM Tris-HCl pH 8.0; 0.1% SDS (w/v);
10 mM EDTA] and the fragmentation of chromatin was performed by soni-
cation.
The chromatin was sonicated with 10 pulses of 30 s each at an amplitude
of 35% with Vibra cell sonicator (Sonics and Materials) to obtain fragments
between 300-600 bp. After verification of the right size of fragments, the
fragmented chromatin was centrifuged at 1700 g for 10 min at 4◦C, and the
supernatant was transferred to a new tube. The absorbance at 260 nm was
measured and the samples were then diluted 10 times in IP buffer [16.7 mM
Tris-HCl pH 8.1; 167 mM NaCl; 0.01% SDS; 1.1% X-100 Triton; 1.2 mM
EDTA] (3.5 units of chromatin per sample for each antibody). From this
point the protocol continues as described in the previous section (Nu-ChIP).
3.11 Egr1 knockdown
MLP29 cells were cultured in 100 mm plates to 50-60% confluence and
treated with 40 µl of Lipofectamine RNAi Max (Invitrogen) per plate and 25
nM of either scrambled siRNA (Ambion 4390843), Egr1 siRNA 1 (Ambion
4390771, ID: S65378), or Egr1 siRNA 2 (Ambion 4390771, ID: S65380) fol-
lowing the instructions of the manufacturer. The cells were then incubated
in CO2 atmosphere for 8-10 h at 37
◦C, and the medium was replaced by
DMEM with 0.5% bovine fetal serum. After 20 h, the cells were treated with
TPA.
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3.12 Extraction and quantification of proteins
The cells were washed with PBS and lysed in RIPA buffer [50 mM Tris-
HCl pH 7.5; 150 mM NaCl; 1% SDS; 1% Triton x100; 0.5% deoxycholic acid
sodium salt (w/v)], supplemented with 2 µl/ml protease inhibitors (Sigma)
and 10 µl/ml phosphatase inhibitor (Sigma).
The sample was sonicated with 2 pulses of 5 s each at an amplitude of 30%
and centrifuged at 1700 g for 15 min at 4◦C. The supernatant was recovered
and quantified using the Pierce BCA Protein Assay Kit (Thermo Scientific),
following the manufacturer’s instructions.
3.13 Western blot
For the electrophoresis, protein extracts were diluted with loading buffer
[0.3 M Tris-HCl pH 6.8; 50% glycerol (v/v); 10% SDS (w/v); 25% 2-mercap-
toethanol; 0.05% bromophenol blue] and were denatured by incubation at
95◦C for 5 min. 20 µg of protein extract were loaded in a 12% SDS-
polyacrylamide gel. After running, proteins were transferred into a nitro-
cellulose membrane (Bio-Rad) using the Mini-protean II system (Bio-Rad)
with transfer buffer (Bio-Rad) supplemented with 20% methanol.
The membranes were blocked in 5% BSA-containing TTBS [20 mM Tris-
HCl pH 7.6; 137 mM NaCl, 0.1% Tween 20] during 1 h at room temperature
on a shaking platform and incubated overnight at 4◦C with the primary an-
tibodies: anti-EGR1 diluted 1/500 (Santa Cruz Biotechnology, sc-110) and
anti-β actin diluted 1/2000 (Sigma, A5441) in 1% BSA-containing TTBS.
Then, membranes were washed 3 times with TTBS and incubated with the
secondary antibody (anti-rabbit, Sigma) diluted 1/5000 for 1 h at room tem-
perature.
For detection, the ECL Western Blotting detection kit reagent (GE Health-
care) was used. The films were developed in the tabletop processor CURIX
60 (AGFA).
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3.14 RNAseq data analysis
The RNAseq data analysis was performed using the protocol described by
Trapnell and collaborators (187). The advantages of using these free software
tools are that their execution time is short, that the protocol starts with raw
sequencing reads and that the software allows the transcriptome assembly
and the output of lists of differentially expressed transcripts of regulated
genes.
3.14.1 Data collection
The RNAseq data from HCT116 (replicate PJ: SRX378081; replicate PF:
SRX378080; replicate: SRX841184), DLD-1 (SRX388825), Caco-2 (replicate
a: SRX209063; replicate b: SRX209064), RKO (ERX183571) and SW48
(ERX183572) colorectal cancer cell lines (Homo sapiens) were downloaded
from the database of Sequence Read Archive (SRA). In all cases, these
RNAseq data had been obtained using a Paired-End Sequencing system (Il-
lumina), starting from cDNA samples.
3.14.2 Assembly and estimation of transcript abun-
dance
The FastQC software was used for checking the quality of reads (for more
information see http://www.bioinformatics.babraham.ac.uk/projects/fastqc).
After that, the FASTX-Toolkit (for more information see http://hannonlab.
cshl. edu/fastx toolkit/) was used for Short-Reads FASTAFASTQ files pre-
processing.
First, the sequencing adapters/linkers were removed:
$ fastx clipper -i HCT116a.fastq -o HCT116b.fastq -a GCACACGTC -v
Then, the first ten nucleotides of low quality were eliminated (the noise):
$ fastx trimmer -i HCT116b.fastq -o HCT116c.fastq -f11 -Q33 -v
The overall low quality sequences were eliminated:
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$ fastq quality filter -i HCT116c.fastq -o HCT116d.fastq -q 20 -p 80 -Q
33 -v
Finally, the reads of less than 30 nucleotides were deleted because they
are very short for further analysis:
$ fastx clipper -i HCT116d.fastq -o HCT116e.fastq -l30 -v
After obtaining a data set of good quality for further analysis, one can
proceed to index the human genome. To do this, the hg19 version of human
genome (ftp://ftp.ensembl.org/pub/release-62/) and the bowtie sofware (for
more information see http://bowtie-bio.sourceforge.net/index.shtml) was used:
$ bowtie2-build human GRCh3762.fa human GRCh3762
TopHat program was used for alignment of RNAseq reads (produced by
the Illumina Genome Analyzer) to the human genome, in order to identify
exon-exon splice junctions (http://ccb.jhu.edu/software/tophat/index.shtml).
TopHat builds a database of possible splice junctions and then maps the
reads against these junctions to confirm them, generating the BAM file (Bi-
nary tab-delimited text) (192):
$ tophat2 -p4 -o HCT116 -G Homo sapiens.GRCh37.62.gtf
human GRCh3762 HCT116e.fastq
The BAM file was used to look for the variations in the sequence of tran-
scripts with respect to the reference genome (e.g. SNPs). To do this the Inte-
grative Genomics Viewer (IGV) (IGVtools from http://www.broadinstitute.
org/igv) was used.
Once checked the respective mutations in the oncogenes, the BAM file
was used by the Cuﬄinks program (http://cole-trapnell-lab.github.io/ cuf-
flinks) along with the genome reference file to estimate the abundance of each
transcript:
$ cuﬄinks -p 4 -o cuff2HCT116 -G Homo sapiens.GRCh37.62.gtf
HCT116accepted hits.bam
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3.14.3 Analysis of the differentially expressed genes
and transcripts
The abundance of transcripts was compared among the cell lines (HCT116,
DLD-1, Caco-2, RKO vs. SW48), using cuffmerge and cuffdiff programs.
First, Cuffmerge was used to create a file of coordinates (.gtf). This file,
made from the transcripts reported in the BAM files, contains the informa-
tion on the position of transcripts. To do this, Cuffmerge seeks the position
of each transcript by aligning them on a file containing the coordinates of the
sequence of the entire genome. Subsequently, Cuffdiff uses the files created by
Cuffmerge to compare the level of the aligned transcripts from the different
cell lines to analyse the changes in the expression of both, genes and isoforms.
$ cuffmerge -p 4 -g human3762.gff -s genome.fa -o mergeRKO SW48
lista.txt
To report the differential expression, Cuffdiff uses two statistical param-
eters, namely the maximum a posteriori estimation and the highest density
intervals. The results for the changes in expression were finally given as the
abundance per kilobase of reads per million mapped fragments (FPKM). For
more information on the Cuffdiff procedure see (192).
$ cuffdiff -o cuffdiff RKO SW48 mergemerged.gtf -L HCT116,SW48
RKOaccepted hits.bam SW48accepted hits.bam
Finally, the quality control of the overall results of the analysis done by
Cuffdiff, namely the estimates and over-dispersion displays for each sample,
was carried out with CummeRbund. This R-Bioconductor package takes the
various output files from a Cuffdiff run and creates a SQLite database of
the results describing appropriate relationships betweeen genes, transcripts,
transcription start sites, and coding DNA sequence regions. The main func-
tions are described below and the protocol is described in detail in the user
package manual.
Create SQLite database via cummerbund, using as input file generated
by Cuffdiff:
cuffDB = readCuﬄinks(dir = “.cuffdiffRKOSW48”,
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dbFile = “cuffData RKO SW48.db”,
gtfFile = “.cuffdiffRKOSW48RKOSW48merged.gtf”,
genome = “human GTCh3762.fa”,
driver = “SQLite”, package = “cummRbund”, rebuild = TRUE)
3.14.4 Classification of alternative splicing
The SpliceR is an R package for classification of alternative splicing and
prediction of coding potential from RNAseq data (193). The main functions
are described below and the protocol is described in detail in the user pack-
age manual.
cuffDB spliceR = prepareCuff(cuffDB)
mySpliceRList = spliceR(cuffDB spliceR, compareTo= “preTranscript”,
filters=c(“expressedGenes”,“geneOK”,“isoOK”,“expressedIso”,
“isoClass”), useProgressBar=F)
62
CHAPTER 4
RESULTS AND DISCUSSION
4.1 Nucleosome - specific, time - dependent
changes in histone modifications during
activation of the Egr1 gene
The Egr1 gene encodes a zinc finger protein that acts as a transcrip-
tional factor. This protein participates in the regulation of genes involved
in cancer progression, senescence and apoptosis (133). It was established in
previous studies carried out in the laboratory that the Egr1 gene is quickly
activated upon addition of TPA to cultures of the MLP29 cell line (78). This
experimental model was also initially chosen for the present work. On the
one hand, both the use of liver cells and the involvement of EGR1 protein
in pathological processes may allow correlating the data obtained with liver
diseases. On the other hand, induction of the signalling pathways by TPA,
especially those affecting immediate-early genes, is more specific than that
obtained with other types of stresses. TPA was used at a concentration of 50
nM, which gives a fast and significant response, without affecting the mor-
phology of the cells. Under these conditions, the activation of the murine
Egr1 gene is detected as soon as 5 min after adding TPA, to result in a tran-
sient expression cycle, the transcription returning to the basal level by 180
min. Moreover, in these previous studies, the time course of factor assembly
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in the Egr1 promoter has also been characterized (78).
It has also been reported that the mediator complex assembles on the
proximal promoter of the gene to stimulate productive transcription by RNA
polymerase II (194), but nothing is known about the influence of chromatin
structure on the binding of that complex and of the transcription factors.
Therefore, Egr1 offers a convenient model to study the structural and epige-
netic chromatin changes occurring in a promoter, both in the activating and
repressing phases of the transient expression process.
4.1.1 Nucleosome occupancy at Egr1 promoter and
proximal coding region in MLP29 cells
It is obvious that a prerequisite to study the structural and epigenetic
changes occurring in chromatin upon the activation and the subsequent re-
pression of the Egr1 is to know whether nucleosomes are positioned or not
over the region under study. If they were, once determined their positioning
under repressing and activating conditions, the epigenetic marks at single
nucleosomes could be determined by Nu-ChIP.
Therefore, the possible positions of nucleosomes in the promoter and in
the proximal transcribing region of the Egr1 gene were first studied. This was
accomplished by means of a MNase protection assay along 1200 bp, ranging
from -800 to +400 relative to TSS. As previously mentioned, the primers for
the PCR analysis were designed to define overlapping amplicons, which are
further referred to by the position of their centres.
As shown in Fig.4.1 A, the results indicate the presence of three pro-
tected areas, two in the promoter and the third one at the beginning of the
coding region. The nuclease-protected area between the amplicon -746 and
-425 has an estimated size between a minimum of 265 bp and a maximum
of 380 bp, so it coincides with the nucleosomal size. The protected zone in
the promoter closer to the TSS, between the amplicon -307 and -126, has an
estimated size of between 140 and 230 bp also coinciding with a nucleosome
size. Therefore, we henceforward assumed that they respectively correspond
to nucleosome -2 (N-2) and -1 (N-1). The protected area at the beginning
of the coding region is less definite. It is wider than the other areas, being
comprised between the amplicon -69 and +305 and its profile is somewhat
64
Figure 4.1: Time-dependent changes in micrococcal nuclease protection in
the promoter and proximal coding region of the Egr1 gene during TPA in-
duction. The protection against nuclease digestion at different times after
adding TPA, as shown in A-F, was determined and plotted against the dis-
tance to TSS. For comparison purposes, the nuclease protection at 0 min was
shown in all the panels. The plotted experimental points correspond to the
means of three determinations.
65
blurred. It can be assumed that this region is occupied by nucleosome +1.
The position of nucleosomes in the studied area is supported, in general
terms, by the prediction based on the sequence of Egr1 gene, made by the
NuPoP program. The results of the NuPop prediction are shown in Fig. 4.2
A, where a high probability of starting a nucleosome is observed near -600,
keeping a high nucleosome occupancy score until the nucleotide -450 approx-
imately.
Taken together, all these data allowed to propose a map of the promoter,
which shows the positions of the three nucleosomes studied and those of
the different cis-elements to facilitate the description of the following results
(Fig. 4.2 B). The position proposed for nucleosome -1 is mainly based on the
results of in vivo experiments (see below).
Interestingly, the present data of positioning (Fig. 4.1 A) explain some of
the previous published by the group: for example, why the serum-response
factor is constitutively bound to the Egr1 promoter at the two clusters of
serum-response elements that are located between -300 and -400 and be-
tween -83 and -105 relative to the TSS (78), as both of these clusters are
nucleosome-free in nonstimulated cells (Fig. 4.2 B). The same reasoning is
valid to explain the constitutive binding of ELK1, whose binding sites flank
nucleosome -1. It has been previously observed that CREB binds the Egr1
promoter in the absence of TPA (78). The cAMP-response element sites
localize between -50 and -150, i.e. in the nucleosome-free region (Fig. 4.2
B). The binding sites of serum-response factor, ELK1 and CREB, lie in close
vicinity (Fig. 4.2 B), and this may result in a cooperative binding, which,
according to Segal and Widom (53), can reinforce their competition with
nucleosomes in the regions around -400 and the TSS. These would explain
the differences found between the NuPoP prediction and the experimental
results. The labile binding of SP1 may be weaker than that of the other fac-
tors, because, although bound in the absence of TPA, it leaves the promoter
as soon as transcription starts (78). In this way, the present data would
explain why the SP1 factor prefers a noncanonical CG box at -49 to bind the
promoter under basal conditions instead of the canonical site at -277 (78),
which lies within nucleosome -1 (Fig. 4.2 B).
Once the position of nucleosomes in the basal state of the gene (time
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Figure 4.2: Nucleosome occupancy at the promoter and proximal coding
region of the Egr1 gene. A) prediction of the nucleosome occupancy score
(red) and of the probability of starting nucleosomes (blue), as determined
by the NuPoP program (195). B) map of the Egr1 region under study,
showing the location of cis-elements and the experimental positions of the
nucleosomes in noninduced MLP29 cells (red). The proposed position of
nucleosomes -2 and +1 30 min after TPA addition is also shown (green).
The proposed positions of nucleosomes are based on the experiments of Figs.
4.1 and 4.4
.
0) was established, research was continued with the study of nucleosomal
dynamics throughout the cycle of activation and repression of Egr1. As pre-
viously mentioned, by using an RNApol-ChIP assay (196), Tur et al found
that transcription of Egr1 can be detected in MLP29 cells as early as 5 min
after adding TPA, that it peaks at 30 min, and that at 180 min the activity
of the gene is no longer observed (78). In the Fig.4.1 B-F, it is shown that
clear changes occur in the nucleosome occupancy and that the time course
of these changes parallels that of transcription.
Five min after adding TPA, protection to nuclease slightly diminishes in
the region of nucleosomes -1 and +1 (Fig.4.1 B). This diminution is clearly
significant at 15 min, a time point in which a downstream sliding of nu-
cleosome -2 began to be detected (Fig.4.1 C). These changes are especially
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obvious at 30 min (Fig.4.1 D). Then, at 60 min it is observed that the profile
of protection against MNase begins to return to baseline state (Fig.4.1 E).
Once this wave of Egr1 expression has finished, i.e. 180 min after adding
TPA, the chromatin structure returns to its initial state (Fig.4.1 F). With
respect to the area under the peak of the nucleosomes, in all graphs in Fig.
4.1 is shown that the N-2 did not appreciably change with time. This sug-
gests that the nucleosome simply slides downstream.
Conversely, densitometrie determinations of two experiments similar to
that of Fig.4.1 showed that the area under the peak of N-1 dropped to 75% of
the control value at 30 min after adding TPA. In this sense, the nucleosome
+1 dropped to about 33% at 15 min and to about 65% of the control value
at 30 min. These results may indicate that nucleosome eviction took place
in some of the cells upon induction of the gene.
To further explore if nucleosome eviction actually occurred, the presence
of histone H3 in the promoter was determined. ChIP experiments with an
antibody against the C-terminal domain of histone H3 were carried out with
chromatin sonicated to an average DNA length of 500 bp. The presence of
H3 was quantified by real time PCR at amplicons -550, -494 (N-2), -240, -178
(N-1), +171, and +241 (N+1), and the results were averaged for each nucle-
osome. As shown in Table 4.1, the results of the study of the presence of H3
in the nucleosome -2 indicate that the amount of H3 diminishes only slightly
from 0 to 30 min, i.e. 9% at 15 min and 13% at 30 min when compared with
the amount at 0 min. However in a general way, the H3 signal significantly
decreases in the regions of nucleosomes -1 and +1, compared with the values
of the N-2. The presence of H3 in the nucleosome -1 diminishes in a 21% at
15 min and in a 44% at 30 min.
These data indicate that, although nucleosome -2 is not appreciably lost
on induction of the gene, the histone octamer is evicted from the regions of
nucleosomes -1 and +1. Of note, the amount of H3 in the region of nucleo-
some +1 is roughly 2-fold increased relative to nucleosomes -2 and -1, when
compared with 0 min, despite the lower protection to nuclease in that region.
Tur et al. found, by a semi-quantitative ChIP analysis, that the BRM
and BRG1 components of the SWI/SNF complex were present in the non-
induced promoter of Egr1. These components of the remodelling complex
left the promoter upon induction, to return when the gene was again si-
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lenced (78). Moreover, Sakurai et al. (197) reported that BRM negatively
regulates human EGR1 by binding to a region between -1293 and -502. If
these results may be extrapolated to the murine model, it may be concluded
that a BRM/BRG1-containing complex is somewhat related to the sliding of
nucleosome N-2.
Presence of H3 relative to input
Amplicon Nucleosome 0 min 15 min 30 min
-550 N-2 6.8 ±1.2 6.2 ±0.7 5.9 ±0.7
-494
-240 N-1 6.1 ±0.7 4.8 ±0.7 3.4 ±0.4
-178
+171 N+1 11.9 ±0.6 6.0 ±0.2 4.2 ±0.2
+241
Table 4.1: Presence of H3 in the Egr1 promoter. The presence of H3 was
quantified by RT-qPCR at the amplicons indicated, and the results were
averaged for each nucleosome.
The proposed 5’ ends of nucleosome -2 in resting and induced cells coin-
cide with points of maximal probability of starting a nucleosome (Fig. 4.2
A). If this actually occurs in live cells, the nucleosome would be maintained
in the upstream position in the absence of TPA stimulus, and the remodeller
complex would be continuously consuming ATP to maintain that position.
Upon activation of the gene, the remodeller leaves the promoter and the
nucleosome shifts toward the downstream position, probably by the action
of an unidentified remodeller, with the effect of unblocking the EGR1 site
at -595. As a matter of fact, after sliding, nucleosome -2 still lies over the
EGR1 site, but the latter is now approximately located in the superhelical
positions 1 and 2 of nucleosomal DNA, and their spontaneous unwrapping
(198; 199; 200) would allow EGR1 to invade its binding site.
Finally, the partial eviction of nucleosome -1 does not uncover any critical
cis-element (Fig. 4.2 B), but it may serve the purpose of leaving room for
the assembly of the mediator complex. This complex, which stimulates the
initiation of transcription by previously bound RNA polymerase II, binds the
murine Egr1 promoter mainly between the TSS and -400 (194).
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4.1.2 Nucleosome occupancy at Egr1 promoter and
proximal coding region during liver regeneration
after partial hepatectomy
It was next asked whether the above described mechanism involving the
sliding of nucleosome -2 and the partial eviction of nucleosomes -1 and +1
is a peculiarity of the MLP29 cells or constitutes a general way for Egr1
activation at a chromatin level. To address this question, an in vivo model,
namely the activation of the gene during hepatic regeneration after partial
hepatectomy, was selected.
An RT-qPCR assay was performed to quantify the amount of Egr1 mRNA
at different times after partial hepatectomy. The values were normalized rel-
ative to those of the sham-operated animals. The results are given in Fig.4.3,
which shows that the accumulation of mRNA 30 min after surgery increased
about two-fold over the basal value and went on increasing to reach a peak 3
h after partial hepatectomy. Finally, the Egr1 expression, as estimated from
the mRNA level, decayed and returned to the basal level by 24 h. Therefore,
Egr1, being an immediate-early gene, becomes activated at the onset of liver
regeneration, although the time course of transcription is, as expected, dif-
ferent from that observed in cultured MLP29 cells. In the latter model, the
maximum level of mRNA accumulation obviously occurs after the maximal
transcription (78). Assuming that the rate of mRNA turnover is comparable
in both experimental systems, the maximum of transcriptional rate in regen-
erating liver might be estimated to take place at 1.75 h after hepatectomy.
The assay of protection against digestion with MNase at 1.75 h and at
24 h after partial hepatectomy was performed. The results in Fig. 4.4 show
that the same features detected in MLP29 cells (Fig. 4.1) are observed when
the pattern of nuclease resistance is compared with that obtained in sham-
operated animals.
As it occurs in MLP29 cells after 30 min of the treatment with TPA
(Fig. 4.1 D), the nucleosome N-2 slides downstream after 1.75 h of partial
hepatectomy (Fig. 4.4 A).
It is then interesting to note that both models behave in a similar way.
It can be taken for granted that the sliding of nucleosome -2 is required for
EGR1 protein to bind its site at -595, which, in turn, leads to the repression
of the gene after recruiting NAB1 and NAB2 (78). Nab1 gene is constitu-
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Figure 4.3: Effects of partial hepatectomy on the Egr1 mRNA level. The
results of quantitative RT-qPCR, normalized against those of sham-operated
animals (red) are given at different times after surgery. The results are the
average ± SD for 5 mice.
tively expressed, but Nab2 is induced by EGR1, thus originating a negative
feedback loop (201).
The results given in Fig.4.4 also agree with the idea that the nucleosome
-1 is partially evicted when the gene is being actively transcribed. These
characteristics were observed in all the six liver regeneration experiments
performed.
A peculiarity of the in vivo experiments is that the nuclease protection
in the region of nucleosome +1 is enhanced relative to MLP29 cells, and
this allowed to map the basal position of this nucleosome roughly within one
of the regions predicted by the NuPoP program (Fig. 4.2) and to propose
that, apart from being partially evicted, nucleosome +1 slides downstream,
roughly 30-40 bp, upon induction of the gene.
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Figure 4.4: Time-dependent changes in micrococcal nuclease protection in
the promoter and proximal coding region of the Egr1 gene during partial
hepatectomy. The protection against nuclease digestion at 1.75 h (green)
and 24 h (blue) after partial hepatectomy, as shown in A and B, was deter-
mined and plotted against the distance to TSS. For comparison purposes,
the nuclease protection in the sham-operated animals (red) was shown in all
the panels. The plotted experimental points correspond to the mean of three
determinations.
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In MLP29 cells, nucleosome +1 is more accessible to nuclease than the
other two nucleosomes, despite the higher density of H3 in that region. This
suggests that nucleosome +1, apart from being evicted during induction, is
already destabilized in noninduced cells. It can be assumed that this is re-
lated to the fact that an immediate-early gene in cultured cells is in some
sense permanently poised for transcription. As already mentioned, the nucle-
ase protection in the region of nucleosome +1 is much more noticeable in the
in vivo experiments than in those using MLP29 cells. This may be related to
the reduced transcriptional potential of Egr1 in liver when compared with
cultured cells. At any rate, the good definition of the protected area in vivo
allows to conclude that the protection is displaced downstream when the
gene is being actively transcribed. The causes of this sliding are not known,
although genome-wide analysis shows that the 5’ border of nucleosome +1
in active genes peaks 30 bp downstream relative to inactive genes (202).
Finally, as shown in Fig. 4.4 B, at 24 h after partial hepatectomy, the
profile of protection against MNase returns to baseline.
4.1.3 Effects of Egr1 knockdown in MLP29 cells on
the nuclease protection in the promoter region
and in the gene expression
High resolution ChIP analysis showed that EGR1 protein binds its own
gene promoter especially at the -595 site (78). As discussed above, the sliding
of nucleosome -2 may facilitate the access of EGR1 to that site. EGR1 re-
cruits NAB1 and NAB2 after 30 min of TPA stimulation of MLP29 cells (78),
and this results in the repression of the gene, which is thus only transiently
expressed. With these circumstances in mind, it can be wondered whether
the presence of the EGR1 protein causes in some way the sliding of nucle-
osome -2. To answer this question, the expression of Egr1 was knocked down.
First, experiments with non-induced cells, to verify the conditions of
knocking down, were performed using two different siRNAs. The levels of
basal mRNA decreased to 53% relative to scrambled siRNA for siRNA 1 and
to 34% for siRNA 2 (Fig. 4.5 A). Then, experiments at 0, 15, 30, 60, 120
and 180 min after the TPA-induction, with the two different siRNAs were
carried out.
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Figure 4.5: Effects of Egr1 knockdown on the level of mRNA and on the
content of EGR1 protein. A) Effects of Egr1 knockdown at the basal level of
mRNA in MLP29 cells treated with scrambled (blue) and two Egr1 siRNAs
(siEgr1 -1 in red and siEgr1 -2 in light brown). B) Level of Egr1 mRNA at
different times after TPA addition to MLP29 cells treated with scrambled
and two Egr1 siRNAs. C) Effects of Egr1 knockdown on the level of EGR1
protein. Western blot shows the level of EGR1 protein at different times
after TPA addition to MLP29 cells treated with scrambled or siEgr1 -2.
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The results of Fig. 4.5 B, show that both Egr1 siRNAs, decrease the
mRNA levels. However, siRNA 2 is more efficient: the mRNA level de-
creased to 43% at 15 min, to 31% at 30 min and to 15,4% at 60 min after
treatment with TPA when compared with the scrambled siRNA. Despite
knocking down the expression of Egr1, at long times after adding TPA (120
min and 180 min), the mRNA relative to scrambled siRNA level is higher in
cells treated with Egr1 siRNA. These results are more evident with siRNA
2, with which the silencing effect is more noticeable. In this instance, the
mRNA levels increase more than 60% at 120 min and 180 min after treatment
with TPA. These results suggest that the inhibition of Egr1 transcription is
delayed in knocked down cells when compared with cells treated with control
siRNA. The differences tend to vanish at longer times.
Moreover, EGR1 protein levels during treatment with control siRNA and
siRNA 2 were studied. The results show that after treatment with Egr1
siRNA 2, the knockdown is effective at protein level, since this was unde-
tectable by Western blotting either in the absence of added TPA or at any
time after its addition (Fig. 4.5 C).
In view of the above results, the study of nucleosome occupancy at the
Egr1 promoter of MLP29 cells knocked down for Egr1 was performed. The
results of the Fig. 4.6 show that in cells transfected with control siRNA and
Egr1 siRNA 2, the downstream sliding of nucleosome -2 is more noticeable
and more durable than in nontransfected MLP29 cells (Fig. 4.6 A). The
maximum of nuclease protection occurs at amplicon -494 instead of -550,
and the nucleosome remains slid even at 60 min after TPA addition to cells
(compare Figs. 4.1 and 4.6 A). Moreover, subtle but significant differences
between control and Egr1 -silenced cells were found. Actually, neither the
position nor the nuclease protection of nucleosome -2 change in passing from
30 to 60 min after TPA addition in knocked down cells.
However, temporary changes in the nucleosome -1 (Fig. 4.6 B) are unaf-
fected after treatment with siRNA Egr1 2, i.e. at 30 min after treatment with
TPA the level of protection against MNase decays and returns to basal values
at 60 min after treatment with TPA, for the control siRNA and the siRNA 2.
It has been shown that the downstream sliding of nucleosome -2 with the
concomitant uncovering of the EGR1 site at -595 is a transcription-associated
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Figure 4.6: Effects of Egr1 knockdown in MLP29 cells on the nuclease pro-
tection in the regions of nucleosome A) -2 and B) -1. The nuclease protection
was measured, as in Fig. 4.1, at 0, 30 and 60 min after adding TPA, in cells
treated with si-control and siEgr1 -2. Points correspond to the means of three
determinations.
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phenomenon, and therefore, the results of Fig. 4.6 are compatible with the
idea that in Egr1 -silenced cells transcription is still active 60 min after TPA
addition. More interestingly, the present results show that EGR1 is not in-
volved in the sliding of nucleosome -2 but rather in its return to the basal
position. The delay in Egr1 repression may explain the relative increase in
the accumulation of mRNA observed in Fig. 4.5 B.
It is worth noting that, after induction, nucleosome -1 returns to its initial
state at 60 min, although nucleosome -2 is still altered (Fig. 4.1 E). This fact
agrees with previous observation that EGR1, NAB1, and NAB2, at that time
point, still remain bound to Egr1 promoter (78). The re-assembly of nucle-
osome -1 at 60 min, when the actual transcription is only residual, probably
means that the presence of the mediator complex is no longer required.
4.1.4 Histone epigenetic marks at Egr1 promoter and
proximal coding region in MLP29 cells
The gross epigenetic changes when MLP29 cells are activated by TPA
treatment were analysed in previous work from the laboratory (78). The
analysis was then carried out by conventional ChIP at the whole Egr1 pro-
moter. Results were obtained by semi-quantitative PCR in the repressed
gene and after 30 min of TPA treatment. A more thorough analysis is de-
scribed here. First, the mononucleosomal immunoprecipitation technique
(Nu-ChIP) was used, thus allowing to differentiate the marks in every single
nucleosome. To do this, mononucleosomes were immunoprecipitated with
the appropriate antibodies, and their DNA was used as template for real
time PCR. These determinations were done at two amplicons within each of
the nuclease-protected regions corresponding to the nucleosomes. The excel-
lent coincidence between the data obtained from both amplicons (see below)
provided an internal control of the results. Moreover, the analysis covered
several time points, so the epigenetic changes can be studied from a dynamic
point of view at both the activating and repressing phases of gene expression.
The results for the analysis of epigenetic modifications in histones are
shown in Fig. 4.7. The immunoprecipitations and posterior analysis were
repeated at least three times, and in every instance the results were consis-
tent. In general, the results of Fig. 4.7 show a close correspondence between
the results for both of the amplicons in every nucleosome and the epige-
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netic marks vary qualitatively and/or quantitatively from one nucleosome to
another. Additionally, with only a few exceptions, the intensity of a given
mark at 180 min coincides with the basal one. This means that once the gene
ceases to be transcribed, the epigenetic state of the nucleosomes returns to
its basal value. Finally, the analysis of incompatible epigenetic marks, such
as acetylation and methylation of the same lysine residue, gave opposite re-
sults. This obvious finding may also be considered as an internal control of
the reliability of the methods used.
The levels of H3S10phK14ac were first determined (Fig. 4.7 A). This
double label is a characteristic hallmark of immediate early genes (203), and
it had been previously found that it appears in the Egr1 gene, reaching a
maximal level 15 min after TPA treatment, and that it returns to the basal
level by 30 min (78). The present results at a mononucleosomal level show
that this modification preferentially occurs in nucleosome +1, in which it
can be detected as soon as 5 min of activation, and it returns to the basal
level by 30 min. This fast and transient modification precedes other mod-
ifications and the transcription itself, which arrives at a maximum at 30 min.
The phosphorylation of H3S10, known as the nucleosomal response (204)
and catalyzed by MSK1/2, is a primary event in the signal transduction
to chromatin, mediated by the ERK and p38 MAPK pathways (205; 206).
The subsequent acetylation of lysine 14 is linked to the phosphorylation, and
these combined marks seem to be decisive for the recruitment of RNA poly-
merase II S5ph to the p21 promoter (207). In the case of mouse Egr1, RNA
polymerase is present in the promoter in the absence of TPA, although its
presence is increased in parallel with the induction of the gene. Inhibition
of either p38 or MEK1/2 kinases causes a reduction of RNA polymerase re-
cruitment to the promoter (78). Taken together, all these data suggest that
phosphoacetylation of H3 in the +1 nucleosome is decisive for a productive
recruitment of RNA polymerase but, in view of the transient pattern of the
dual modification H3S10phK14ac (Fig. 4.7 A), this is not required for a
maintained transcription.
H3K14ac was initially recognized as an activating histone modification
(208). In the present model, the intensity of the mark peaks at 15 min after
stimulation with TPA in all the nucleosomes studied, especially in nucle-
osomes -1 and +1 (Fig. 4.7 B). It seems clear that after 15 min of TPA
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Figure 4.7: Time course of histone modifications and the presence of HP1
in nucleosomes -2, -1, and +1 after adding TPA to MLP29 cells. A-F show
the levels of different modifications in a representative experiment, plotted
as percent of input, for two amplicons in every nucleosome. In I the levels
of HP1 are shown. Error bars represent the standard deviation of three
determinations. The times after adding TPA are given are at the bottom.
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treatment, the time course of H3S10phK14ac variation in nucleosome +1 is
parallel to that of H3K14ac. In that nucleosome, both H3S10phK14ac and
H3K14ac return to their basal value 30 min after TPA addition.
Moreover, the modifications H3K4me3 (Fig. 4.7 D), H3K9me3 (Fig. 4.7
E), and H3K27me3 (Fig. 4.7 G), are specific to nucleosome +1 to a greater
or lesser degree.
Genomic analyses show that H3K4me3 is, in general, present at the start
sites of actively transcribed genes (209). This is the case of the Egr1 gene,
in which, under basal conditions, H3K4me3 is more abundant in nucleosome
+1 than in promoter nucleosomes. In the latter, the mark did not change
with induction of the gene, although in nucleosome +1 there is a distinct
time-dependent increase of the mark (Fig. 4.7 D). Interestingly, the level of
the mark at 180 min, when the transcription has completely ceased instead
of returning to the basal value, reached its maximal value. This question will
be discussed later.
H3K4 methyltransferases associate with the C-terminal domain S5ph
form of RNA polymerase II (210), and this explains why H3K4me3 is pref-
erentially associated with the nucleosomes of the proximal coding region
(211; 212; 213). However, histone exchange frequently occurs in the “hot”
nucleosomes found in regulatory regions and at the beginning of the gene
body, and Henikoff (54) proposed that methylation of H3K4 is related to
histone turnover. This may explain why H3K4 remained trimethylated when
Egr1 transcription had finished (Fig. 4.7 D).
The distribution of H3K9me3 was next determined. This epigenetic mark
has been described as characteristic of heterochromatin (214) and related to
gene repression (215). H3K9me3 recruits HP1, involved in the formation of
heterochromatin and, in consequence, in gene silencing (216). It may seem
surprising that this epigenetic mark be found in nucleosome +1, especially
between 15 and 60 min after TPA addition (Fig. 4.7 E), when the transcrip-
tional rate is higher. To further analyse this question, the presence of HP1γ
in the promoter was next studied by Nu-ChIP (Fig. 4.7 I), which showed
that the protein level parallels that of the H3 modification. HP1γ is espe-
cially present in nucleosome +1, in particular at 15 min after TPA addition.
These results are in accordance with those of Vakoc et al. (217), who found
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that the presence of H3K9me3 and HP1γ is associated with transcriptional
elongation. Obviously, both the results of Vakoc et al. and those described
in this Thesis suggest that the histone code cannot be univocally read. The
presence of HP1γ in N-2, in which the H3K9m3 mark is negligible (Fig. 4.7
E) suggests that some other epigenetic mark contributes to recruit HP1γ.
The changes in H3K27me3 follow a pattern to that of H3K9me3. Nucle-
osomes -2 and -1 are only scarcely methylated, although nucleosome +1 is
clearly modified, with a maximum at 30-60 min after TPA addition. The
genome-wide analysis of Barski et al. (211) found that the presence of
H3K27me3 is very low in actively transcribing genes and that the modifi-
cation occurs roughly with similar frequency over the promoters and coding
regions of silent genes (Fig. 4.7 G). Mouse Egr1 does not obey that general
pattern, at least in the neighborhood of TSS, as the patterns of the promoter
and +1 nucleosomes are different, and the latter is clearly modified.
H3K27me3 has been classically described as a repressor mark (81), and
the results show that both H3K4me3 and H3K27me3 are preferentially as-
sociated with the same nucleosome (Fig. 4.7 D and G), although we do not
know whether they reside on the same histone tail. Sacilotto et al observed
the existence of methylated H3K4 and H3K27 in the same nucleosome in the
Gas1 gene (218), and the occurrence of these bivalent marks is a somewhat
frequent phenomenon. The present results, with their time-dependent anal-
ysis of the histone modifications, allow to propose an explanation for the ap-
parent contradiction of finding both “repressive” and “activating” marks on
the same nucleosome. The presence of H3K4me3, according to the Henikoff
hypothesis (54; 219), would be a consequence of histone turnover, although
that of H3K27me3, which inhibits elongation by RNA polymerase II (220),
would be related to the decrease of transcriptional rate from 30 min onward,
as this is the moment in which the modification in nucleosome +1 is espe-
cially noticeable (Fig. 4.7 G).
Subsequently, the time course and nucleosome distribution of the acety-
lation of H4 lysine 16 was examined. The TPA-induced increase in H4K16ac
is preferentially found in the promoter nucleosomes, especially in nucleosome
-1, where the acquisition of the mark is a very early event in gene activation
(Fig. 4.7 C). Five minutes after adding TPA, the label increased to almost
4-fold the basal value, and the maximal level of the mark, at 15 min, reached
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6-7-fold the basal value. This maximum precedes those of transcriptional
rate and of nucleosome -1 eviction.
As expected, the pattern of H3K27 (Fig. 4.7 F) and H3K9 (Fig. 4.7
H) acetylation is opposite that of the methylation of the same residues and
the most heavily acetylated nucleosomes, i.e. those at the promoter are only
scarcely methylated and vice versa.
H3K27ac is considered as a mark well correlated with gene expression
(209). A global increase in H3K27ac upon activation of the gene 30 min
after adding TPA was previously detected (78), but present results show
that the mark is acquired earlier, especially in the promoter nucleosomes
(Fig. 4.7 F).
Finally, the changes in H3K9ac in nucleosome -1 are particularly interest-
ing, because the peak of this modification, which occurs at 30 min after TPA
addition, implies a 5 to 6-fold increase relative to the basal level (Fig. 4.7
H). The modification, which has been classically related to transcriptional
activation (208) and specifically to transcriptional initiation (221; 222), maps
close to the initiation site and its extent parallels that of transcription itself.
The modifications H4K16ac and H3K9ac are especially intense at nu-
cleosome -1. It is tempting to speculate that they may be associated with
the observed eviction of this nucleosome. H4K16ac precedes from a tem-
poral point of view to nucleosome eviction, whereas the profile of H3K9ac
coincides with that of -1 eviction. The ChIP-chip analysis of Horikoshi et
al. (223) revealed a significant association of the nucleosomes carrying the
H4K16ac mark with CREB sites. Interestingly, a functional cAMP-response
element, to which CREB is constitutively bound, lies immediately down-
stream of nucleosome -1 (Fig. 4.2 B), and its maximal acetylation (15 min)
coincides with the maximal CREB phosphorylation (78), but it is not known
whether a functional relationship exists between these two findings. The time
course of H3K9 acetylation (Fig. 4.7 H) coincides with those of nucleosome
-1 eviction and transcriptional activity. H3K9 is acetylated by p300 (224),
and CREB-binding protein, a related p300 paralog, is present in the Egr1
promoter (78). Anyway, in agreement with Henikoff and Shilatifard (219), it
can be concluded that drawing causal conclusions simply based on the cor-
relation of histone modification patterns is a risky question.
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Figure 4.8: Model of the structural changes and histone modifications during
the activation and repression of the Egr1 gene. The position of nucleosomes
-2, -1, and +1 is given at four different times after TPA addition. The partial
eviction of nucleosomes is symbolized by increasing the transparency of the
ovals. The location of transcription factors serum-response factor, ELK1,
SP1, and CREB and the phosphorylation of the latter is based on previous
results (78). The tentative positions of the BRM-containing remodeler and
the preinitiation complex (PIC) are also shown. The transcriptional rate is
symbolized by placing more or less arrows over the RNA pol II molecule.
The relative level of histone modifications is given according to the color
code depicted at the top.
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The results obtained in this chapter, together with the results previously
obtained (78) allow designing a model of the structural changes and his-
tone modifications during the activation and repression of the Egr1 gene
(Fig. 4.8). The advantages of carrying out these studies at mononucleoso-
mal resolution may be clearly noticed as the remodelling of chromatin and
the acquisition of the activating or repressing marks may act in a distinct
nucleosome-specific manner. The ultimate aim of an epigenetic study ought
to be the establishment of causal relationships between epigenetic modifica-
tions and their downstream effects, but further research would be required
to establish these connections.
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4.2 Analysis of RNAseq data in CRC cell lines
carrying a G13D mutation in KRAS gene.
The studies described hitherto, carried out in the chromatin of the murine
Egr1 gene, have served the purpose of establishing the conditions to study
changes in chromatin structure and in epigenetic marks at a mononucle-
osomal resolution. Once these objectives were accomplished, the research
described in this thesis, proceeded to its next one, namely the study of the
influence of chromatin structure and epigenetic modifications on the alter-
native splicing of genes potentially involved in KRAS mutation-associated
resistance of CRC to anti-EGFR drugs.
It has been previously mentioned that 92-94% of human genes are sub-
jected to alternative splicing and that the regulation of this phenomenon
depends on the cell type, developmental stage and pathological conditions
(106). In this way, alternative splicing is not only related to the huge diver-
sity of the products of gene expression, but also to the onset and progression
of several diseases, including cancer. It has also been mentioned that chro-
matin structure and epigenetic modifications play a key regulatory role in
alternative splicing (113). Moreover, it has been well established that muta-
tions in some proto-oncogenes are frequently involved in the acquisition of a
neoplastic phenotype (136).
Taking all the above considerations into account, present research will
go on trying to find the genes in which their alternative splicing is dysreg-
ulated as a consequence of a particular mutation in an oncogene, namely
the mutation G13D in KRAS (172). This piece of work corresponds to the
first part of the second objective of the present thesis, in which the potential
genes will be identified out by means of RNAseq analysis. The rationale for
selecting the G13D mutation is that, as mentioned under the Introduction, it
results in resistance to anti-EGFR drugs, an issue in whose study our group
is particularly interested. The RNAseq analysis will be then carried out by
comparing data from CRC cell lines carrying that mutation with those of
other cell lines possessing the wild type codon 13.
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4.2.1 Genes and isoforms that are differentially ex-
pressed in presence of KRAS G13D mutation
To identify the genes expressing differential isoforms produced by alter-
native splicing in dependence of the KRAS G13D mutation, eight sets of
RNAseq data were used. They were downloaded from the SRA database
and correspond to the cell lines RKO, SW48, Caco2 (two sets), HCT116
(three sets) and DLD1. The relevant genotypic properties of these lines are
shown in Table. 4.2. SW48 cells are wild type in the four oncogenes reported
and therefore it is used as control in the RNAseq comparisons with the other
cell lines. Caco2 is not used as control, because it harbours a mutation
in TP53. DLD1 and HCT116 share the same KRAS G13D mutation, but
DLD1 harbours different mutations in PIK3CA and TP53 while HCT116 is
wild type in the latter gene. RKO cells share the PIK3CA mutation with
HCT116, but they additionally possess a BRAF mutation.
Cell line MSI status CIMP 1 CIMP 2 CIN KRAS BRAF PIK3CA TP53
DLD1 MSI + + -46 G13D wt E545K; D549N S241F
HCT116 MSI + + - G13D wt H1047R wt
RKO MSI + + - wt V600E H1047R wt
SW48 MSI + + - wt wt wt wt
Caco2 MSS + - +48 wt wt wt E204X
Table 4.2: CRC cell lines classified by the molecular pathways CIN, MSI and
CIMP, and mutation status of some oncogenes [adapted from (225)].
Once the RNAseq raw data were filtered to select only reads of good
quality, the reads were aligned along the reference human genome. It was
verified at this stage that the cDNA sequences actually contained the muta-
tions described in Table 4.2 for each cell line.
The efficiency of overall mapping was 73.1% for the data set of SW48 cell
line, 90.9% for RKO cells, 73.3% for Caco2 (average of the two sets) and an
average of 89% was obtained for the three sets of HCT116 cell line. The reads
from DLD1 were poorly aligned, hovering around 70%. In summary, more
that 70% of the reads from the total series of data sets could be effectively
aligned.
As expected, the four data sets corresponding to cell lines harbouring the
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Figure 4.9: Verification of the G13D mutation in KRAS gene in the RNAseq
data. The coverage of KRAS G13D mutation in the reads of each data set
(dark red) vs wt (in dark blue) is indicated. A) the results for DLD1 and
HCT116 cell lines are shown. B) the results for SW48 cell lines, RKO and
Caco2 are shown. The SAM file was visualized in IGV software.
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KRAS mutation reported in Table 4.2, namely the DLD1 set and the three
sets of HCT116, actually possess the mutation G > A (C > T in the cDNA)
in codon 13, resulting in the substitution of a glycine for an aspartic acid
residue (Fig. 4.9 A). The reads show a mutation coverage ranking between
40-60% for the mutated allele, which is depicted in red in the figure, while
the wild type allele is represented in blue.
It was also checked that neither the control cells SW48 nor the RKO and
Caco2 cells harbour mutation in the codon 13 (Fig. 4.9 B). The presence of
the other mutations reported in Table 4.2 for the studied cell lines was also
checked in this stage of the analysis (data not shown). On these grounds,
the RNAseq analysis was designed as summarized in Fig. 4.10.
Figure 4.10: Scheme of the confrontation of data in the analysis of RNAseq.
It has four data set that have the KRAS G13D mutation and three that do
not possess this. Each of this is contrasted with the SW48 cell line data, to
get the results of expression difference.
After the initial analysis described, the CummeRbund program was used
to incorporate to R the results given by the Cuffdiff program. Once the
quality of the data were ascertained, the data were further analysed with the
splicer package, which looks for the differences in the expression of isoforms
and, moreover, gives information on the alternative splicing event type that
gave origin to the transcript. The final result is a list of differentially ex-
pressed isoforms for each cell line.
The above lists were then confronted as shown in Fig. 4.11. First, the iso-
form lists from cell lines harbouring the KRAS G13D mutation, i.e. DLD1,
and the three sets (r1, r2 and r3) of HCT116 were compared. With the
isoforms coinciding in all the comparisons, list 1 was built. The latter list
was then compared with those of the cell lines with no mutation in codon
13, namely RKO and the two duplicates of Caco2, to sequentially generate
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Figure 4.11: Scheme of the selection of isoforms that are differentially ex-
pressed according to KRAS G13D mutation. In a first comparison, the
isoforms selected are only those that are in all four data set with the G13D
mutation (List 1). Subsequently, the lists 2, 3 and the end isoforms list, are
obtained by comparing the data set of the list 1, with the list that do not
have the mutation, and discarding the match isoforms.
Gene name Name trans ENS ID Gene sig Splicing type Biotype
ENO1 TCONS 00015435 ENST00000234590 No 1 ESI, 1 MESI, 1 A3 Protein coding (434aa)
RPL13 TCONS 00087260 ENST00000491523 No 1 ISI, 1 A5, 1 ATSS, 1 ATTS No protein
ZNF518B TCONS 00173221 ENST00000507515 Yes 1 MESI Protein coding (75aa)
EPDR1 TCONS 00208723 ENST00000425345 No 1 ATSS Protein coding (163aa)
HSP90B1 TCONS 00063866 ENST00000299767 No - Protein coding (803aa)
Table 4.3: List of isoforms with differential expression in presence of G13D
mutation in KRAS gene, obtained by spliceR. The gene name, the transcript
name and his identification in Ensembl are indicated. It also specifies whether
the gene is differentially expressed according to the spliceR analysis. Also
are shown the types of alternative splicing that originated the transcript,
according to the spliceR analysis and if the isoforms encodes or not a protein.
The alternative splice types found are: single exon skipping/inclusion (ESI),
multiple exon skipping/inclusion (MESI), intron retention/inclusion (ISI),
alternative 5’/3’ splice sites (A5 / A3), alternative transcription start site
(ATSS) and alternative transcription termination site (ATTS).
lists 2, 3 and, finally, a list of differentially expressed isoforms. In every com-
parison the isoforms of the previous list not appearing in the list from the
non-mutated cells were selected. In this way, the final list of differentially
expressed isoforms contains those whose expression depends on the KRAS
G13D mutation. These isoforms (Table 4.3) correspond to ENO1, RPL13,
ZNF518B, EPDR1 and HSP90B1 genes, and their in silico expression values
is given in Fig. 4.12 in FPKM units.
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Figure 4.12: Expression level in FPKM units, of isoforms selected after anal-
ysis of spliceR. The data were obtained averaging the value of expression of
each transcript in the cell lines HCT116 (triplicate) and DLD1, and these
data were standardized against the value of expression of these transcripts
in the cell line SW48.
4.2.2 Experimental verification of the in silico data
The results obtained in the in silico analysis were experimentally checked
by RT-qPCR. The diagrams of Figs. 4.13-4.17 schematically show the struc-
ture of the five genes given in table 4.3 and Fig. 4.12. The position of the dif-
ferent exons, and the composition of the coded transcripts is given in these fig-
ures, build from the Ensembl database information (http://www.ensembl.org
/index.html).
Ideally, oligonucleotides amplifying every single isoform should be de-
signed. Nevertheless, this was not possible for some of the genes reported
by spliceR analysis. For instance, it is evident from Fig. 4.13 that primers
to amplify only the transcript 491523 of RPL13, it being the isoform differ-
entially expressed in connection with KRAS mutation (Table 4.3), cannot
be designed. Moreover, this isoform mRNA is not translated to protein. In
view of these circumstances, a further experimental analysis of RPL13 was
discarded.
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Figure 4.13: Scheme of the RPL13 gene and its isoforms. Transcripts are
named according to their code in the Ensembl database. Nucleotide 1 is
taken as the start of the gene sequence reported in the database. The exons
are shown in red and introns are shown by a black line. Exons included in
the primary transcript are shown in green. The transcript reported after
analysis of spliceR is highlighted in a red box. The scale of the diagram is
10 bp per pixel.
91
F
igu
re
4.14:
S
ch
em
e
of
th
e
E
N
O
1
gen
e
an
d
its
isoform
s.
T
ran
scrip
ts
are
n
am
ed
accord
in
g
to
th
eir
co
d
e
in
th
e
E
n
sem
b
l
d
atab
ase.
N
u
cleotid
e
1
is
taken
as
th
e
start
of
th
e
gen
e
seq
u
en
ce
rep
orted
in
th
e
d
atab
ase.
T
h
e
ex
on
s
are
sh
ow
n
in
red
an
d
in
tron
s
are
sh
ow
n
b
y
a
b
lack
lin
e.
E
x
on
s
in
clu
d
ed
in
th
e
p
rim
ary
tran
scrip
t
are
sh
ow
n
in
green
.
P
u
tative
ex
on
s
are
rep
resen
ted
b
y
b
ox
es
in
yellow
.
T
h
e
tran
scrip
t
rep
orted
after
an
aly
sis
of
sp
liceR
is
h
igh
ligh
ted
in
a
red
b
ox
.
T
h
e
p
osition
of
th
e
d
esign
ed
p
rim
ers
are
rep
resen
ted
b
y
arrow
s.
T
h
e
scale
of
th
e
d
iagram
is
10
b
p
p
er
p
ix
el.
92
F
ig
u
re
4.
15
:
S
ch
em
e
of
th
e
H
S
P
90
B
1
ge
n
e
an
d
it
s
is
of
or
m
s.
T
ra
n
sc
ri
p
ts
ar
e
n
am
ed
ac
co
rd
in
g
to
th
ei
r
co
d
e
in
th
e
E
n
se
m
b
l
d
at
ab
as
e.
N
u
cl
eo
ti
d
e
1
is
ta
ke
n
as
th
e
st
ar
t
of
th
e
ge
n
e
se
q
u
en
ce
re
p
or
te
d
in
th
e
d
at
ab
as
e.
T
h
e
ex
on
s
ar
e
sh
ow
n
in
re
d
an
d
in
tr
on
s
ar
e
sh
ow
n
b
y
a
b
la
ck
li
n
e.
E
x
on
s
in
cl
u
d
ed
in
th
e
p
ri
m
ar
y
tr
an
sc
ri
p
t
ar
e
sh
ow
n
in
gr
ee
n
.
P
u
ta
ti
ve
ex
on
s
ar
e
re
p
re
se
n
te
d
b
y
b
ox
es
in
ye
ll
ow
.
T
h
e
tr
an
sc
ri
p
t
re
p
or
te
d
af
te
r
an
al
y
si
s
of
sp
li
ce
R
is
h
ig
h
li
gh
te
d
in
a
re
d
b
ox
.
T
h
e
p
os
it
io
n
of
th
e
d
es
ig
n
ed
p
ri
m
er
s
ar
e
re
p
re
se
n
te
d
b
y
ar
ro
w
s.
T
h
e
sc
al
e
of
th
e
d
ia
gr
am
is
10
b
p
p
er
p
ix
el
.
93
F
igu
re
4.16:
S
ch
em
e
of
th
e
E
P
D
R
1
gen
e
an
d
its
isoform
s.
T
ran
scrip
ts
are
n
am
ed
accord
in
g
to
th
eir
co
d
e
in
th
e
E
n
sem
b
l
d
atab
ase.
N
u
cleotid
e
1
is
taken
as
th
e
start
of
th
e
gen
e
seq
u
en
ce
rep
orted
in
th
e
d
atab
ase.
T
h
e
ex
on
s
are
sh
ow
n
in
red
an
d
in
tron
s
are
sh
ow
n
b
y
a
b
lack
lin
e.
E
x
on
s
in
clu
d
ed
in
th
e
p
rim
ary
tran
scrip
t
are
sh
ow
n
in
green
.
P
u
tative
ex
on
s
are
rep
resen
ted
b
y
b
ox
es
in
yellow
.
T
h
e
tran
scrip
t
rep
orted
after
an
aly
sis
of
sp
liceR
is
h
igh
ligh
ted
in
a
red
b
ox
.
T
h
e
p
osition
of
th
e
d
esign
ed
p
rim
ers
are
rep
resen
ted
b
y
arrow
s.
T
h
e
scale
of
th
e
d
iagram
is
100
b
p
p
er
p
ix
el.
94
F
ig
u
re
4.
17
:
S
ch
em
e
of
th
e
Z
N
F
51
8B
ge
n
e
an
d
it
s
is
of
or
m
s.
T
ra
n
sc
ri
p
ts
ar
e
n
am
ed
ac
co
rd
in
g
to
th
ei
r
co
d
e
in
th
e
E
n
se
m
b
l
d
at
ab
as
e.
N
u
cl
eo
ti
d
e
1
is
ta
ke
n
as
th
e
st
ar
t
of
th
e
ge
n
e
se
q
u
en
ce
re
p
or
te
d
in
th
e
d
at
ab
as
e.
T
h
e
ex
on
s
ar
e
sh
ow
n
in
re
d
an
d
in
tr
on
s
ar
e
sh
ow
n
b
y
a
b
la
ck
li
n
e.
E
x
on
s
in
cl
u
d
ed
in
th
e
p
ri
m
ar
y
tr
an
sc
ri
p
t
ar
e
sh
ow
n
in
gr
ee
n
.
T
h
e
tr
an
sc
ri
p
t
re
p
or
te
d
af
te
r
an
al
y
si
s
of
sp
li
ce
R
is
h
ig
h
li
gh
te
d
in
a
re
d
b
ox
.
T
h
e
p
os
it
io
n
of
th
e
d
es
ig
n
ed
p
ri
m
er
s
ar
e
re
p
re
se
n
te
d
b
y
ar
ro
w
s.
T
h
e
sc
al
e
of
th
e
d
ia
gr
am
is
10
b
p
p
er
p
ix
el
.
95
The ENO1 isoform reported by spliceR analysis (Table 4.3) cannot be
either individually amplified. Isoform 234590 can be amplified together with
isoform 464920, and the latter can be individually amplified (Fig. 4.14). The
value for the level of isoform 234590 was then obtained by subtracting the
experimentally obtained value for isoform 464920 from the value obtained for
both isoforms 234590 and 464920. Primers can also be designed to amplify
together all the ENO1 isoforms, with the exception of isoform 464920 (Fig.
4.14), so the expression value for whole ENO1 was obtained by adding the
individual value of isoform 464920 to that of the remaining isoforms.
The HSP90B1 isoform reported by spliceR analysis (Table 4.3) may be
individually amplified (Fig. 4.15), but it is not possible to obtain a value for
the whole gene, as there are no regions common to all the isoforms.
In the case of EPDR1 gene, it is possible to design primers to separately
analyse the four isoforms, as well as a pair of primers to quantify the expres-
sion of the whole gene (Fig. 4.16).
Finally, it is also possible to determine the expression of all the isoforms
of ZNF518B. The expression of isoforms 500268, 515072, 507515 and 326756
may be individually analysed by using the primers shown in Fig. 4.17. The
primers within exon 3 depicted under isoform 503068 may be used to am-
plify this isoform together with 500268. Then, by subtracting the value of
the latter from that of the sum of isoforms 503068 and 500268, the expression
of the former may be obtained. The expression of the whole gene may be
obtained by adding the value corresponding to the isoform 507515 to that
corresponding to the other four isoforms.
In consequence, once discarded the experimental analysis of RPL13, the
other four genes reported in the in silico spliceR analysis, ENO1, HSP90B1,
EPDR1 and ZNF518B, may be experimentally analysed for their global ex-
pression, as well as for that of their different isoforms. The results obtained
by RT-qPCR for the isoforms given in Table 4.3 are shown in Fig. 4.18. The
experimental results for EPDR1 and ZNF518B are in excellent agreement
with those of the in silico analysis, in that there exist a significant differ-
ence in the expression of those isoforms when the lines carrying the KRAS
G13D mutation, HCT116 and DLD1, are compared with those with wild type
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Figure 4.18: Verification by RT-qPCR, of the expression of isoforms ob-
tained from the in silico analysis, in CRC cell lines. A) expression of the
ENST00000299767 isoform, belonging to HSP90B1 gene. B) expression of
the ENST00000507515 isoform, belonging to ZNF518B gene. C) expression
of the ENST00000234590 isoform, belonging to ENO1 gene. D) expression
of the ENST00000425345 isoform, belonging to EPDR1 gene.
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KRAS. The genes EPDR1 and ZNF518B are especially interesting, because
the negligible presence of the selected isoforms in the cells carrying wild type
KRAS (Fig. 4.18 B and D) suggests that the transcription of these genes
is activated by KRAS mutation. In the case of ENO1 and HSP90B1 the
experimental results are also satisfactory for HCT116 cells, but a clear rela-
tion between by KRAS mutation and gene expression does not exist in those
genes (Fig. 4.18 A and C).
Due to the above reasons, only the genes EPDR1 and ZNF518B will be
selected for further experimental analysis of their global expression and that
of their individual isoforms. For a deep analysis of the expression of these
genes, which depends on KRAS mutational status, two packs of isogenic cell
lines based on the parental HCT116 and DLD1 cell lines were used: HAE6
(-/G13D) and HAF1 (+/-) derived from HCT116; and D-Mut1 (-/G13D)
and DWT7 (+/-) derived from DLD1. The lines Caco2, RKO and SW48,
which harbour wild type KRAS, were used for comparative purposes.
The results with the EPDR1 gene are shown in Fig. 4.19. It is obvious
that there are differences among the different cell lines in the expression of
the gene, a result that does not agree with the outcomes of the spliceR anal-
ysis. Nevertheless, in accordance with the in silico data, a difference in the
expression of isoform 425345 was observed in relation with the mutations of
KRAS. This difference is obvious in the cell lines derived from DLD1. In ab-
solute terms, the major transcript corresponds to isoform 199448 (Fig. Fig.
4.19 C), whereas isoforms 425345 and 423717 represent only a minority (Fig.
Fig. 4.19 B and D; note the different expression scales). Isoform 476620 is
not expressed in the cell lines under study.
The global expression of ZNF518B gene also differ from line to line (Fig.
4.20 A). In contrast with the results obtained with EPDR1 (Fig. 4.19), in
the case of ZNF518B, the cells based on HCT116 exhibit a higher expression
level than the cells derived from DLD1. Interestingly, not only the isoforms
reported by in silico analysis, but also the global expression of both genes
depends on the mutational status of KRAS in DLD1-based cells. As far
as the particular isoform expression is concerned, it is obvious that isoforms
326756, 507515 and 503068 account for the majority of transcripts (Fig. 4.20,
B, C and E) the isoforms 515072 and 500268 being only a small minority of
transcripts (Fig. 4.20 D and F).
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Figure 4.19: EPDR1 gene and its isoforms expression in CRC cell lines. A)
Total EPDR1 gene expression. B) expression of the 425345 isoform. C)
expression of the 199448 isoform. D) expression of the 423717 isoform.
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Figure 4.20: ZNF518B gene and its isoforms expression in CRC cell lines.
A) Total ZNF518B gene expression. B) expression of the 326756 isoform.
C) expression of the 507515 isoform. D) expression of the 515072 isoform.
E) expression of the 503068 isoform. F) expression of the 500268 isoform.
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Therefore, experimental data corroborate the in silico analysis in these
two genes. Any one of them could be selected for further studies on the
relationships between chromatin structure and alternative splicing. The gene
of choice has been ZNF518B. The published data on it are particularly scarce.
It has been described as a potential marker of gout (226) and recent proteomic
analyses report that the protein regulates the levels of H3K9me2, due to its
interaction with histone methyltransferase complexes (227).
This fact is particularly interesting in view of the ultimate goals at which
the work of the laboratory is aimed. The fact that the function of the protein
is not yet fully understood adds another interesting point to its study, because
its potential participation in cancer processes may open an interesting way
to further studies and may result in finding novel targets for anti-cancer
therapy.
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4.3 Chromatin structure and epigenetic mod-
ifications in the alternative splicing and
termination sites of ZNF518B gene in
colorectal cancer
The ZNF518B gene, localized in chromosome 4 (4p16.1) from 10.439.874
to 10.457 .410, gives rise to five transcripts. Two out of them, according to the
data retrieved from Ensembl database (http://www.ensembl.org/index.html),
code for proteins. Transcript ENST00000326756, further referred in the
present work to as T1, encodes a 1074 amino acids, zinc-finger protein belong-
ing to the C2H2-zf clan (code CL0361, PF00096 in Pfam database). This
clan contains multiple protein families, whose members display, according
to the number and positions of the zinc finger motifs, different functions.
These roles may be related to gene transcription, translation, protein fold-
ing, mRNA trafficking and chromatin remodelling, among others.
The 1074 amino acid product of T1 has not yet been purified and, there-
fore, its three-dimensional structure is not known and most of the struc-
tural details mentioned below result from the bioinformatic analysis of its
sequence. Most of these analyses conclude that the protein contains three
zinc fingers, from residues 162 to 184, 190-213 and 1036-1058. According to
the data of the Human Protein reference Database, the protein may contain
an additional zinc finger from 135 to 157. The number and position of these
zinc fingers suggest that the protein may bind DNA and for this reason, a
role in transcriptional regulation has been attributed to the protein in the
UniProtKB database (code Q9C0D4). Interestingly, EGR1 protein, whose
gene has been studied in the present thesis (section 4.1), belongs to this clan.
Transcript ENST00000507515 from ZNF518B, further referred to as T2
results from multiple exon-skipping /including and alternative termination
events. It is also putatively translated, and gives rise to a short protein
containing the first 75 residues. Nothing is known about to its presence in
cells and on its possible role. Fig. 4.21 shows the map of the gene, the struc-
ture of isoforms T1 and T2, as well as the localization of the encoded proteins.
The region selected for the study of chromatin structure is that covering
the region of exon 4 that includes its 5’ end and the site of putative alter-
102
F
ig
u
re
4.
21
:
S
ch
em
e
of
th
e
Z
N
F
51
8B
ge
n
e
an
d
th
ei
r
is
of
or
m
s
th
at
ar
e
en
co
d
in
g
p
ro
te
in
s.
A
)
S
h
ow
n
th
e
ge
n
e
st
ru
ct
u
re
,
p
oi
n
ti
n
g
th
e
ar
ea
fo
r
th
e
ch
ro
m
at
in
st
u
d
y
(r
ec
ta
n
gl
e
in
b
lu
e)
.
B
)
T
h
e
E
N
S
T
00
00
03
26
75
6
(T
1)
is
of
or
m
an
d
th
e
p
ro
te
in
th
at
en
co
d
e.
C
)
T
h
e
E
N
S
T
00
00
05
07
51
5
(T
2)
is
of
or
m
an
d
th
e
p
ro
te
in
th
at
en
co
d
e.
N
u
cl
eo
ti
d
e
1
is
ta
ke
n
as
th
e
st
ar
t
of
th
e
ge
n
e
se
q
u
en
ce
re
p
or
te
d
in
th
e
d
at
ab
as
e.
T
h
e
tr
an
sc
ri
p
t
re
p
or
te
d
af
te
r
an
al
y
si
s
of
sp
li
ce
R
is
h
ig
h
li
gh
te
d
in
a
re
d
b
ox
.
T
h
e
sc
al
e
of
th
e
d
ia
gr
am
is
10
b
p
an
d
3.
2
aa
p
er
p
ix
el
.
103
native polyadenylation of mRNA (Fig. 4.21). This region also includes the
intron-exon 4 boundary, which is involved in one of the alternative splicing
events that gives rise to the T1 and T2 mRNAs. By using the same experi-
mental approaches employed to study the promoter of murine Egr1 gene, the
nucleosome occupancy in that region will be first studied. Once established
the chromatin structure, it will be possible to select the amplicons at which
the epigenetic marks may be determined by Nu-ChIP.
4.3.1 Nucleosome occupancy
For select the cell lines for the chromatin studies, the ratio between the
expression of the ZNF518B isoforms T2 versus T1 was measured (Fig. 4.22).
As expected, the highest difference was observed between cell lines DLD1
(G13D/+) and D-Mut1 (G13D/-), which differ in the mutational status of
KRAS in that the last line only harbours the mutated allele, while the DLD1
cells are heterozygotic for KRAS mutation. Therefore, these two lines were
selected for the following experiments. As a control, the SW48 cell line, in
which the gene is not expressed at all (Fig. 4.20) will be used.
The aim of this part of the present work is to detect the chromatin struc-
ture and epigenetic modifications related to alternative splicing and termina-
tion events, and not the ultimate causes, other than KRAS mutation, that
produce the differences in these events. In this way, the circumstance that
the SW48 cell line is not isogenic to the DLD1-based cells is irrelevant.
The results of MNase protection assays, carried out with the three se-
lected cell lines along more than 800 bp in the region marked in Fig. 4.21,
are given in Fig. 4.23. If this figure is compared with that of the murine
Egr1 promoter (Fig. 4.1 A) an obvious difference appears. Actually, the
protected regions in the Egr1 promoter describe some clear-cut areas, which
may easily be attributed to positioned nucleosomes.
In the present instance, however, the protection profile is less defined,
indicating that nucleosomes are not strictly positioned. This idea is in ac-
cordance with the prediction retrieved from the NuPop program (Fig. 4.24),
which does not give a clear pattern of probability to start nucleosomes and
the occupancy score plateaux are either too short or too low to accommodate
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Figure 4.22: Ratio of change in expression levels of the T2 versus T1 isoforms
of the ZNF518B gene.
positioned nucleosomes. Nevertheless, the MNase protection shows a ragged
profile (Fig. 4.23), in which three peaks may be seen. This suggests that
some preference for the positioning of three nucleosomes still exists. The
nucleosomes centred at amplicons 11621, 11768 and 11988 will be further
referred to as N1, N2 and N3. Interestingly, the profile is almost identical
in DLD1 and D-Mut1 cells, in which the gene is actively transcribed, but
it is quite different in SW48 cells, which do not express ZNF518B. On the
whole, a higher MNase protection is observed in SW48 cells, which may be in
connection with the transcription-dependent loss of histones, forced by the
passage of RNA pol II through the gene body (94).
The proximal intronic region in the neighborhood of exon 4 seems to be
deprived of nucleosomes in view of its low MNase protection. This result is
in accordance with the widely accepted idea that exons are more enriched in
nucleosomes than introns and that the first 50 bp of intronic regions close
to the 3’ splicing sites are particularly scarce in nucleosomes (228). One of
the peaks observed in the profile of Fig. 4.23 is located close to the 5’ end
of exon 4 (N1) and other peak is observed in the region in which the alter-
native termination of T2 occurs (N3). Neither the position of the peaks nor
their intensity change from DLD1 to D-Mut1 cells, in spite of the differences
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Figure 4.23: Changes in micrococcal nuclease protection in the region of
alternative splicing of the ZNF518B gene, in the SW48, DLD1 and D-Mut1
cell lines. The plotted experimental points correspond to the mean of three
determinations.
in splicing and termination in these lines. Working with the MLH1 gene in
cells derived from Lynch syndrome patients, Sloane et al. (229) have recently
reported that mutations that alter the splicing do not produce changes in nu-
cleosome positioning. The present results are thus in accordance with this
observed absence of changes in nucleosome positioning related to changes in
splicing patterns.
The highest MNase protection in DLD1 and D-Mut1 cell lines is observed
flanking the point of alternative termination. This may result in a decrease
of the speed of the transcribing RNA pol II, which would allow for deciding
between the two possible termination events. Nevertheless, the absence of
changes in nucleosome density or position when the MNase resistance profiles
of cell lines DLD1 and D-Mut1 are compared suggests that the differences in
splicing and/or termination experimentally found between these lines are not
directly due to kinetic coupling (see section 1.2.4). Therefore, the alternative
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Figure 4.24: Nucleosome occupancy at the region of alternative splicing of
the ZNF518B gene. A) prediction of the nucleosome occupancy score (red)
and of the probability of starting nucleosomes (blue), as determined by the
NuPoP program. B) map of the ZNF518B region under study, showing the
experimental positions of the nucleosomes in the CRC cells.
mRNA processing events that differentiate between both cell lines may be
probably related to epigenetic causes. For this reason, some relevant epige-
netic marks in histones of the nucleosomes present in the ZNF518B region
under study will be described in the next section.
4.3.2 Histone epigenetic marks
The histone modifications studied in the selected region were H3K36me3,
H4K20me1, H3K27ac and H3K9ac, which are those more frequently re-
ported in the literature as being connected with alternative mRNA processing
events. The analysis was carried out by Nu-ChIP at the points corresponding
to the maxima of MNase protection assay of Fig. 4.23, i. e., at amplicons
11621, 11768 and 11988, assuming that these points correspond to the max-
imal preference for nucleosome localization. The PCR data obtained in the
Nu-ChIP analysis were normalized relative to the MNase protection in the
same amplicons to account for the differences in nucleosome occupancy, and
are shown in Fig. 4.25.
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It can be observed that the level of modifications in the cell line SW48 is
very low when compared with that of the other two lines. This fact is surely
related with the absence of expression of the ZNF518B gene.
Figure 4.25: Histone modifications in the nucleosomes 1, 2 and 3 of the
ZNF518B gene in the CRC cell lines. A-D show the levels of different mod-
ifications in a representative experiment, plotted as percent of input. For
the study, the amplicons of the maximum peak of each nucleotide were used.
Error bars represent the standard deviation of three determinations.
The distribution of the H3K36me3 mark is homogeneous along the gene
region under study in the cell line DLD1. It is widely known that H3K36me3
is enriched in exons of active human genes. This fact surely results from the
association of Setd2, the methyltransferase responsible for this modification,
with the CTD of the elongating RNA pol II (230). Moreover, the methyl-
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transferase Setd2 has been described to be associated with the ribonucleo-
protein hnRNP-L, involved in splicing (231) and this add another connection
between splicing and the presence of H3K36me3. In fact, Zhou et al. carried
out a genome-wide analysis trying to correlate the presence of epigenetic
modifications and the different types of alternative splicing and they con-
cluded that H3K36me3 is preferentially found in the regions where A3SS
and/or A5SS occur (232). It remains to be determined whether alterna-
tive polyadenylation may be mechanistically related to any of these splicing
events, but Lee et al. (233) have found in the course of a bioinformatic
analysis that H3K36me3 is more abundant in regions involved in alternative
polyadenylation sites than in genes with single polyadenylation sites. The
chromatin of the cell line D-Mut1 is more enriched in the H3K36me3 mark
in the region under study, especially in nucleosomes N1 and N3 (Fig. 4.25
A). Interestingly, the isoform T2, which is characterized by the premature
termination and MESI in the region covered by N3 and N1 respectively, is
more abundant in the D-Mut1 line. These facts might be explained if some
unidentified factor recruited by this epigenetic mark participated in the pre-
mature termination of isoform T2.
The epigenetic modifications H4K20me1, H3K27ac and H3K9ac have also
been found to correlate with A3SS and A5SS (232). To check whether they
are also associated with the alternative termination and MESI events that
differentiate between isoforms T1 and T2, the presence of these three modi-
fications was also determined in the ZNF518B region studied.
The results obtained in the analysis of H4K20me1 also show an enrich-
ment of the mark in N1 and N3 in the case of D-Mut1 line (Fig. 4.25 B).
H4K20me1 is preferentially found in exons (234) and its presence has been
associated with exon skipping-related processes as well as with alternative
splicing site selection (232). N1 may be involved in exon 3 skipping and,
therefore, the abundance of this mark can be explained in terms of these
data.
H3K27ac is present at high levels in N1 and N3 in both cell lines, espe-
cially in D-Mut1 (Fig. 4.25 C). It is tempting to speculate that the increase
of this modification in the line that express more isoform T2 is related to the
alternative termination and MESI giving rise to this isoform.
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Finally, the distribution of H3K9ac shares its main features with the above
modifications. There is an increased level of modification in N1 and N3, and
this level is higher in D-Mut1 line than in DLD1. The presence of H3K9ac
has been related with the kinetic coupling model to explain alternative splic-
ing (230). The acetylation of H3K9 favours decondensation of chromatin
allowing RNA pol II to transcribe faster. It remains to be determined how
this circumstance might aid in the selection of T2 isoform, because the mod-
ification is higher in the cell line expressing more T2. It has been shown that
the speed of RNA pol II plays a dual role in alternative splicing. Depending
on the strength of the flanking intronic splicing sites, fast elongation may or
may not favours the inclusion of an exon (235), but nothing is known as to
the influence of RNA pol II speed in alternative termination.
Podlaha et al. (236) have recently published a comprehensive study of
the associations between epigenetic marks and the diversity of transcripts in
both, normal and tumour cells. Their results are in accordance with those
reported above in that the four modifications studied here are highly related
to the alternative splicing events in cancer and normal cells. Much work
remains to be done, however, to understand the complete set of mechanisms
involved in the recognition of a given modification and the selection of a
particular splicing or termination mode.
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4.4 Nucleosome occupancy and epigenetic
modifications in the alternative splicing
site of KRAS gene in colorectal cancer
In the present thesis, after developing a methodology to study changes in
chromatin structure and epigenetic modifications of histones at mononucle-
osomal resolution by using the model of murine Egr1 activation, attention
has been focused on some of oncogenic consequences of KRAS mutation.
Among these consequences, the laboratory of Chromatin and Epigenetics in
which the experimental work has been carried out is particularly interested
in the KRAS mutation-related alterations in pre-mRNA splicing. The bioin-
formatic in silico analysis of RNAseq data allowed selecting a human gene,
ZNF518B, in which the global expression and alternative splicing in colorec-
tal cancer cell lines are altered as a consequence of KRAS G13D mutation
(section 4.2). In consequence, the chromatin structure and epigenetic changes
in a region critical for the transcriptional machinery to decide between the
two isoforms translated into protein were studied (section 4.3).
It has been described under the Introduction (section 1.4.1.3) that the
KRAS gene itself gives rise to two isoforms, usually referred to as 4A and
4B, according to the nature of the fourth protein-coding exon. However the
situation is more complex. The gene possesses 7 exons and, as retrieved
from the Ensembl database, it is transcribed to 4 mRNA isoforms, all of
them translatable to proteins. The Ensembl numbers corresponding to these
isoforms are ENST00000311936, ENST00000256078, ENST00000556131 and
ENST00000557334. The first two isoforms correspond to KRAS 4B and 4A,
respectively. As shown in Fig. 4.26, a simplified notation is proposed for
the four isoforms, which will be further referred to as T1, T2, T3 and T4,
respectively. The isoform T1 corresponds, then, to KRAS 4B and T2 to
KRAS 4A. Fig. 4.26 also shows the structure of mRNAs and proteins for
the 4 isoforms.
Isoforms T1 (4B) and T2 (4A) have been widely studied. Isoform T2
promotes apoptosis, while isoform T1 is antiapoptotic (237) and it has been
found that the higher the ratio T1/T2 the poorest the prognostic in patients
from CRC (238). Curiously enough, the ratio T1/T2 is lower in HCT116
cells, which harbour the G13D mutation in one KRAS allele, than in SW48
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cells, which do not possess that mutation (239). Additionally, due to the dif-
ferent subcellular location of isoforms T1 and T2, it has been suggested that
the study of these isoforms may contribute to the development of anti-KRAS
drugs (240). In view of these circumstances and to the already mentioned im-
portance of KRAS mutations in oncogenesis (see section 1.4.1), it has been
judged convenient to include the analysis of the chromatin structure and
epigenetic marks in the region of KRAS gene involved in the selection be-
tween the isoforms. The G13D mutation-dependent differences in the KRAS
T1/T2 ratio have not been detected in the spliceR analysis, probably because
they are below the threshold employed in the analysis but, in spite of this
fact, the study of KRAS splicing may be interesting to complete the present
research.
4.4.1 Expression level of the KRAS isoforms in CRC
cells
The first step of this study is the determination of the expression level
of the four KRAS isoforms in different CRC cell lines. As mentioned above,
the published studies are limited to the isoforms T1 (4B) and T2 (4A). In
the present work, the other two isoforms are also included.
Figure 4.26, based on the data retrieved from Ensembl, gives a schematic
representation of the gene that includes the different exons, the exon struc-
ture of the four transcripts and the translatable regions. The three regions
critical for selecting among the different isoforms are also marked below the
general scheme of the gene. The primers selected to experimentally deter-
mine the expression of every singe isoform are also depicted.
It can be seen in Fig. 4.26 that the primary transcript undergoes multi-
ple alternative splicing events. The one most studied in the literature is the
exon 6 skipping, which gives rise to isoforms T1 (4B) and T2 (4A). T1 mRNA
codes for a 188 amino acids protein, which possess a GTPase domain from
residues 3 to 164. This domain belongs to the P-loop-NTPase superfamily.
The protein coded by transcript T2 has 189 residues. Its GTPase domain
is identical to that of T1 and the differences between these two isoforms are
concentrated in the C-terminal region. The putative protein encoded by T3
has not been isolated to date. It has 43 amino acids, harbouring a GTPase
domain from residues 3 to 37 that also belongs to the P-loop-NTPase su-
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perfamily. Within this domain, a type A motif (GXXXXGK[S/T]) starting
at residue 10 is found. These circumstances are also valid for the putative
protein encoded by T4, which possess 75 amino acids and an additional P-
loop-NTPase domain from residues 27 to 52 (data obtained from analysis
with the tools of specialized Blast).
The above data suggest that the putative proteins encoded by T3 and
T4, if they actually occur, would possess a biological function. This factor
also prompted us to determine the expression level of T3 and T4 mRNAs. To
begin with, an RT-qPCR study of the expression of the whole gene and its
four individual isoforms was carried out in 9 CRC cell lines (Fig. 4.27). The
expression of the whole gene is highly variable from cell line to cell line, be-
ing higher in Caco2 and lower in RKO and SW48. The expression is roughly
similar in lines HCT116 and DLD1 and the cells derived from these parental
lines show a lower expression level, although a compensatory effect for the
loss of one of the alleles seems to occur (Fig. 4.27 A). The expression of
individual isoforms is given in Fig. 4.27 B the expression relative to β-actin
and in Fig. 4.27 C the normalized values are represented as the percentage
of every isoforms in each line. It can be seen that T1 is the major isoform in
all the lines studied, while the expression of T4 is negligible in all the lines
except Caco2, which shows a residual expression level. As plainly seen in
Fig. 4.27 C, T2 represents roughly a 20% of the total transcripts in Caco2
and in HCT116 cells and their derived lines. The amount of T3 ranges from
only a 2% of transcripts in RKO cells to almost a 10% in HAE6 and D-Mut1.
In the latter cell line, the expression of T3 is even higher than that of T2.
To aid the selection of the more convenient lines to study chromatin struc-
ture and epigenetic modifications, the ratio of isoforms T2 (4A)/T1 (4B) is
given in Fig. 4.28 A. On the one hand, it is obvious that a clear difference
does not exist between HCT116 and their derived cell lines HAE6 and HAF1
and the same occurs between parental DLD1 and their derived cell lines D-
Mut1 and DWT7. On the other hand, the largest differences in the ratio
T2/T1 were observed between the group SW48/RKO and Caco2/HCT116-
based cells. The cell lines finally selected for further research were SW48 and
HCT116. This selection is based in several reasons. First, both lines differ
in the mutational status of KRAS. Second, although the ratio T2/T1 differs
more between SW48 and HAF1 than between SW48 and HCT116, being this
line the parental one relative to HAF1, it has been more widely studied and
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Figure 4.27: Expression of KRAS gene and their isoforms in the CRC cells.
A) mRNA levels of the KRAS gene in CRC cell lines. B) mRNA levels of the
four isoforms of KRAS gene in the nine cell lines studied. C) Expression of
the isoforms expressed in percent for each cell line. The corresponding colours
are shown in the upper panel. The plotted experimental points correspond
to the mean of three determinations.
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Figure 4.28: Ratio of change in expression levels of the T2 isoform of the
KRAS gene in the CRC cells (A). B) Level of expression relative to human
actin-β of the four KRAS isoforms in the HCT116 and SW48 cell lines.
characterized. Third, as shown in the pie diagram of Fig. 4.28 B, in terms
of percentage, there is a large difference in the expression of T2, while the
expression of isoforms T3 and T4 is roughly similar. In this way, the possi-
ble differences found in chromatin structure and/or epigenetic modifications
would be only attributable to the change of the T2/T1. The fact that SW48
and HCT116 are not isogenic is irrelevant for the causes discussed above (see
section 4.3.1).
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4.4.2 Nucleosome occupancy in the alternative splic-
ing regions
The MNase protection assays were carried out in the three regions marked
in Fig. 4.26, which cover the relevant alternative splicing sites. The first one,
corresponding to exon 5 may be involved in the exon skipping that results
in the production of isoforms T3 and T4 and/or in the exon inclusion on
isoforms T1 and T2. The second region covers exon 6, which is skipped in
all the isoforms but for T2. The third region is located in the boundary
intron-exon 7 and its study is also interesting in view of the splicing events
that give rice to isoforms T1, T2 and T4.
For these three regions, oligonucleotides defining tiled amplicons were de-
signed (Table 3.3) and the three regions were analysed for MNase protection.
In the first region (exon 5 and neighbouring intronic sequences), a protected
area covering the entire exon is observed. The width of this area (roughly 150
bp) fits the size of a single mononucleosome (Fig. 4.29 A). It is a common
finding that short metazoan exons accommodate single nucleosomes (228).
The intronic sequences close to exon 5 seem to be depleted of nucleosomes,
as indicated by the low MNase protection, although the profile of Fig. 4.29
A suggests that nucleosomes may occur at more distal intronic sequences.
The same is true for exon 6, in which a protected region of mononucleosomal
size is also found. In this case, a second nucleosome is detected in the 5’ in-
tron around 100 bp upstream of the exonic nucleosome (Fig. 4.29 B). These
two nucleosomes are separated by more than 100 bp, so the polypyrimidine
tract at the 3’ ends of the intron would be nucleosome-free. Again, this sit-
uation is very frequent in introns (228). Finally, the region studied in the
boundary intron-exon 7 accommodates two nucleosomes, one on the bound-
ary itself and the other one in the intronic sequences, leaving room too for
a nucleosome-free region covering the polypyrimidine tract. A second exonic
nucleosome may occur at the 5’ end of the region under study (Fig. 4.29
C). The three exonic nucleosomes found in these experiments will be further
referred to as N-E5, N-E6 and N-E7, respectively.
As previously described for ZNF518B, the chromatin structure is almost
coincident between the two cell lines used. Only minor differences were ob-
served in N-E7 suggesting a slightly higher density of nucleosomes in HCT116
cells, which surely does not account for the differences in KRAS splicing be-
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Figure 4.29: Nucleosome occupancy, in the region where occurs the alterna-
tive splicing in the exon 6, and in the neighboring exons 5 y 7, in the KRAS
gene. A) micrococcal nuclease protection in the exon 5 region of the KRAS
gene in the SW48 and HCT116 cell lines. B) micrococcal nuclease protec-
tion in the exon 6 region of the KRAS gene in the SW48 and HCT116 cell
lines. C) micrococcal nuclease protection in the exon 7 region of the KRAS
gene in the SW48 and HCT116 cell lines. The plotted experimental points
correspond to the mean of three determinations.
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tween both cell lines. Consequently, the study of the epigenetic modifications
is mandatory to look for the possible causes of the differences in the selection
of T2 isoform.
4.4.3 Epigenetic marks in histones in the alternative
splicing regions of KRAS
The MNase protection assays, described in the previous section, revealed
the presence of well-positioned nucleosomes in contrast with the results ob-
tained in the ZNF518B gene. Therefore the selection of the amplicons to
study the epigenetic marks by Nu-ChIP is a straightforward question: in all
the instances the study will be carried out at the amplicons giving the max-
imal value in the assay of Fig. 4.29. The experiments reported below were
restricted to nucleosomes N-E5, N-E6 and N-E7, because the exonic nucleo-
somes are, according to the literature, the most decisive in splicing processes.
The results of these experiments are shown in Fig. 4.30. The Nu-
ChIP data were normalized relative to the nucleosome density, as estimated
from the MNase protection assay. Generally speaking, N-E7 is most heavily
marked than the other two nucleosomes. Clear differences in most of the
marks are observed between the cell lines HCT116 and SW48. For instance
in the two acetylations studied, these differences can be seen in the three
nucleosomes. In other cases, the differences are only observed in one nu-
cleosome, as it occurs in H3K36me3. The two acetylation marks, H3K9ac
and H3K27ac, are more abundant in the three nucleosomes in the HCT116
cell line. As these acetylations are usually related to a decondensed state of
chromatin, it is probable that, in spite of the similarity between the nucle-
osome profile in both lines, RNA pol II speed is higher in HCT116 cells all
over the region studied. This cell line is characterized by a higher content
of the isoform T2, in which exon 6 is included. As mentioned above (section
4.3.2), the kinetic coupling model for splicing explains that the polymerase
speed plays a dual role: in some instances, a high transcribing speed favours
ES and, in other cases favours exon inclusion. The latter one seems to be
operative in the inclusion of exon 6 in the mature transcripts of KRAS gene.
For this fast elongation-dependent exon inclusion it is required that the 3’
splicing sites of exons 6 and 7 be strong (235). The sequence of 3’ splicing
site for exon 6 is GTTTTACAATGCAG and that of the exon 7 is TTTAT-
GTATTTCAG. Both of them may be considered strong, as they show 9/14
119
Figure 4.30: Histone modification in the region where occurs the alternative
splicing in the exon 6, and in the neighboring exons 5 y 7, in the KRAS gene.
A-G show the levels of different modifications in a representative experiment,
plotted as percent of input, for the first nucleosome in the exons 5, 6 and 7.
Error bars represent the standard deviation of three determinations.
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and 10/14 matches with the consensus sequence of 3’ splicing sites.
The recruitment model also seems to be partially operative in this in-
stance. Working with the fibroblast growth factor receptor 2 (FGFR2) gene,
it has been shown that the presence of H3K4me3 in the downstream exon,
favours exon inclusion. This effect is due to the fact that the modification
reduces the recruitment of the adaptor protein MRG15. This protein binds
the negative splicing factor PTB, resulting in exon skipping and, in this way,
the enrichment in H3K4me3 is related to exon inclusion (241). In the present
instance, H3K4me3 is more abundant in N-E7 of HCT116 cells (Fig. 4.30 C)
and this would favour the retention of the upstream exon 6, giving rise to an
increased proportion of isoform T2.
The marks H3K27me3 and H3K27ac cannot occur simultaneously in the
same histone tail. It is not surprising that both marks show opposite ratios
in the three nucleosomes when comparing both cell lines (Fig. 4.30 D and F).
Interestingly, the levels of H3K27ac are usually low and those of H3K27me3
high in ES events (236). As shown in Fig. 4.30 D and F, this in accordance
with the absence of the ES event that results in the higher proportion of
isoform T2 in HCT116.
The marks H3K9me3 and H3K9ac are also incompatible in the same
histone tail. Nevertheless, both, acetylation and methylation are more abun-
dant in the three nucleosomes of HCT116. With the present data it cannot
be decided whether these marks coexist on the same nucleosomes, being
both copies of the H3 histone differently marked, or the differences are due
to the somewhat selective presence of each mark on a different allele of the
gene. The curious fact that H3K9ac is only found in the nucleosomes of the
heterozygotic cells HCT116 may slightly point towards the possibility of the
second hypothesis, but more research has to be carried out to decide between
the two possibilities.
In summary, the results presented in the last two sections of this the-
sis have provided some novel data on the relationships between alternative
splicing and chromatin structure and modifications. Their interest may be
reinforced by the fact that the splicing of two genes selected for the study is
related in one or another way to oncogenesis and this opens novel possibilities
for future work.
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CHAPTER 5
CONCLUSIONS
In the present thesis, the murine Egr1 model has been used to develop a
methodology to study structure and epigenetic modifications of chromatin at
mononucleosomal level. The methodology has been afterwards applied to the
study of the involvement of chromatin in the alternative splicing of a gene of
potential oncogenic interest, selected by in silico analysis and of the KRAS
gene. The experiments carried out allow drawing the following conclusions:
1. Three positioned nucleosomes are present in the Egr1 promoter and
proximal coding region. These nucleosomes, present in both, cells from
the line MLP29 and in in vivo mouse liver, are further referred to as
N-2, N-1 and N+1.
2. In both, cultured cells and regenerating liver models, Egr1 transcrip-
tion results in the downstream sliding of N-2 and in the partial eviction
of N-1 and N+1. The first change allows EGR1 to bind the promoter,
eventually resulting in transcriptional repression. All the changes are
reversible and the nucleosomes return to the basal situation after the
transcription cycle has finished.
3. Knocking-down studies with siRNA suggest that EGR1 is not involved
in the sliding of N-2, but rather in its return to the basal position.
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4. The time-dependent change of eight histone modifications along the
cycle of activation-repression of the gene has been studied at mononu-
cleosomal level. Most of the modifications are nucleosome-specific and
vary qualitative and/or quantitatively from one nucleosome to another.
At the end of the transcriptional cycle, most of the modifications return
to their basal state.
5. The acetylation of H4K16, H3K9 and H3K27 predominates in the pro-
moter nucleosomes; the trimethylation of H3K4, H3K9 and H3K27 are
specific to N+1 to a greater or lesser degree. The acetylation H3K14 is
relatively homogeneous in the three nucleosomes, while H3S10phK14ac
is more abundant in N+1.
6. In a search for isoforms generated by alternative splicing events and ex-
pressed differentially depending on the G13D mutation of KRAS gene,
the in silico spliceR analysis allows the identification of a list of iso-
forms corresponding to five genes. For two of these genes, EPDR1
and ZNF518B, the results were experimentally validated by RT-qPCR
analysis in isogenic cell lines derived from the parental DLD1.
7. By means of an MNase protection assay, the nucleosome occupancy
at the region of alternative splicing and termination of the ZNF518B
gene was studied. Although no strict positioning occurs, the presence
of three peaks in the profile suggests that a preferential position does
exist for three nucleosomes, one at the start of exon 4, and the other
two around the alternative PAS.
8. The MNase resistance profile is almost identical for lines DLD1 and
D-Mut1, which differ in the KRAS mutational status and in the splic-
ing events. Nevertheless, the profile is different in SW48 cell line, in
which the ZNF518B gene is not expressed. Therefore, the nucleosomal
organization does not influence alternative splicing in this instance.
9. The distribution of the marks H3K36me3, H4K20me1, H3K27ac and
H3K9ac has been studied in the three nucleosomal peaks found. In
general, all the modifications are more abundant in the gene-expressing
DLD1 and D-Mut1 cell lines than in SW48 cells. Only slight differences
were found from one to another nucleosomal peak for each of the modifi-
cations. The distribution of most of the modifications is in accordance
with the roles assigned for them in the literature. Additionally, the
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present results suggest that H3K27ac might be involved in alternative
polyadenylation.
10. The expression of KRAS gene and of its splicing isoforms has also been
studied in nine CRC cell lines. Apart from the isoforms 4A and 4B,
for which there are many published data, the expression of the two
remaining isoforms has also been determined. In view of the results,
the cell lines HCT116 and SW48 were selected to study their chro-
matin structure and epigenetic modifications in the regions critical for
splicing.
11. In MNase protection assays, three well positioned nucleosomes, N-E5,
N-E6 and N-E7, were found on the exons involved in alternative splicing
of KRAS gene, with only minor differences between the HCT116 and
SW48 cell lines.
12. The presence of H3K9me3, H3K36me3, H3K4me3, H3K27me3, H3K9ac,
H3K27ac and H4K20me1 has been quantified after Nu-ChIP in the
three above-mentioned nucleosomes. The analysis of the distribution
of acetylated histones suggests that the splicing events are controlled,
in part, by the kinetic coupling model, but the abundance of H3K4me3
in N-E7 is compatible with the participation of other mechanisms for
the selection of the splicing event.
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CHAPTER 6
RESUMEN
6.1 Introduccio´n
La cromatina es una compleja estructura compuesta por DNA, RNA y
prote´ınas, que permite compactar el genoma en las ce´lulas eucariotas. Siendo
el cromosoma el nivel ma´s alto de compactacio´n y el nucleosoma la subunidad
fundamental de la misma. El nucleosoma esta´ compuesto por un octa´mero
de histonas, siendo H2A, H2B, H3 y H4 las cano´nicas. Este octa´mero se
encuentra envuelto por 147 pb de DNA doble cadena. Entre los nucleosomas
se encuentra una zona de DNA flanqueante y la histona H1 (o H5 en algunos
casos), que principalmente cumple una funcio´n en la estabilidad del nucleo-
soma.
La estructura de la cromatina tiene un papel crucial en la regulacio´n de to-
dos los procesos celulares que implican al DNA, entre ellos, la transcripcio´n.
En este sentido, la dina´mica nucleosomal representa un nivel adicional de
la regulacio´n transcripcional. Los cambios epigene´ticos que ocurren en las
histonas, mayoritariamente en la cola N-terminal, ayudan o promueven que
el nucleosoma sea desplazado, parcialmente desensamblado o reestructurado
durante la transcripcio´n. Esto es posible, ya que la combinacio´n de eventos
de modificacio´n de histonas, crea una superficie de unio´n para complejos pro-
teicos espec´ıficos. Esta combinacio´n de eventos es denominado como co´digo
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de histonas.
Los tipos de modificaciones estudiados frecuentemente son la acetilacio´n,
la metilacio´n y la fosforilacio´n de histonas. La acetilacio´n consiste en la
adicio´n de un grupo acetilo al grupo amino de la cadena lateral del residuo
lisina (K-ac). Esta reaccio´n es realizada por las prote´ınas histona acetil-
transferasas (HATs) y el proceso contrario, denominado desacetilacio´n, es
catalizado por las prote´ınas histona deacetilasas (HDACs). Este tipo de
modificacio´n epigene´tica se encuentra relacionada con la activacio´n de la
transcripcio´n.
La metilacio´n corresponde a la adicio´n de uno, dos o tres grupos metilo,
al a´tomo de nitro´geno de las cadenas laterales de los aminoa´cidos arginina
(R-me1, R-me2, R-me3) y lisina (K-me1, K-me2, K-me3). Esta reaccio´n
es catalizada por las enzimas lisina metiltransferasas (PKMTs) y arginina
metiltransferasas (PRMTs) y el proceso contrario es catalizado por las his-
tona desmetilasas. Esta modificacio´n se encuentra involucrada tanto en ac-
tivacio´n como en represio´n ge´nica. Por otro lado, la fosforilacio´n consiste en
la adicio´n de un grupo fosfato al grupo hidroxilo de los residuos serina (S-
ph), treonina y tirosina (T-ph). Esta reaccio´n es catalizada por las prote´ınas
quinasas y el proceso contrario lo es por las prote´ınas fosfatasas. Esta mod-
ificacio´n esta implicada en mu´ltiples procesos celulares.
Estos eventos de modificacio´n en las histonas, permiten reclutar, entre
otros, los complejos remodeladores. Los remodeladores actu´an, junto con
otros factores, empaquetando y desempaquetando el DNA. Se distinguen cua-
tro familias de remodeladores en eucariotas: SWI/SNF, ISWI, CHD y INO80.
Cada una posee un papel particular, por ejemplo, la familia SWI/SNF esta´
implicada en el desplazamiento y en la salida del nucleosoma, mientras que
la familia ISWI se encarga del ensamblaje de los nucleosomas.
Por lo tanto, la estructura de la cromatina y los cambios dina´micos de
e´sta, constituye un nivel adicional en la regulacio´n de la transcripcio´n en
ce´lulas eucariotas.
La transcripcio´n es el proceso por el cual la informacio´n del DNA es
transferida al RNA. En el contexto del presente trabajo se describe solo la
transcripcio´n de los genes estructurales, proceso que es catalizado por la RNA
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pol II y tiene lugar en la eucromatina. El proceso de s´ıntesis del RNA men-
sajero involucra una compleja maquinaria transcripcional y se divide en tres
etapas: iniciacio´n, elongacio´n-ayuste y terminacio´n. En cada una de estas
etapas, la regulacio´n epigene´tica es fundamental.
La etapa de iniciacio´n empieza con la formacio´n del complejo de preini-
ciacio´n (PIC), que involucra una serie de procesos altamente ordenados. Una
vez que los factores de unio´n al DNA, llamados factores trans, se unen a se-
cuencias espec´ıficas en el promotor del gen, llamados elementos cis, se inicia
una cascada de reclutamiento de complejos coactivadores, entre los que se en-
cuentran enzimas modificadoras de histonas, remodeladores y el complejo me-
diador. E´ste u´ltimo constituye un puente entre los factores de transcripcio´n
en trans espec´ıficos del gen unidos a sus sitios cis y los factores generales de
la maquinaria de transcripcio´n, que incluyen TFIIA, TFIIB, TFIID, TFIIE,
TFIIF, y TFIIH.
Un modelo de como la cromatina podr´ıa estar implicada en la formacio´n
del PIC, considera que un elemento en trans reconoce y se une a una zona
libre de nucleosoma en el promotor del gen. Este elemento en trans, es recono-
cido por coactivadores como son los remodeladores de la familia SWI/SNF y
algunas HATs, lo que resulta en la hiperacetilacio´n de H3 y H4 en la regio´n
del promotor proximal, aumentando la movilidad de los nucleosomas. Este
hecho junto con el posible remplazo de histonas, regular´ıa la iniciacio´n de la
transcripcio´n.
Tras la formacio´n del PIC y la posterior fosforilacio´n del CTD, comienza
la etapa de elongacio´n. En el inicio de esta etapa, en genes inmediato tempra-
nos, la polimerasa puede estar pausada y ser activada por algunas sen˜ales.
Durante la elongacio´n, el DNA aguas abajo se separa para proporcionar
acceso al sitio activo de la RNA pol II y posteriormente al paso de la en-
zima se enrolla nuevamente aguas arriba. En este sentido, los nucleosomas
representan una barrera en la s´ıntesis del RNA, por lo que deben ser par-
cial o totalmente expulsados y reestructurados durante la transcripcio´n. En
consecuencia debe existir una sofisticada gama de factores que controlen la
estructura de la cromatina. Por todo lo expuesto aqu´ı, actualmente se pro-
pone que la estructura de la cromatina es uno de los elementos reguladores
fundamentales en el mecanismo de la elongacio´n transcripcional.
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Las modificaciones de fosforilacio´n en las serinas 5 y 2 podr´ıan estar
promoviendo la activacio´n de la polimerasa que, como se menciona anteri-
ormente, se encuentra pausada en algunos genes. A su vez, estas modifica-
ciones estar´ıan involucradas en la alteracio´n de la estructura de la cromatina.
Un gran numero de factores esta´n participando de esta regulacio´n (ver Fig.
1.9). Entre los cuales se encuentran metiltransferasas como Set2, que catal-
iza la acumulacio´n de H3K4me3 en el 5’ final del ORF y la H3K36me3 en
el extremo 3’. Las HATs son reclutadas delante de la RNApol II, inducen
acetilacio´n de las histonas lo que, junto con la accio´n de las chaperonas de his-
tonas, contribuye al desensamblaje y reensamblaje de los d´ımeros H2A/H2B
de los nucleosomas, desestabiliza´ndolos y facilitando el procesamiento por
la RNApolII con la ayuda de remodeladores. Finalmente, la H3K36me3 es
reconocida por el cromo-dominio de las desacetilasas, desacetila los nucleoso-
mas y los estabiliza despue´s de la transcripcio´n. El potencial mecanismo es-
tablecido anteriormente puede explicar ma´s o menos la compleja maquinaria
requerida para que la RNApol II para llevar a cabo la s´ıntesis de mRNA
durante la elongacio´n. Sin embargo, como es tambie´n conocido el mRNA
maduro no incorpora todo el mRNA sintetizado, y se precisa un procesado
del mismo mediante ayuste que transcurre simulta´neamente a la elongacio´n
de la transcripcio´n.
El ayuste se define cano´nicamente como el proceso por el cual los intrones
de un gen, que se esta´ transcribiendo en el mRNA naciente, son eliminados
para obtener un mRNA maduro. Este proceso se lleva a cabo por el ayusto-
soma, compuesto por pequen˜as ribonucleoprote´ınas nucleares y otros factores
de ayuste (SFs). El ayustosoma reconoce los elementos cis en las zonas flan-
queantes entre el intro´n-exo´n correspondiente.
Sin embargo, los 20.000-25.000 genes identificados que codifican prote´ınas
en el genoma humano no explican la gran diversidad de prote´ınas en las
ce´lulas eucariotas, por lo que se conoce que ma´s del 90% de los genes presen-
tan ayuste alternativo. Se han identificado varios tipos de ayuste alternativo
entre los que se encuentran la omisio´n de exo´n (ES), la retencio´n de intro´n
(IR), el sitio 3’ (A3SS) y el sitio 5’ de empalme alternativo (A5SS), y el sitio
de poli-adenilacio´n alternativo (PAS), entre otros.
El mecanismo por el cual el ayuste alternativo se lleva a cabo au´n no
esta´ del todo claro, pero se sabe que la dina´mica de la cromatina partic-
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ipa en la regulacio´n del mismo (ver Fig. 1.10 y 1.12). Usualmente, los
exones cortos se encuentra formando parte de un nucleosoma y se cree que
se debe a la composicio´n de nucleo´tidos de estas zonas. Esta a´rea tambie´n
se caracteriza por la presencia de algunas modificaciones epigene´ticas, como
son: H2BK5me1, H3K4me1, H3K4me2, H3K9me1, H3K9me2, H3K9me3,
H3K27me1, H3K27me2, H3K27me3, H3K36me3, H3K79me1, H3R2me1, R2-
me2, H4K20me1, H4K20me3 y H4R3me2 en los exones y H3K36me1 en los
intrones. Existe evidencia de que la maquinaria epigene´tica puede contribuir
incluso en la seleccio´n de un transcrito sobre otro, lo que puede afectar a su
vez al funcionamiento normal de la ce´lula.
Evidentemente, es necesario proporcionar ma´s datos experimentales sobre
el papel de la cromatina en el proceso del ayuste alternativo para estable-
cer los mecanismos implicados. La transcripcio´n controla todos los procesos
celulares, incluyendo la proliferacio´n celular y a su vez es influenciada direc-
tamente por ellos.
Los desajustes en la transcripcio´n pueden dar lugar a alteraciones en el
ciclo celular. E´ste posee cuatro fases: G1, S, G2 y M. La duracio´n del ciclo y
de sus fases no es uniforme. En las ce´lulas que se reemplazan ra´pidamente es
ma´s corto que en las de recambio ma´s lento. Incluso algunas ce´lulas pueden
dejar de dividirse por senescencia o por entrar en un estado de quiescencia
celular, etapa llamada G0. Mientras que la senescencia es un evento irre-
versible, las ce´lulas quiescentes conservan la capacidad de retornar al ciclo
celular tras la recepcio´n de sen˜ales adecuadas desde el entorno celular. Es
lo que ocurre, por ejemplo, en el h´ıgado. La mayor´ıa de sus ce´lulas son qui-
escentes, pero el ciclo celular se activa ra´pidamente tras una hepatectomı´a
parcial, que provoca la regeneracio´n hepa´tica. Este modelo de regeneracio´n
es de gran intere´s en el estudio in vivo de la sen˜alizacio´n durante el ciclo
celular y en el de los genes inmediatos-tempranos implicados en este proceso.
Junto con otros, un gen inmediato-temprano es EGR1. Pertenece a una
familia de genes que se activan, ra´pida pero transitoriamente, por una amplia
variedad de est´ımulos extracelulares, como mito´genos. Codifica la prote´ına
EGR1, que actu´a como un factor de transcripcio´n. EGR1 contiene un do-
minio de unio´n a DNA altamente conservado compuesto por tres dedos de
zinc que se unen a la secuencia de consenso GCG(G/T)GGGCG.
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En trabajos anteriores en el laboratorio, usando la l´ınea celular progen-
itora de hepatocitos de rato´n MLP29, activada con TPA, se ha mostrado
que la transcripcio´n de Egr1 se inicia a los 5 min de la induccio´n y vuelve
a los valores basales 180 min despue´s de la adicio´n de TPA. El ma´ximo de
transcripcio´n se da a los 30 min de la adicio´n de TPA. El promotor de Egr1
contiene un sitio similar al ETS (ELK1), elementos de respuesta al suero
(SRE), de respuesta a cAMP (CRE), de unio´n al propio producto EGR1
(EBS) y dos elementos para SP1 (Fig. 1.13). EGR1 se une principalmente
en el sitio -593 y, por el reclutamiento de NAB1/2 contribuye a la represio´n
posterior de la transcripcio´n. Tambie´n se ha estudiado el curso temporal de
unio´n de todos estos factores. Algunos estudios han mostrado que el sitio
EBS se encuentra en el promotor de genes implicados en el crecimiento celu-
lar y en la progresio´n del ca´ncer, por lo que el estudio del gen EGR1 es
interesante en el campo de la oncolog´ıa.
El ca´ncer colorrectal (CCR) es el tercer ca´ncer ma´s comu´n en todo el
mundo, con una incidencia superior a 1,36 millones cada an˜o, que aumenta
ra´pidamente en varias a´reas histo´ricamente de bajo riesgo, incluyendo Espan˜a.
Se cree que tales tendencias desfavorables reflejan una combinacio´n de fac-
tores que incluyen cambios en los ha´bitos alimentarios, obesidad y un mayor
la prevalencia del consumo de tabaco. Menos del 10% de los casos de CCR
se explican por la herencia.
Para los casos espora´dicos de CCR, como para otros tipos de ca´ncer,
las tres causas principales en su desarrollo son la inestabilidad cromoso´mica
(CIN), la inestabilidad de microsate´lites (MSI) y la metilacio´n de las islas
CpG, que causa el silenciamiento de genes. Estos tres procesos no son mutu-
amente exclusivos y pueden ocurrir juntos en ciertos casos. En los con CIN se
da un conjunto caracter´ıstico de mutaciones en oncogenes y genes supresores
de tumores. No esta´ claro si CIN crea un entorno apropiado para la acumu-
lacio´n de estas mutaciones o viceversa. Los genes ordinariamente mutados en
pacientes con CCR con CIN son APC, PT53 y KRAS. Asimismo, en CCR
hay unas v´ıas espec´ıficas de sen˜alizacio´n implicadas en su desarrollo, entre
las que se encuentran la ruta de Wnt, alterada por una o ma´s mutaciones en
el 93% de los pacientes, o la ruta RTK/RAS/PI3K que se altera en ma´s del
80% de los pacientes.
Las mutaciones en el oncoge´n KRAS se observan en el 60% a 95% de los
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focos de criptas aberrantes no-displa´sicos o hiperpla´sicos, dando lugar a la
activacio´n constitutiva de la ruta de sen˜alizacio´n. Las mutaciones de TP53 se
presentan en 50% -75% de los CCRs. Otros eventos, como la sobreexpresio´n
aberrante de la ciclooxigenasa-2 (COX-2) (43% de los adenomas y 86% de los
carcinomas) y la pe´rdida ale´lica en el cromosoma 18q (70% de CCR primario)
tambie´n participan en el proceso de tumorige´nesis. La gran cantidad de in-
formacio´n ha aumentado la comprensio´n de la enfermedad y todos los genes
mencionados anteriormente son potenciales marcadores moleculares para el
diagno´stico, el prono´stico y la terapia dirigida, pero queda mucho trabajo
pendiente en este campo.
Los tratamientos tradicionales para el CCR son la cirug´ıa, la ablacio´n y la
radiacio´n (estadio II, III, IV), la quimioterapia (estadio II, III, IV) y la terapia
dirigida (estadio IV y recidivante). La quimioterapia utiliza medicamentos
para interrumpir el crecimiento de ce´lulas cancerosas, o evitar su multipli-
cacio´n. La terapia dirigida incluye anticuerpos monoclonales e inhibidores
de la angioge´nesis, que atacan de forma espec´ıfica a las ce´lulas cancerosas sin
dan˜ar a las normales. En la pra´ctica cl´ınica, la terapia dirigida ma´s utilizada
es la que incluye anticuerpos monoclonales contra el dominio extracelular
del receptor del factor de crecimiento epide´rmico (EGFR). En condiciones
homeosta´ticas, la activacio´n del receptor esta´ regulada por la disponibilidad
de ligandos, que forman colectivamente la familia del factor de crecimiento
EGF.
La activacio´n del EGFR estimula una sen˜alizacio´n intracelular compleja,
cuyas principales rutas son las de RAS/RAF/MEK/ERK, PI3K/AKT y PLC
/PKC. La desregulacio´n de la actividad de EGFR se ha relacionado con el
desarrollo, la progresio´n y la diseminacio´n metasta´sica. Por eso, se han con-
centrado esfuerzos en el desarrollo de inhibidores que se dirigen efectivamente
a EGFR, debido a que la sobreexpresio´n, el aumento de la actividad o la pres-
encia de mutaciones en EGFR puede ser un factor causal en la etiolog´ıa de
ca´nceres epiteliales humanos. Se emplean actualmente dos anticuerpos mon-
oclonales, el cetuximab aprobado en 2004 por la FDA y el panitumumab,
aprobado en 2006.
Cetuximab es un anticuerpo monoclonal, que bloquea directamente la
unio´n del ligando al EGFR, y limita la activacio´n de varias v´ıas de trans-
duccio´n de sen˜al. Panitumumab es un anticuerpo monoclonal totalmente
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humano que se une al dominio extracelular de EGFR con una alta afinidad y
bloquea la unio´n de ligandos. Asimismo, inhibe la activacio´n de las ce´lulas de
los tumores dependientes de EGF, la fosforilacio´n de la tirosina de EGFR, y
la proliferacio´n. Tambie´n se emplea en terapia dirigida, incluso en pacientes
con CCR metasta´sico (CCRm) el regorafenib, un inhibidor de la actividad
prote´ına quinasa de muchas enzimas.
La combinacio´n de terapias dirigidas a pacientes con meta´stasis hepa´ticas
que poseen KRAS de tipo salvaje ha ampliado la tasa de respuesta antitu-
moral hasta ma´s del 70%. Sin embargo, la terapia dirigida no es eficaz en
todos los pacientes y el prono´stico para los pacientes CCR metasta´sico sigue
siendo pobre. Muchos estudios muestran que el tratamiento en los pacientes
portadores de mutaciones en el gen KRAS no resulta beneficioso, y la su-
pervivencia tras el tratamiento con anticuerpos anti-EGFR solos o en com-
binacio´n con quimioterapia es baja. Por lo tanto, es evidente la necesidad de
obtener nuevas dianas para la terapia contra la CCR.
Los mecanismos epigene´ticos juegan un papel esencial el desarrollo y pro-
gresio´n del ca´ncer y su desregulacio´n puede provocar la expresio´n aberrante
de patrones que dan origen a todas las caracter´ısticas t´ıpicas de ca´ncer. En
la actualidad ya existe una primera generacio´n de terapias epigene´ticas que
incluyen fa´rmacos dirigidos contra las DNA metiltransferasas, las desaceti-
lasas de histonas y la quinasa Janus 2 (JAK2). Sin embargo, estas terapias
alteran de forma no totalmente espec´ıfica los patrones epigene´ticos y pueden
tener efectos secundarios no deseados. Se esta´n desarrollando nuevas ter-
apias epigene´ticas, en fase precl´ınica y cl´ınica, que incluyen inhibidores de la
enzima poli-ADP ribosa polimerasa (PARP), de histona desmetilasas, de his-
tona acetiltransferasas, etc. A pesar de estos avances prometedores, todav´ıa
hay muchas cuestiones sin respuesta. Por ejemplo, ser´ıa deseable encontrar
los mecanismos que permitan una regulacio´n epigene´tica espec´ıfica de genes,
o de sus isoformas. Tambie´n es interesante saber co´mo una sola mutacio´n
en un oncoge´n, como es el caso del KRAS, puede influir en la respuesta al
tratamiento del ca´ncer y co´mo puede estar involucrada la maquinaria epi-
gene´tica.
El gen KRAS es, junto con NRAS y HRAS miembro de la familia
Ras. Esta´ localizado en el brazo corto del cromosoma 12 en la posicio´n
12,1 (Chr12: 25358180- 25403870, GRCh37) y codifica una prote´ına de 21
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kDa, que pertenece a la superfamilia de GTPasas pequen˜as. Da lugar a dos
prote´ınas muy estudiadas, KRAS 4A y KRAS 4B. Las mutaciones en KRAS
representan el 86% de las mutaciones RAS que se encuentran en CCR con
una incidencia de aproximadamente el 15% en todos los tumores humanos y
de 30 a 50% en el CCR. Las mutaciones en los codones 12 y 13 dan cuenta de
la mayor´ıa de las mutaciones activadoras, y hay tambie´n algunas mutaciones
menos comunes en el los codones 61, 63 y 146 (<5% de las mutaciones totales
en KRAS ). Estas mutaciones de limitan el uso de terapias anti-EGFR ya que
hacen constitutivamente activa la ruta de sen˜alizacio´n con independencia de
la unio´n de ligando al receptor.
Aunque estudios recientes han demostrado que las diferentes mutaciones
en KRAS, tienen diferentes repercusiones en las rutas de sen˜alizacio´n y en la
respuesta al tratamiento de CCR, quedan por resolver muchas cuestiones rel-
ativas a las u´ltimas consecuencias de la alteracio´n de las v´ıas de sen˜alizacio´n.
Por otra parte, tambie´n es de destacar que, aunque las mutaciones que
afectan al gen KRAS esta´n bien caracterizadas, la epigene´tica de este gen no
esta´ bien estudiada.
En los u´ltimos an˜os se han desarrollado nuevas tecnolog´ıas y herramientas
bioinforma´ticas para el ana´lisis de la expresio´n ge´nica. En el an˜o 2006 se de-
sarrollo´ una te´cnica de segunda generacio´n para secuenciar todo el transcrip-
toma, la secuenciacio´n masiva en paralelo de ARN (RNAseq) en forma de
cDNA. Con RNAseq no so´lo es posible comparar los niveles de transcripcio´n
en diferentes condiciones, sino tambie´n conocer la secuencia del transcrito de
cDNA. Este fue un paso importante en el estudio a gran escala del ayuste
alternativo, lo que permitio´ el descubrimiento de nuevas isoformas y su cuan-
tificacio´n. Todos estos resultados han proporcionado informacio´n valiosa en
el estudio de la ocurrencia del ayuste alternativo en ce´lulas de ca´ncer.
En 2010 Trapnell et al. pusieron a disposicio´n de la comunidad cient´ıfica
un protocolo de ana´lisis de RNAseq. Este protocolo consiste en la utilizacio´n
del Software Bowtie para indexar el genoma de referencia; el software TopHat,
para alinear las secuencias en el genoma de referencia; el software Cuﬄinks
para estimar la abundancia de cada transcrito en una muestra; el software
Cuffmerge para tener una referencia de coordenadas de su posicio´n en el
genoma de las lecturas de dos o mas muestras; el software Cuffdiff para com-
parar la abundancia de genes e isoformas entre dos o ma´s muestras.
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El ana´lisis RNAseq permite estudiar las diferencias entre el transcriptoma
de dos o ma´s condiciones celulares debidas, por ejemplo, a una u´nica mu-
tacio´n. De esta manera se puede establecer una relacio´n entre la presencia
de la mutacio´n y los cambios en la expresio´n de genes que directa o indi-
rectamente esta´n siendo afectados. El poder de estas nuevas estrategias de
estudio permite dilucidar los mecanismos por los que una sola mutacio´n, en
sinergia con otras, puede alterar la regulacio´n celular. De esta manera, las
herramientas bioinforma´ticas proporcionan un me´todo valioso para identi-
ficar, mediante un ana´lisis in silico, nuevas dianas terape´uticas a la vez que
permiten predecir los posibles efectos in vitro.
6.2 Objetivos
El presente trabajo estudia los mecanismos de regulacio´n de la expresio´n
ge´nica a nivel mononucleosomal. Dos aspectos de estos mecanismos fueron
analizados espec´ıficamente. En primer lugar, los cambios que ocurren en el
promotor, ya que tienen una importancia decisiva para la iniciacio´n de la
transcripcio´n. En segundo lugar, los mecanismos implicados en la regulacio´n
del ayuste alternativo, que, a su vez, implica en muchos casos el escape de
RNA polimerasa a partir de un complejo de pausa, y el acoplamiento entre
la procesividad de la RNA polimerasa y el ayuste.
Para lo anterior se desarrollaron las siguientes objetivos:
Estudiar los cambios en la cromatina que se producen
en el promotor de un gen mediante la aplicacio´n de una
metodolog´ıa para el estudio del posicionamiento y las
modificaciones epigene´ticas a nivel mononucleosomal.
Para este primer objetivo general se selecciono´ el gen murino Egr1, dado
que previamente en el laboratorio se hab´ıan caracterizado muchos aspectos
de la arquitectura de su promotor [ver (78)]. Estas circunstancias hacen a
este gen el material de eleccio´n para poner a punto la metodolog´ıa que per-
mita detectar los cambios temporales en la ocupacio´n nucleosomal y en las
marcas epigene´ticas a nivel mononucleosomal. Se utilizara´n dos modelos de
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induccio´n de la transcripcio´n del gen Egr1.
1. Un modelo in vitro utilizando la l´ınea celular de rato´n MLP29 tratada
con TPA, para:
(a) Determinar la posicio´n de los nucleosomas en el promotor proximal
y el inicio de la regio´n transcribible del gen Egr1.
(b) Estudiar el efecto del silenciamiento de Egr1 en la posicio´n de
nucleosomas individuales en el promotor de este gen.
(c) Analizar los cambios temporales de las modificaciones de las his-
tonas en nucleosomas individuales sobre el promotor proximal y
en la regio´n de inicio de la transcripcio´n del gen Egr1.
2. Un modelo in vivo de regeneracio´n hepa´tica tras hepatectomı´a parcial
en ratones, para:
(a) Comprobar si la metodolog´ıa para el posicionamiento nucleosomal
utilizado en los experimentos in vitro se pueden extrapolar in vivo.
(b) Comparar la posicio´n de los nucleosomas con la del modelo in vitro
en la regio´n estudiada.
Estudiar el posicionamiento y las modificaciones epi-
gene´ticas en los genes con eventos de ayuste alternativo
alterados en las l´ıneas celulares de CCR en funcio´n del
estado mutacional del gen KRAS.
La desregulacio´n del ayuste alternativo esta´ involucrado en muchos proce-
sos patolo´gicos, incluyendo el ca´ncer. El grupo de investigacio´n del que formo
parte esta´ trabajando actualmente en un proyecto dedicado a la investigacio´n
de la influencias de la mutacio´n de KRAS en la resistencia a los fa´rmacos
anti-EGFR en CCR. Los resultados preliminares sugieren que algunos pa-
trones epigene´ticos y ciertos cambios estructurales de la cromatina pueden
influir en oncogenicidad al afectar al ayuste alternativo. De esta manera, el
estudio de los mecanismos de regulacio´n de ayuste alternativo a nivel de la
cromatina tiene especial relevancia.
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Los objetivos espec´ıficos son:
1. Identificar, mediante el ana´lisis in silico de datos de RNAseq , genes
que muestran isoformas diferenciales producidos por ayuste alternativo
en relacio´n al estado mutacional de KRAS, en l´ıneas celulares de CCR.
2. Seleccionar, a partir de la anterior lista de genes, los que tienen mayor
intere´s en oncolog´ıa traslacional y verificar el nivel de expresio´n difer-
encial de las isoformas en l´ıneas celulares que difieren en la mutacio´n
de KRAS.
3. Estudiar el posicionamiento nucleosomal y las modificaciones epigene´ticas
en las regiones de la cromatina del ayuste alternativo que tienen lugar
en los genes seleccionados.
Estudiar el posicionamiento y las modificaciones epi-
gene´ticas en la regio´n de ayuste alternativo del gen
KRAS en l´ıneas celulares de CCR.
Se ha descrito que el gen KRAS da lugar a dos isoformas, KRAS 4A y
KRAS 4B, por un evento de ayuste alternativo, lo que genera dos prote´ınas
que difieren en su localizacio´n subcelular y en su actividad. Se ha demostrado
que un aumento de la relacio´n KRAS 4B/KRAS 4A se asocia a un peor
prono´stico en pacientes con CCR. Por todo ello se decidio´ incluir el ana´lisis
de la estructura de la cromatina y marcas epige´neticas en la regio´n de KRAS
implicada en la seleccio´n entre estas dos isoformas.
Los objetivos espec´ıficos son:
1. Determinar los niveles de expresio´n de las isoformas del gen KRAS
generadas por ayuste alternativo en l´ıneas de CCR.
2. Estudiar el posicionamiento nucleosomal y las modificaciones epigene´ticas
en la regio´n de ayuste alternativo del gen KRAS.
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6.3 Resultados y discusio´n
Posicionamiento y modificaciones de histonas en el pro-
motor del gen Egr1
En los resultados previos obtenidos en el laboratorio, se establecio´ el ciclo
de activacio´n/represio´n del gen Egr1, mediante el tratamiento con TPA en
la l´ınea celular MLP29 y se caracterizaron los elementos de su promotor.
Por lo tanto, Egr1 ofrece un modelo pra´ctico para estudiar los cambios en
la estructura y la epigene´tica de la cromatina que ocurren en un promotor,
tanto en la fase de activacio´n como de represio´n en el proceso de expresio´n
transitoria del gen.
Se determino´ en primer lugar las posiciones de los nucleosomas en el pro-
motor y en la regio´n proximal de la transcripcio´n del gen Egr1 por medio de
un ensayo de proteccio´n a MNasa en la regio´n de -800 a 400 en relacio´n con
TSS. Como se muestra en la Fig.4.1 A, los resultados indican la presencia de
tres a´reas protegidas, dos en el promotor y la tercera al principio de la regio´n
codificante. Estas regiones son de taman˜o compatibles con la presencia de
nucleosomas, por lo que se le denominan como nucleosomas -2 (N-2), -1 (N-1)
y +1 (N+1). La posicio´n de los nucleosomas en el a´rea de estudio coincide en
te´rminos generales con la probabilidad de localizacio´n de nucleosomas hecha
por el programa NuPoP (Fig. 4.2 A).
Una vez que la posicio´n de los nucleosomas en el estado basal del gen
(tiempo 0) fue establecida, la investigacio´n se continuo´ con el estudio de la
dina´mica nucleosomal en el ciclo de la activacio´n/represio´n de Egr1. Los
resultados muestran la presencia de cambios claros en la ocupacio´n nucleoso-
mal que se producen en paralelo al de la transcripcio´n. Los nucleosomas N-1
y N+1 disminuyen la proteccio´n frente a la digestio´n con MNasa cuando el
gen se activa, mientras que en el nucleosoma N-2 se observa un deslizamiento
aguas abajo (Fig. 4.1). Estos cambios son apreciables ya desde los 5 min
despue´s de la adicio´n de TPA a las ce´lulas MLP29 y alcanza su ma´ximo a los
30 min, mientras que a los 180 min los nucleosomas vuelven a su estado basal.
Para conocer si el deslizamiento del nucleosoma -2 y el desalojo parcial de
los nucleosomas -1 y +1 es una peculiaridad de las ce´lulas MLP29, o consti-
tuye una forma general de activacio´n a un nivel de la cromatina para Egr1, se
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hicieron ensayos similares de proteccio´n a nucleasa durante la regeneracio´n
hepa´tica tras hepatectomı´a parcial.
Primero se estudia el ciclo de activacio´n del gen Egr1 en el modelo in
vivo mediante qRT-PCR. Los resultados indican que el gen se transcribe ya
a los 30min despue´s de la hepatectomı´a parcial, observa´ndose un pico de acu-
mulacio´n de mRNA a las 3 horas para los tiempos estudiados. Por u´ltimo,
la expresio´n de Egr1 decayo´ y volvio´ al nivel basal a las 24 h. Suponiendo
que la tasa de recambio de mRNA es comparable en ambos sistemas experi-
mentales, el ma´ximo de la tasa de transcripcio´n en la regeneracio´n hepa´tica
podr´ıa tener lugar a 1,75 h despue´s de la hepatectomı´a parcial (ver Fig. 4.3).
El ensayo de proteccio´n frente a la digestio´n con MNasa a 1,75 h y a
24 h despue´s de la hepatectomı´a parcial, comparado con los animales con
operacio´n simulada, mostro´ que ambos modelos biolo´gicos se comportan de
una manera similar (Fig. 4.4). Como ocurre en las ce´lulas MLP29 despue´s
de 30 min del tratamiento con TPA (Fig. 4.1 d), en el modelo in vivo el
nucleosoma N-2 se desliza aguas abajo despue´s de 1,75 h de hepatectomı´a
parcial. Los nucleosomas N-1 y N+1 disminuyen su proteccio´n, aunque el
nucleosoma N+1 se encuentra mejor posicionado que en el modelo in vitro
y se desplaza aguas abajo como ocurre con N-2 (Fig. 4.4 A). Finalmente, a
las 24 h despue´s de la hepatectomı´a parcial, el perfil de proteccio´n frente a
la MNasa vuelve a su estado basal al igual que lo hace la expresio´n del gen
(Fig. 4.4 B). Por lo anterior se puede afirmar que los cambios observados en
los nucleosomas no se deben a una peculiaridad del modelo.
Por otra parte, es posible que el deslizamiento del nucleosoma -2 se re-
quiere para que la prote´ına EGR1 pueda unirse a su sitio en -595, lo que
a su vez, podr´ıa conducir a la represio´n del gen despue´s de reclutar NAB1
y NAB2. Por lo que, para determinar si la presencia de la prote´ına EGR1,
que se observa en los ensayos ChIP de alta resolucio´n, es de alguna manera
la causa el deslizamiento de nucleosoma -2, se realizaron ensayos de silenci-
amiento ge´nico con siRNAs.
Los resultados muestran que los siRNAs de Egr1 disminuyen los niveles
de mRNA hasta un 43% en 15 min, a 31% en 30 min y 15, 4% a los 60 min de-
spue´s de tratamiento con TPA cuando se compara con el siRNA inespec´ıfico
(Fig. 4.5 B). Adema´s, la prote´ına EGR1 es indetectable en Western blot tras
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el tratamiento con siRNA Egr1 -2 a los distintos tiempos de activacio´n del
gen (Fig. 4.5 C).
El estudio de la ocupacio´n nucleosomal tras el silenciamiento de Egr1
en las ce´lulas MLP29, muestra que en las ce´lulas transfectadas con Egr1
siRNA-2, el deslizamiento aguas abajo del nucleosoma -2 es ma´s notable y
ma´s duradero que en las ce´lulas MLP29 transfectadas con el siRNA control
y a los 60 min permanece en la misma posicio´n que a los 30 min (Fig. 4.6 A).
Por otra parte, los cambios temporales en el nucleosoma -1 (Fig. 4.6 B) no
se ven afectados despue´s del tratamiento con siRNA Egr1, es decir, a los 30
min despue´s del tratamiento con TPA el nivel de proteccio´n contra MNasa
decae y vuelve a los valores basales, a los 60 min.
Los presentes resultados sugieren que EGR1 esta´ involucrada en la represio´n
del gen Egr1. Este hecho esta´ de acuerdo con datos previos que indican que
EGR1, NAB1 y NAB2, permanecen unidos al promotor de Egr1.
Finalmente, se estudian las modificaciones en histonas de nucleosomas
individuales (mediante Nu-ChIP) en el promotor y al inicio de la regio´n
transcribible, durante el ciclo de activacio´n/represio´n del gen Egr1 en las
ce´lulas MLP29.
El ana´lisis de las marcas epigene´ticas incompatibles, tales como aceti-
lacio´n y metilacio´n del mismo residuo de lisina, dio resultados opuestos, los
que puede ser considerado como un control interno de la fiabilidad de los
me´todos utilizados.
El nivel de la modificacio´n H3S10phK14ac, que constituye un doble sello
caracter´ıstico de genes inmediatos-tempranos, alcanza en el gen Egr1 un nivel
ma´ximo 15 min despue´s del tratamiento con TPA, y vuelve al nivel basal a
los 30 min. Por otra parte, esta modificacio´n se produce preferentemente
en el nucleosoma +1. Esta modificacio´n ra´pida y transitoria precede a otras
modificaciones y a la transcripcio´n en s´ı, que llega a un ma´ximo a los 30 min
de la induccio´n. Estos datos sugieren que la fosfoacetilacio´n de H3 en el N+1
es decisiva para un reclutamiento productivo de la RNA polimerasa, pero no
es necesaria para el mantenimiento de la transcripcio´n.
La marca H3K14ac, reconocida inicialmente como una modificacio´n de
histona activadora, se encuentra intensa en todos los nucleosomas estudi-
ados a los 15 min despue´s de la estimulacio´n con TPA, especialmente en
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nucleosomas -1 y +1 (Fig. 4.7 B). Parece claro que, despue´s de 15 min de
tratamiento, el curso temporal de la variacio´n H3S10phK14ac en nucleosoma
+1 es paralela a la de H3K14ac. En ese nucleosoma, tanto H3S10phK14ac
como H3K14ac regresan a su valor basal a los 30 minutos despue´s de la
adicio´n de TPA. Por otra parte, las modificaciones H3K4me3 (Fig. 4.7 D),
H3K9me3 (Fig. 4.7 E) y H3K27me3 (Fig. 4.7 G), son espec´ıficas del nucle-
osoma +1 en mayor o menor grado.
La marca epigene´tica H3K9me3 ha sido descrita como caracter´ıstica de
la heterocromatina, es capaz de reclutar HP1, que participa en la formacio´n
de heterocromatina y, en consecuencia, en el silenciamiento de genes. Puede
parecer extran˜o que esta marca epigene´tica puede encontrarse en el N+1, es-
pecialmente entre 15 y 60 min despue´s de TPA adicio´n (Fig. 4.7 E), cuando
la tasa de transcripcio´n es ma´s alta. El estudio por Nu-ChIP (Fig. 4.7 I)
de la presencia de HP1 en el promotor mostro´ que su presencia era paralela
a la modificacio´n de H3, y estaba presente en N+1, en particular, a los 15
min despue´s de la adicio´n de TPA. Estos resultados esta´n de acuerdo con los
datos de algunos autores que encuentran que la presencia de H3K9me3 y de
HP1 esta´ asociada con la elongacio´n de la transcripcio´n.
Los cambios en H3K27me3 siguen un patro´n similar al de H3K9me3. Los
nucleosomas -2 Y -1 esta´n apenas metilados, aunque el N+1 es claramente
modificado, con un ma´ximo a los 30-60 min despue´s de la adicio´n de TPA.
H3K27me3 se ha descrito cla´sicamente como una marca de represio´n, y los re-
sultados muestran que la “marca bivalente activadora/represora de H3K4me3
y H3K27me3” se asocian preferencialmente con el mismo nucleosoma (Fig.
4.7 D y G). No es posible saber si lo hacen en la misma cola de histonas,
o si son el resultado aditivo de dos eventos diferentes, la H3K4me3 para el
recambio de la histona, y la H3K27me3, que inhibe la elongacio´n por la ARN
pol II, relacionado con la disminucio´n de la tasa de transcripcio´n de 30 min
en adelante.
Como era de esperar, el patro´n acetilacio´n de H3K27 (Fig. 4.7 F) y H3K9
(Fig. 4.7 H) es opuesta al de metilacio´n de los mismos residuos y los nucle-
osomas ma´s fuertemente acetilados, es decir, los localizados en el promotor
esta´n apenas metilados y viceversa. Las modificaciones H4K16ac y H3K9ac
son especialmente intensas en el nucleosoma -1.
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Los resultados obtenidos permiten el disen˜o de un modelo de cambios es-
tructurales y de modificaciones de histona durante la activacio´n y la represio´n
del gen Egr1 (Fig. 4.8). Las ventajas de llevar a cabo estos estudios a res-
olucio´n mononucleosomal son importantes para la remodelacio´n de la cro-
matina y la adquisicio´n de marcas activadoras o represoras, ya que estas
pueden actuar de manera distinta y espec´ıfica de nucleosoma. El obje-
tivo final de un estudio epigene´tico debe ser el establecimiento de relaciones
causales entre las modificaciones epigene´ticas y sus efectos aguas abajo del
gen, pero es necesario realizar investigacio´n adicional para establecer estas
conexiones.
Una vez que se has establecido las condiciones para estudiar los cambios
en la estructura de la cromatina y en las marcas epigene´ticas a una resolucio´n
mononucleosomal en el modelo murino del gen Egr1, la investigacio´n se dirigio´
al estudio de la influencia de la estructura de la cromatina y modificaciones
epigene´ticos en el ayuste alternativo de genes potencialmente implicados en
la resistencia a los fa´rmacos anti-EGFR asociada a la mutacio´n G13D en el
gen KRAS en el CCR.
Seleccio´n de un gen candidato para el estudio de la es-
tructura y funcio´n de la cromatina en el ayuste
Este trabajo corresponde a la primera parte del segundo objetivo de la
presente tesis. En el que mediante estudios de RNAseq se seleccionan genes
candidatos que poseen isoformas producidas por ayuste alternativo y difer-
encialmente expresadas en relacio´n a la mutacio´n G13D en el oncoge´n KRAS.
Para ello, ocho conjuntos de datos de RNAseq, que corresponden al tran-
scriptoma de las l´ıneas celulares RKO, SW48, Caco2 (dos juegos), HCT116
(tres conjuntos) y DLD1, fueron descargados desde la base de datos de SRA.
La l´ınea celular SW48 es de tipo salvaje en los cuatro oncogenes descritos y
por lo tanto se utiliza como control en las comparaciones. Las l´ıneas celulares
DLD1 y HCT116 comparten la misma mutacio´n KRAS G13D, pero DLD1
alberga diferentes mutaciones en PIK3CA y TP53 mientras HCT116 es de
tipo salvaje en el u´ltimo gen. La l´ınea celular RKO comparte la mutacio´n
PIK3CA con HCT116, pero RKO poseen una mutacio´n en BRAF. La l´ınea
celular Caco2 alberga una mutacio´n en TP53 (ver Tabla 4.2).
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Tras la aplicacio´n de los paquetes informa´ticos descritos en materiales
y me´todos, se obtiene una lista final de isoformas diferencialmente expre-
sadas en relacio´n a la presencia de la mutacio´n KRAS G13D (Tabla 4.3).
Estas isoformas pertenecen a los genes ENO1, RPL13, ZNF518B, EPDR1 y
HSP90B1, y sus valores de expresio´n in silico expresados en en FPKM, se
muestra en la Fig. 4.12. Los resultados obtenidos en el ana´lisis in silico se
verificaron experimentalmente por RT-qPCR.
De los genes encontrados tras el ana´lisis de spliceR, se han seleccionado
EPDR1 y ZNF518B para continuar el ana´lisis experimental, por dos razones
principales: por un lado, los resultados experimentales esta´n en excelente
acuerdo con los del ana´lisis in silico, en el que existe una significativa ex-
presio´n diferencial de las isoformas cuando las l´ıneas que llevan la mutacio´n
KRAS G13D, en concreto HCT116 y DLD1, se comparan con las l´ıneas celu-
lares KRAS salvaje; Por otro lado los resultados sugieren que la transcripcio´n
de estos genes esta activada por la mutacio´n en KRAS.
En los genes RPL13, ENO1 o HSP90B1, o bien los datos in silico fueron
poco concordantes con los experimentales, o bien no es posible disen˜ar oligonu-
cleo´tidos para amplificar regiones u´nicas en las diferentes isoformas para es-
tudiarlas separadamente.
Para continuar el estudio, se utilizan las l´ıneas celulares derivadas de
HCT116 (HAE6 y HAF1) y las derivadas de DLD1 (D-Mut1 y DWT7). En
el caso del gen ZNF518B, cuando se observan los resultados de expresio´n
obtenidos en la las l´ıneas celulares DLD1 y sus isogenicas, parece existir una
clara relacio´n entre el estado mutacional del gen KRAS y los niveles de ex-
presion de e´ste y de sus isoformas. En relacio´n con la expresio´n particular
de las isoformas, las isoformas 326756, 507515 y 503068 dan cuenta para
la mayor´ıa de las transcripciones (Fig. 4.20, B, C y E), mientras que las
isoformas 515072 y 500268 corresponden a una pequen˜a minor´ıa de las tran-
scripciones del gen (Fig. 4.20 D y F).
De entre los dos genes mencionados, se ha elegido el gen ZNF518B para
el estudio en profundidad del posicionamiento de nucleosomas y las mar-
cas epigene´ticas en las regiones de ayuste alternativo del mismo. Los datos
publicados hasta el momento sobre el mismo son particularmente escasos.
ZNF518B se ha descrito como un marcador potencial de la gota y un estudio
144
proteo´mico reciente describio´ que la prote´ına regula los niveles de H3K9me2,
debido a su interaccio´n con complejos de histona metiltransferasa. Este he-
cho es particularmente interesante en vista de los objetivos finales a los que
el trabajo del laboratorio esta´ dirigido. El hecho de que la funcio´n de la
prote´ına au´n no se entienda completamente an˜ade otro punto interesante
para su estudio, ya que tiene potencial para ser propuesto como una nueva
diana para las terapias antitumorales en CCR.
Posicionamientos y modificaciones en el evento de poli-
adenilacio´n alternativa en el gen ZNF518B
El gen ZNF518B, da lugar a cinco transcritos, aunque solo dos de ellos
codifican prote´ınas. El trascrito que se denomina T1, codifica una prote´ına
con dedos de zinc de 1074 aminoa´cidos. El transcrito denominado como T2
es el resultado de mu´ltiples eventos de omisio´n/inclusio´n de exo´n y de una
terminacio´n alternativa. Tambie´n es supuestamente traducido, lo que dar´ıa
lugar a una prote´ına corta que contiene los primeros 75 residuos. Nada se
sabe acerca de su presencia en las ce´lulas y de su posible papel. La Fig. 4.21
muestra el mapa del gen, la estructura de las isoformas de T1 y T2, as´ı como
la localizacio´n de las prote´ınas codificadas. El ana´lisis del ratio de expresio´n
de la isoforma T2 frente a T1 de ZNF518B muestra diferencias entre las
l´ıneas celulares DLD1 (G13D/+) y D-Mut1 (G13D/-), lo que se correlaciona
con el estado mutacional de KRAS, cuando se compara con la l´ınea celular
control SW48.
La regio´n seleccionada para el estudio de la estructura de la cromatina en
las isoformas del gen ZNF518B, cubre la regio´n de la frontera intro´n-exo´n 4
que esta´ implicada en uno de los eventos de ayuste alternativo que da lugar
a los transcritos T1 y T2. Mediante el uso del mismo enfoque experimen-
tal empleado para estudiar el promotor de gen murino Egr1, se estudio´ la
ocupacio´n nucleosoma en esa regio´n y se seleccionaron los amplicones para
analizar las marcas epigene´ticas por Nu-ChIP.
Los resultados de ensayos de proteccio´n a MNasa en la regio´n de estudio
de 800 pb (Fig. 4.23), sen˜alan que los nucleosomas no esta´n tan posicionados
si se compara con el promotor de Egr1 (Fig. 4.1 A). Esto esta´ de acuerdo
con la prediccio´n realizada por el programa NuPop (Fig. 4.24), en el que
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no se tiene un claro patro´n de probabilidad para comenzar los nucleosomas
y las mesetas de ocupacio´n nucleosomal son cortas o demasiado bajas para
obtener a los nucleosomas claramente posicionados.
La proteccio´n frente a MNasa muestra un perfil desigual (Fig. 4.23), en
el que se pueden observar tres picos de posicionamiento nucleosomal. Uno
de los picos observados se encuentra cerca del extremo 5’ terminal del exo´n
4 (N1), y otro pico se observa en la regio´n donde se produce la terminacio´n
alternativa de la T2 (N3). Ni la posicio´n de los picos ni su intensidad cambia
significativamente en las ce´lulas DLD1 al comparar los datos con D-Mut1, a
pesar de la diferencias en el empalme y terminacio´n en estas l´ıneas celulares.
En cambio, al comparar los perfiles de proteccio´n con la l´ınea celular SW48
que no expresa el gen ZNF518B, se observan cambios.
Por lo tanto, los eventos de ayuste alternativo en el procesamiento diferen-
cial de los mRNA entre ambas l´ıneas celulares, puede estar relacionados con
causas epigene´ticas y no con causas estructurales profundas. Por esta razo´n,
algunas marcas epigene´tica relevantes en las histonas fueron analizadas en
los nucleosomas presentes en la regio´n de estudio en el gen ZNF518B.
Se puede observar que el nivel de las modificaciones H3K36me3, H4K20me1,
H3K27ac y H3K9ac, estudiadas en la regio´n seleccionada, es muy baja en la
l´ınea celular SW48 en comparacio´n con la de las otras dos l´ıneas celulares:
DLD1 y D-Mut1. Lo que sin duda puede estar relacionadas con la ausencia
de expresio´n del gen ZNF518B en la l´ınea celular SW48.
Por su parte, la distribucio´n de la marca H3K36me3 es homoge´nea a lo
largo de la regio´n de estudio en la l´ınea celular DLD1, lo que esta´ de acuerdo
con los datos de que H3K36me3 se enriquece en los exones de los genes
humanos activos. As´ı mismo, la cromatina de la l´ınea celular D-Mut1 esta´
ma´s enriquecida en la marca H3K36me3 en la regio´n en estudio, sobre todo
en los nucleosomas N1 y N3 (Fig. 4.25). Por otra parte, la isoforma T2, que
se caracteriza por la prematura terminacio´n y por eventos MESI, en la regio´n
cubierta por N3 y N1 respectivamente, es ma´s abundantes en la l´ınea D-Mut1
(Fig. 4.22). Estos hechos pueden explicarse si algu´n factor no identificado es
reclutado por esta marca epigene´tica y participa en la prematura terminacio´n
de la isoforma T2.
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Organizacio´n de la cromatina y marcas epigene´ticas en
los sitios de ayuste alternativo del gen KRAS en CCR
Se ha descrito en la bibliograf´ıa que el gen KRAS da lugar a dos isoformas,
conocidas como 4A y 4B. En realidad la situacio´n es ma´s compleja. Segu´n
los datos de Ensembl, el gen posee 7 exones y puede dar lugar a un total de 4
isoformas. En el presente trabajo se denominan T1 (correspondiente a 4B),
T2 (4A), T3 y T4 (Fig. 4.26). Se sabe que la forma T2 es apopto´tica, mien-
tras que T1 es anti-apopto´tica. Las isoformas T3 y T4 pueden dar lugar a
prote´ınas, pero su presencia y posible funcio´n se desconocen. Como algunos
datos sugieren que la relacio´n T1/T2 puede variar en los mutantes de KRAS,
el estudio propuesto en esta seccio´n encaja con los objetivos de la presente
tesis.
En primer lugar, se determino´ en nueve l´ıneas celulares de CCR, el nivel
de expresio´n global del gen y el de las cuatro isoformas individuales. Para
ello, se disen˜aron oligonucleo´tidos para el ana´lisis por qPCR (Fig. 4.26). Los
resultados del ana´lisis se muestran en la Fig. 4.27, en la que se puede obser-
var que hay una variacio´n en la expresio´n global del gen entre las diferentes
l´ıneas celulares. En cuanto a la expresio´n de las isoformas, se puede apreciar
que T1 es mayoritaria en todas las l´ıneas, pero en nivel de la isoforma T3,
no descrita hasta ahora, no es despreciable, e incluso es superior al de T2
en la l´ınea D-Mut1. Para facilitar la seleccio´n de las l´ıneas que se van a
emplear en el ana´lisis de la cromatina, sirven de ayuda la Fig. 4.27 B y C
y la Fig. 4.28. A la vista de los datos contenidos en ellas, se seleccionaron
las l´ıneas SW48 y HCT116, ya que muestran gran diferencia en la relacio´n
T2/T1, mientras que la proporcio´n de las otras dos isoformas pra´cticamente
no var´ıa. Adema´s, las dos l´ıneas difieren en el estado mutacional de KRAS.
La organizacio´n nucleosomal en la regio´n correspondiente a los exones 5,
6 y 7, donde se producen los acontecimientos que dan lugar por ayuste al-
ternativo a las isoformas T1 y T2, se estudio´ mediante ensayos de proteccio´n
a MNasa. Los resultados (Fig. 4.29) muestran que en cada uno de los ex-
ones 5 y 6 se encuentra bien posicionado un u´nico nucleosoma, que cubre
la pra´ctica totalidad del exo´n. La presencia de nucleosomas en los intrones
flanqueantes esta´ clara en el caso del exo´n 6 e insinuada en el del exo´n 5. En
cuanto al exo´n 7, se detecta un nucleosoma en el borde intro´n-exo´n, otro en
el intro´n aguas arriba y se insinu´a otro nucleosoma aguas abajo dentro del
147
exo´n. Es interesante que la organizacio´n nucleosomal es coincidente entre
las dos l´ıneas celulares empleadas, a pesar de que el ayuste no es ide´ntico en
ambas. Esto sugiere que la seleccio´n del mecanismo de ayuste no se realiza
en base a diferencias en la estructura de la cromatina y apunta hacia la con-
veniencia de investigar si las posibles diferencias de ayuste se deben a causas
epigene´ticas.
El ana´lisis de las modificaciones epigene´ticas se realizo´ mediante Nu-ChIP
en la regio´n cubierta por los nucleosomas exo´nicos, que se nombran como
N-E5, N-E6 y N-E7. Los resultados de este ana´lisis, en el que se han deter-
minado cuantitativamente los niveles de H3K9me3, H3K36me3, H3K4me3,
H3K27me3, H3K9ac, H3K27ac y H4K20me1, se recogen en la Fig. 4.30.
Se puede observar que, en general, N-E7 es el nucleosoma ma´s densa-
mente marcado. Adema´s, se observan claras diferencias en las marcas entre
las dos l´ıneas celulares estudiadas, diferencias que a veces se encuentran en los
tres nucleosomas y otras veces, como en el caso de H3K36me3 son patentes
solo en uno de ellos. Las acetilaciones estudiadas son ma´s abundantes en la
l´ınea HCT116. Puesto que esas modificaciones facilitan la procesividad de la
RNA pol II, los resultados permiten emitir la hipo´tesis de que el acoplamiento
cine´tico condiciona parcialmente el ayuste. Esto no descarta la posibilidad
de que el modelo de reclutamiento sea tambie´n parcialmente operativo, como
sugiere la distribucio´n de la marca H3K27me3.
Finalmente, las marcas H3K9me3 y H3K9ac, que no pueden darse si-
multa´neamente en la misma cola de histona, son abundantes en los tres
nucleosomas de HCT116. No se puede decidir con los datos presentes si
ambas marcas se encuentran en copias distintas de la histona en el mismo
nucleosoma o si cada una es caracter´ıstica de uno de los alelos de esa l´ınea
celular heterozigo´tica para KRAS. La ausencia de esta modificacio´n en los
nucleosomas de SW48, en la cual ambos alelos del gen son salvajes, apuntar´ıa
levemente hacia la segunda posibilidad.
6.4 Conclusiones
En la presente tesis, se ha empleado el modelo del gen Egr1 de rato´n
para poner a punto un me´todo para estudiar la estructura y modificaciones
epigene´ticas de la cromatina a nivel mononucleosomal. El me´todo se ha us-
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ado posteriormente para estudiar la implicacio´n de la cromatina en el ayuste
alternativo de un gen de potencial intere´s oncoge´nico, seleccionado por un
ana´lisis in silico, y del gen KRAS. Los resultados experimentales permiten
obtener las siguientes conclusiones:
1. En el promotor de Egr1 y regio´n codificante proximal se encuentran
tres nucleosomas posicionados, tanto en ce´lulas de la l´ınea MLP29 in
vitro como en h´ıgado de rato´n in vivo. Estos nucleosomas se designan
como N-2, N-1 y N+1.
2. Tanto en los cultivos celulares como en un modelo de h´ıgado en re-
generacio´n, la transcripcio´n de Egr1 con lleva un deslizamiento de N-2
hacia 3’ y la pe´rdida parcial de N-1 y N+1. El cambio de N-2 permite
el acceso de EGR1, cuya unio´n, finalmente, da lugar a la represio´n del
gen. Los cambios en los nucleosomas son reversibles y cuando el ciclo
de transcripcio´n finaliza los nucleosomas retornan a su situacio´n basal.
3. Los experimentos de silenciamiento con siRNA sugieren que el factor
EGR1 no esta´ implicado en el deslizamiento de N-2, sino ma´s bien en
su retorno a la posicio´n basal.
4. Se ha estudiado a nivel mononucleosomal el cambio temporal de ocho
modificaciones de histonas durante el ciclo de activacio´n-represio´n del
gen Egr1. La mayor parte de las modificaciones muestran variaciones
cualitativas o cuantitativas espec´ıficas de cada nucleosoma y al final del
ciclo de transcripcio´n vuelven a su estado basal.
5. La acetilacio´n de H4K16, H3K9 y H3K27 predomina en los nucleo-
somas del promotor. La trimetilacio´n de H3K4, H3K9 y H3K27 es
espec´ıfica de N+1 en mayor o menor grado. La acetilacio´n de H3K14
es relativamente homoge´nea en los tres nucleosomas, mientras que la
modificacio´n H3S10phK14ac esta´ ma´s presente en N+1.
6. Se ha realizado una bu´squeda in silico para localizar los genes que dan
lugar a procesos de ayuste alternativo dependiente de la mutacio´n G13D
de KRAS. El ana´lisis mediante spliceR ha permitido la localizacio´n
de isoformas pertenecientes a cinco genes. En dos de ellos, EPDR1 y
ZNF518B, los resultados se han validado experimentalmente por qPCR
en l´ıneas celulares isoge´nicas derivadas de DLD1.
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7. Se ha estudiado mediante ensayos de proteccio´n a MNasa la presencia
de nucleosomas en la regio´n implicada en la terminacio´n y ayuste alter-
nativos del gen ZNF518B. No se encuentra un posicionamiento estricto
de nucleosomas, pero los resultados sugieren que hay una localizacio´n
parcialmente preferente para tres nucleosomas, uno en el principio del
exo´n 4 y otros dos alrededor del sitio alternativo de poliadenilacio´n.
8. El perfil de resistencia a MNasa es pra´cticamente ide´ntico entre las
l´ıneas DLD1 y D-Mut1, aunque difieren en el estado mutacional de
KRAS y en la proporcio´n de isoformas de ayuste. No obstante, el
perfil es diferente en las ce´lulas SW48, que no expresan ZNF518B. La
organizacio´n nucleosomal, por tanto, no influye en el ayuste alternativo
de este gen.
9. Se ha estudiado la distribucio´n de las marcas H3K36me3, H4K20me1,
H3K27ac y H3K9ac en los tres ma´ximos de proteccio´n a MNasa. En
general, las modificaciones esta´n ma´s presentes en las l´ıneas DLD1 y
D-Mut1, que expresan el gen, que en las ce´lulas SW48. Para cada una
de las modificaciones, so´lo se encuentran mı´nimas diferencias entre los
distintos picos nucleosomales. Por otro lado, los resultados sugieren que
la modificacio´n H3K27ac podr´ıa estar implicada en la poliadenilacio´n
alternativa.
10. Se ha estudiado la expresio´n de KRAS y de sus isoformas en nueve
l´ıneas celulares de CCR. Adema´s de las isoformas 4A y 4B, bien de-
scritas en la bibliograf´ıa, el ana´lisis se ha extendido a las otras dos
isoformas. A la vista de los resultados, se han seleccionado las l´ıneas
HCT116 y SW48 para estudios ulteriores sobre organizacio´n y modi-
ficaciones epigene´ticas de la cromatina en las regiones cr´ıticas para el
ayuste alternativo.
11. Los resultados de experimentos de proteccio´n a MNasa permiten con-
cluir que hay tres nucleosomas, N-E5, N-E6 y N-E7, bien posicionados
sobre los exones implicados en el ayuste alternativo. Entre las l´ıneas
HCT116 y SW48 so´lo se han encontrado mı´nimas diferencias.
12. Se ha cuantificado, tras experimentos de Nu-ChIP, la presencia de las
modificaciones H3K9me3, H3K36me3, H3K4me3, H3K27me3, H3K9ac,
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H3K27ac y H4K20me1 en los tres nucleosomas indicados. La dis-
tribucio´n de las histonas acetiladas sugiere que el ayuste alternativo
puede estar controlado, en parte, por acoplamiento cine´tico, aunque la
abundancia de H3K4me3 en N-E7 parece indicar que participan otros
mecanismos en la seleccio´n del modo de ayuste.
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